Mitch Report

date generated: 2023-11-14

Background

Mitch performs unidimensional and multidimensional gene set enrichment analysis. The concept behind this dates to work by Cox and Mann (https://doi.org/10.1186/1471-2105-13-S16-S12). This implementation is suited to R based workflows of multi-omics datasets. This software was developed by Antony Kaspi and Mark Ziemann. Learn more about Mitch at the website: https://github.com/markziemann/Mitch

Input profiles

Here is the first few lines of the input profile.

The profiling data being passed to mitch

	bl	gu
A1BG	-0.2102058	-0.1319328
A1BG-AS1	0.2349686	-0.7637720
A1CF	-0.4174745	-0.4654375
A2BP1	-0.2978746	-0.1608440
A2LD1	-0.2519359	-0.3229581
A2M	-0.9043933	-0.3200584

Here are some metrics about the input data profile:

Profiling data metrics

	Profile metrics
num_genes_in_profile	25716
duplicated_genes_present	0
num_profile_genes_in_sets	10215
num_profile_genes_not_in_sets	15501
profile_pearson_correl	0.17753
profile_spearman_correl	0.19618

Here is a plot of the input profiles. Note the dynamic ranges.

Here is the contour plot of the profile including all detected genes.

Input genesets

Here are some metrics about the gene sets used:

GMT file of genesets: ReactomePathways.gmt

Gene set metrics

	Gene sets metrics
num_genesets	2584
num_genesets_excluded	1038
num_genesets_included	1546

Gene sets by quadrant

Number of significant gene sets (FDR<0.05)= 412

Interactive enrichment scatterplot

All sets with FDR<0.05. Try hovering over the points.

Top N sets irrespective of FDR. Try hovering over the points.

A heatmap of S values for top results

A plot of effect size versus significance

Significance is the -log2(p.adjustMANOVA) and effect size is the s.dist which is the hypotenuse of the s scores.

Results table

Top N= 50 gene sets

## Warning in kable_styling(., "hover", full_width = FALSE): Please specify format
## in kable. kableExtra can customize either HTML or LaTeX outputs. See
## https://haozhu233.github.io/kableExtra/ for details.

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.bl	s.gu	p.bl	p.gu
Class C/3 (Metabotropic glutamate/pheromone receptors)	39	1.81e-10	5.47e-09	0.677	-0.490	-0.468	1.16e-07	4.29e-07
TICAM1-dependent activation of IRF3/IRF7	12	1.24e-03	7.55e-03	0.667	0.450	0.492	6.92e-03	3.16e-03
Scavenging of heme from plasma	12	1.97e-03	1.13e-02	0.643	-0.473	-0.436	4.52e-03	8.98e-03
Eicosanoids	12	2.96e-04	2.14e-03	0.640	0.631	-0.102	1.52e-04	5.41e-01
Pexophagy	11	4.13e-03	2.04e-02	0.626	0.515	0.356	3.11e-03	4.08e-02
SARS-CoV-1 modulates host translation machinery	34	1.09e-07	1.44e-06	0.604	0.522	0.305	1.40e-07	2.11e-03
Sensory perception of sweet, bitter, and umami (glutamate) taste	41	1.17e-08	2.10e-07	0.594	-0.465	-0.370	2.48e-07	4.17e-05
TICAM1,TRAF6-dependent induction of TAK1 complex	10	1.46e-02	5.41e-02	0.580	0.431	0.388	1.82e-02	3.36e-02
Competing endogenous RNAs (ceRNAs) regulate PTEN translation	16	1.27e-04	9.98e-04	0.555	-0.482	0.274	8.37e-04	5.77e-02
Glucuronidation	25	8.06e-05	6.70e-04	0.548	-0.378	-0.397	1.06e-03	5.87e-04
SCF(Skp2)-mediated degradation of p27/p21	58	3.60e-10	9.83e-09	0.547	0.412	0.359	5.52e-08	2.26e-06
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2	50	9.13e-09	1.68e-07	0.543	0.411	0.355	4.82e-07	1.43e-05
APC/C:Cdc20 mediated degradation of Cyclin B	24	1.35e-04	1.05e-03	0.539	0.300	0.448	1.08e-02	1.44e-04
Peptide chain elongation	84	2.22e-14	1.43e-12	0.538	0.466	0.269	1.47e-13	2.00e-05
PINK1-PRKN Mediated Mitophagy	21	4.63e-04	3.18e-03	0.534	0.287	0.450	2.27e-02	3.53e-04
Eukaryotic Translation Termination	87	1.17e-14	7.89e-13	0.534	0.464	0.263	6.84e-14	2.17e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A	50	2.24e-08	3.72e-07	0.527	0.425	0.313	1.99e-07	1.31e-04
p53-Independent DNA Damage Response	50	2.24e-08	3.72e-07	0.527	0.425	0.313	1.99e-07	1.31e-04
p53-Independent G1/S DNA damage checkpoint	50	2.24e-08	3.72e-07	0.527	0.425	0.313	1.99e-07	1.31e-04
Sensory perception of taste	47	9.25e-08	1.25e-06	0.525	-0.365	-0.377	1.49e-05	7.81e-06
Autodegradation of Cdh1 by Cdh1:APC/C	62	5.36e-10	1.40e-08	0.524	0.372	0.370	4.13e-07	4.61e-07
Hh mutants are degraded by ERAD	54	8.26e-09	1.54e-07	0.523	0.408	0.328	2.13e-07	3.10e-05
Eukaryotic Translation Elongation	88	2.89e-14	1.72e-12	0.522	0.458	0.251	1.07e-13	4.71e-05
Autodegradation of the E3 ubiquitin ligase COP1	50	3.12e-08	4.97e-07	0.521	0.433	0.289	1.17e-07	4.03e-04
The role of GTSE1 in G2/M progression after G2 checkpoint	58	2.68e-09	5.59e-08	0.520	0.400	0.333	1.37e-07	1.14e-05
Ubiquitin-dependent degradation of Cyclin D	50	3.46e-08	5.30e-07	0.520	0.425	0.300	1.98e-07	2.43e-04
Viral mRNA Translation	84	2.28e-13	1.01e-11	0.519	0.445	0.267	1.75e-12	2.29e-05
Selenocysteine synthesis	87	8.57e-14	4.42e-12	0.517	0.448	0.258	4.60e-13	3.23e-05
Vpu mediated degradation of CD4	50	5.45e-08	7.95e-07	0.515	0.405	0.318	7.14e-07	9.93e-05
TICAM1, RIP1-mediated IKK complex recruitment	18	2.53e-03	1.39e-02	0.514	0.336	0.389	1.35e-02	4.27e-03
Stabilization of p53	55	1.09e-08	1.98e-07	0.514	0.410	0.310	1.47e-07	6.91e-05
AUF1 (hnRNP D0) binds and destabilizes mRNA	53	2.15e-08	3.69e-07	0.512	0.422	0.289	1.04e-07	2.75e-04
Negative regulation of NOTCH4 signaling	52	3.98e-08	5.91e-07	0.510	0.394	0.324	8.64e-07	5.24e-05
SCF-beta-TrCP mediated degradation of Emi1	53	3.18e-08	5.01e-07	0.509	0.392	0.325	7.97e-07	4.25e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation	48	1.59e-07	2.00e-06	0.507	0.411	0.296	8.06e-07	3.78e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	53	3.31e-08	5.17e-07	0.506	0.412	0.295	2.15e-07	2.07e-04
Condensation of Prometaphase Chromosomes	11	1.98e-02	7.03e-02	0.506	0.142	0.485	4.15e-01	5.33e-03
APC/C:Cdc20 mediated degradation of Securin	66	7.78e-10	1.85e-08	0.503	0.381	0.329	8.61e-08	3.79e-06
Mitochondrial iron-sulfur cluster biogenesis	12	2.09e-02	7.39e-02	0.503	0.281	0.417	9.19e-02	1.24e-02
Mitophagy	27	1.68e-04	1.28e-03	0.500	0.256	0.429	2.12e-02	1.14e-04
Aspirin ADME	44	7.56e-07	8.53e-06	0.498	-0.255	-0.428	3.44e-03	8.73e-07
Response of EIF2AK4 (GCN2) to amino acid deficiency	95	6.80e-14	3.76e-12	0.498	0.427	0.256	5.90e-13	1.62e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	89	5.01e-13	2.09e-11	0.497	0.427	0.254	3.05e-12	3.51e-05
Digestion	18	3.42e-03	1.76e-02	0.497	-0.273	-0.415	4.53e-02	2.28e-03
CASP8 activity is inhibited	11	2.59e-02	8.73e-02	0.496	0.461	0.184	8.10e-03	2.91e-01
Dimerization of procaspase-8	11	2.59e-02	8.73e-02	0.496	0.461	0.184	8.10e-03	2.91e-01
Regulation by c-FLIP	11	2.59e-02	8.73e-02	0.496	0.461	0.184	8.10e-03	2.91e-01
Vif-mediated degradation of APOBEC3G	50	1.72e-07	2.14e-06	0.495	0.404	0.286	7.52e-07	4.60e-04
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	72	2.43e-10	7.02e-09	0.495	0.368	0.331	6.42e-08	1.16e-06
RIPK1-mediated regulated necrosis	27	2.60e-04	1.89e-03	0.494	0.348	0.350	1.73e-03	1.62e-03

---

Results (complete table)

Click HERE to show results for all gene sets

Complete results

set	setSize	pMANOVA	p.adjustMANOVA	s.dist	s.bl	s.gu	p.bl	p.gu
Class C/3 (Metabotropic glutamate/pheromone receptors)	39	1.81e-10	5.47e-09	0.67700	-4.90e-01	-4.68e-01	1.16e-07	4.29e-07
TICAM1-dependent activation of IRF3/IRF7	12	1.24e-03	7.55e-03	0.66700	4.50e-01	4.92e-01	6.92e-03	3.16e-03
Scavenging of heme from plasma	12	1.97e-03	1.13e-02	0.64300	-4.73e-01	-4.36e-01	4.52e-03	8.98e-03
Eicosanoids	12	2.96e-04	2.14e-03	0.64000	6.31e-01	-1.02e-01	1.52e-04	5.41e-01
Pexophagy	11	4.13e-03	2.04e-02	0.62600	5.15e-01	3.56e-01	3.11e-03	4.08e-02
SARS-CoV-1 modulates host translation machinery	34	1.09e-07	1.44e-06	0.60400	5.22e-01	3.05e-01	1.40e-07	2.11e-03
Sensory perception of sweet, bitter, and umami (glutamate) taste	41	1.17e-08	2.10e-07	0.59400	-4.65e-01	-3.70e-01	2.48e-07	4.17e-05
TICAM1,TRAF6-dependent induction of TAK1 complex	10	1.46e-02	5.41e-02	0.58000	4.31e-01	3.88e-01	1.82e-02	3.36e-02
Competing endogenous RNAs (ceRNAs) regulate PTEN translation	16	1.27e-04	9.98e-04	0.55500	-4.82e-01	2.74e-01	8.37e-04	5.77e-02
Glucuronidation	25	8.06e-05	6.70e-04	0.54800	-3.78e-01	-3.97e-01	1.06e-03	5.87e-04
SCF(Skp2)-mediated degradation of p27/p21	58	3.60e-10	9.83e-09	0.54700	4.12e-01	3.59e-01	5.52e-08	2.26e-06
GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2	50	9.13e-09	1.68e-07	0.54300	4.11e-01	3.55e-01	4.82e-07	1.43e-05
APC/C:Cdc20 mediated degradation of Cyclin B	24	1.35e-04	1.05e-03	0.53900	3.00e-01	4.48e-01	1.08e-02	1.44e-04
Peptide chain elongation	84	2.22e-14	1.43e-12	0.53800	4.66e-01	2.69e-01	1.47e-13	2.00e-05
PINK1-PRKN Mediated Mitophagy	21	4.63e-04	3.18e-03	0.53400	2.87e-01	4.50e-01	2.27e-02	3.53e-04
Eukaryotic Translation Termination	87	1.17e-14	7.89e-13	0.53400	4.64e-01	2.63e-01	6.84e-14	2.17e-05
Ubiquitin Mediated Degradation of Phosphorylated Cdc25A	50	2.24e-08	3.72e-07	0.52700	4.25e-01	3.13e-01	1.99e-07	1.31e-04
p53-Independent DNA Damage Response	50	2.24e-08	3.72e-07	0.52700	4.25e-01	3.13e-01	1.99e-07	1.31e-04
p53-Independent G1/S DNA damage checkpoint	50	2.24e-08	3.72e-07	0.52700	4.25e-01	3.13e-01	1.99e-07	1.31e-04
Sensory perception of taste	47	9.25e-08	1.25e-06	0.52500	-3.65e-01	-3.77e-01	1.49e-05	7.81e-06
Autodegradation of Cdh1 by Cdh1:APC/C	62	5.36e-10	1.40e-08	0.52400	3.72e-01	3.70e-01	4.13e-07	4.61e-07
Hh mutants are degraded by ERAD	54	8.26e-09	1.54e-07	0.52300	4.08e-01	3.28e-01	2.13e-07	3.10e-05
Eukaryotic Translation Elongation	88	2.89e-14	1.72e-12	0.52200	4.58e-01	2.51e-01	1.07e-13	4.71e-05
Autodegradation of the E3 ubiquitin ligase COP1	50	3.12e-08	4.97e-07	0.52100	4.33e-01	2.89e-01	1.17e-07	4.03e-04
The role of GTSE1 in G2/M progression after G2 checkpoint	58	2.68e-09	5.59e-08	0.52000	4.00e-01	3.33e-01	1.37e-07	1.14e-05
Ubiquitin-dependent degradation of Cyclin D	50	3.46e-08	5.30e-07	0.52000	4.25e-01	3.00e-01	1.98e-07	2.43e-04
Viral mRNA Translation	84	2.28e-13	1.01e-11	0.51900	4.45e-01	2.67e-01	1.75e-12	2.29e-05
Selenocysteine synthesis	87	8.57e-14	4.42e-12	0.51700	4.48e-01	2.58e-01	4.60e-13	3.23e-05
Vpu mediated degradation of CD4	50	5.45e-08	7.95e-07	0.51500	4.05e-01	3.18e-01	7.14e-07	9.93e-05
TICAM1, RIP1-mediated IKK complex recruitment	18	2.53e-03	1.39e-02	0.51400	3.36e-01	3.89e-01	1.35e-02	4.27e-03
Stabilization of p53	55	1.09e-08	1.98e-07	0.51400	4.10e-01	3.10e-01	1.47e-07	6.91e-05
AUF1 (hnRNP D0) binds and destabilizes mRNA	53	2.15e-08	3.69e-07	0.51200	4.22e-01	2.89e-01	1.04e-07	2.75e-04
Negative regulation of NOTCH4 signaling	52	3.98e-08	5.91e-07	0.51000	3.94e-01	3.24e-01	8.64e-07	5.24e-05
SCF-beta-TrCP mediated degradation of Emi1	53	3.18e-08	5.01e-07	0.50900	3.92e-01	3.25e-01	7.97e-07	4.25e-05
Regulation of activated PAK-2p34 by proteasome mediated degradation	48	1.59e-07	2.00e-06	0.50700	4.11e-01	2.96e-01	8.06e-07	3.78e-04
FBXL7 down-regulates AURKA during mitotic entry and in early mitosis	53	3.31e-08	5.17e-07	0.50600	4.12e-01	2.95e-01	2.15e-07	2.07e-04
Condensation of Prometaphase Chromosomes	11	1.98e-02	7.03e-02	0.50600	1.42e-01	4.85e-01	4.15e-01	5.33e-03
APC/C:Cdc20 mediated degradation of Securin	66	7.78e-10	1.85e-08	0.50300	3.81e-01	3.29e-01	8.61e-08	3.79e-06
Mitochondrial iron-sulfur cluster biogenesis	12	2.09e-02	7.39e-02	0.50300	2.81e-01	4.17e-01	9.19e-02	1.24e-02
Mitophagy	27	1.68e-04	1.28e-03	0.50000	2.56e-01	4.29e-01	2.12e-02	1.14e-04
Aspirin ADME	44	7.56e-07	8.53e-06	0.49800	-2.55e-01	-4.28e-01	3.44e-03	8.73e-07
Response of EIF2AK4 (GCN2) to amino acid deficiency	95	6.80e-14	3.76e-12	0.49800	4.27e-01	2.56e-01	5.90e-13	1.62e-05
Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)	89	5.01e-13	2.09e-11	0.49700	4.27e-01	2.54e-01	3.05e-12	3.51e-05
Digestion	18	3.42e-03	1.76e-02	0.49700	-2.73e-01	-4.15e-01	4.53e-02	2.28e-03
CASP8 activity is inhibited	11	2.59e-02	8.73e-02	0.49600	4.61e-01	1.84e-01	8.10e-03	2.91e-01
Dimerization of procaspase-8	11	2.59e-02	8.73e-02	0.49600	4.61e-01	1.84e-01	8.10e-03	2.91e-01
Regulation by c-FLIP	11	2.59e-02	8.73e-02	0.49600	4.61e-01	1.84e-01	8.10e-03	2.91e-01
Vif-mediated degradation of APOBEC3G	50	1.72e-07	2.14e-06	0.49500	4.04e-01	2.86e-01	7.52e-07	4.60e-04
APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1	72	2.43e-10	7.02e-09	0.49500	3.68e-01	3.31e-01	6.42e-08	1.16e-06
RIPK1-mediated regulated necrosis	27	2.60e-04	1.89e-03	0.49400	3.48e-01	3.50e-01	1.73e-03	1.62e-03
Regulation of necroptotic cell death	27	2.60e-04	1.89e-03	0.49400	3.48e-01	3.50e-01	1.73e-03	1.62e-03
Cross-presentation of soluble exogenous antigens (endosomes)	46	6.30e-07	7.27e-06	0.49000	4.23e-01	2.48e-01	6.80e-07	3.66e-03
Regulation of RUNX3 expression and activity	53	1.13e-07	1.47e-06	0.49000	3.77e-01	3.13e-01	2.03e-06	8.05e-05
Hh mutants abrogate ligand secretion	57	3.79e-08	5.69e-07	0.48800	3.79e-01	3.08e-01	7.52e-07	5.75e-05
Expression and translocation of olfactory receptors	356	8.57e-47	6.62e-44	0.48500	-2.68e-01	-4.04e-01	3.01e-18	1.84e-39
Early Phase of HIV Life Cycle	14	1.10e-02	4.36e-02	0.48200	1.43e-01	4.60e-01	3.54e-01	2.86e-03
p53-Dependent G1 DNA Damage Response	64	8.02e-09	1.52e-07	0.48200	3.63e-01	3.17e-01	4.94e-07	1.18e-05
p53-Dependent G1/S DNA damage checkpoint	64	8.02e-09	1.52e-07	0.48200	3.63e-01	3.17e-01	4.94e-07	1.18e-05
SRP-dependent cotranslational protein targeting to membrane	105	2.33e-14	1.44e-12	0.48100	4.19e-01	2.36e-01	1.21e-13	2.82e-05
Cdc20:Phospho-APC/C mediated degradation of Cyclin A	71	1.29e-09	2.85e-08	0.48000	3.56e-01	3.21e-01	2.08e-07	2.82e-06
Formation of a pool of free 40S subunits	94	6.59e-13	2.61e-11	0.47800	4.23e-01	2.24e-01	1.34e-12	1.73e-04
G1/S DNA Damage Checkpoints	66	6.21e-09	1.26e-07	0.47800	3.60e-01	3.14e-01	4.25e-07	9.98e-06
Olfactory Signaling Pathway	363	3.27e-46	1.68e-43	0.47700	-2.59e-01	-4.00e-01	1.77e-17	1.95e-39
CDK-mediated phosphorylation and removal of Cdc6	71	1.65e-09	3.49e-08	0.47700	3.39e-01	3.36e-01	7.94e-07	9.67e-07
APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint	72	1.52e-09	3.27e-08	0.47400	3.50e-01	3.20e-01	2.76e-07	2.60e-06
Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins	75	7.03e-10	1.75e-08	0.47400	3.41e-01	3.29e-01	3.35e-07	7.98e-07
Defective C1GALT1C1 causes TNPS	18	6.39e-03	2.95e-02	0.47300	-3.36e-01	-3.33e-01	1.35e-02	1.44e-02
APC/C:Cdc20 mediated degradation of mitotic proteins	74	1.04e-09	2.36e-08	0.47300	3.40e-01	3.28e-01	4.14e-07	1.05e-06
GLI3 is processed to GLI3R by the proteasome	58	7.82e-08	1.08e-06	0.47200	3.78e-01	2.83e-01	6.21e-07	1.92e-04
POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation	10	1.89e-02	6.79e-02	0.47100	-1.90e-01	4.31e-01	2.97e-01	1.82e-02
APC-Cdc20 mediated degradation of Nek2A	26	6.02e-04	3.93e-03	0.47100	2.48e-01	4.01e-01	2.89e-02	4.03e-04
Defective CFTR causes cystic fibrosis	59	7.91e-08	1.08e-06	0.46800	3.79e-01	2.75e-01	4.87e-07	2.61e-04
Degradation of GLI2 by the proteasome	58	1.04e-07	1.39e-06	0.46800	3.80e-01	2.73e-01	5.55e-07	3.28e-04
Synthesis of active ubiquitin: roles of E1 and E2 enzymes	27	5.00e-04	3.39e-03	0.46800	2.42e-01	4.00e-01	2.98e-02	3.18e-04
Degradation of DVL	55	2.75e-07	3.37e-06	0.46600	3.73e-01	2.80e-01	1.71e-06	3.31e-04
Josephin domain DUBs	11	4.85e-02	1.40e-01	0.46500	2.70e-01	3.79e-01	1.20e-01	2.95e-02
SARS-CoV-2 modulates host translation machinery	46	2.84e-06	2.78e-05	0.46500	3.94e-01	2.47e-01	3.66e-06	3.79e-03
Phosphorylation of the APC/C	20	3.53e-03	1.79e-02	0.46400	2.12e-01	4.13e-01	1.00e-01	1.39e-03
Regulation of APC/C activators between G1/S and early anaphase	79	6.01e-10	1.52e-08	0.46300	3.15e-01	3.40e-01	1.26e-06	1.77e-07
Selenoamino acid metabolism	103	5.65e-13	2.30e-11	0.46200	3.93e-01	2.43e-01	5.35e-12	1.98e-05
GTP hydrolysis and joining of the 60S ribosomal subunit	104	3.11e-13	1.33e-11	0.46100	4.06e-01	2.19e-01	7.83e-13	1.14e-04
Regulation of ornithine decarboxylase (ODC)	49	2.11e-06	2.13e-05	0.46000	3.63e-01	2.83e-01	1.11e-05	6.16e-04
Senescence-Associated Secretory Phenotype (SASP)	53	8.18e-07	9.10e-06	0.45700	2.68e-01	3.70e-01	7.50e-04	3.09e-06
STAT5 activation downstream of FLT3 ITD mutants	10	6.57e-02	1.71e-01	0.45700	2.15e-01	4.03e-01	2.40e-01	2.73e-02
Defective GALNT12 causes CRCS1	18	9.06e-03	3.85e-02	0.45700	-3.30e-01	-3.15e-01	1.53e-02	2.06e-02
Carnitine metabolism	11	1.41e-02	5.22e-02	0.45600	-3.52e-01	2.91e-01	4.34e-02	9.47e-02
L13a-mediated translational silencing of Ceruloplasmin expression	103	6.90e-13	2.67e-11	0.45600	4.05e-01	2.10e-01	1.18e-12	2.25e-04
Activation of RAC1	11	3.53e-02	1.13e-01	0.45500	-4.50e-01	-7.06e-02	9.78e-03	6.85e-01
APC/C-mediated degradation of cell cycle proteins	86	2.45e-10	7.02e-09	0.45300	3.11e-01	3.30e-01	6.08e-07	1.21e-07
Regulation of mitotic cell cycle	86	2.45e-10	7.02e-09	0.45300	3.11e-01	3.30e-01	6.08e-07	1.21e-07
Degradation of GLI1 by the proteasome	58	3.21e-07	3.84e-06	0.45300	3.51e-01	2.87e-01	3.85e-06	1.60e-04
Interaction With Cumulus Cells And The Zona Pellucida	11	2.55e-02	8.66e-02	0.45300	5.11e-02	-4.50e-01	7.69e-01	9.79e-03
Suppression of phagosomal maturation	13	3.56e-02	1.13e-01	0.45200	3.36e-01	3.03e-01	3.59e-02	5.88e-02
Defective GALNT3 causes HFTC	18	1.00e-02	4.10e-02	0.45100	-3.34e-01	-3.04e-01	1.42e-02	2.57e-02
Cap-dependent Translation Initiation	111	1.84e-13	8.38e-12	0.45100	3.97e-01	2.13e-01	4.65e-13	1.06e-04
Eukaryotic Translation Initiation	111	1.84e-13	8.38e-12	0.45100	3.97e-01	2.13e-01	4.65e-13	1.06e-04
NIK–>noncanonical NF-kB signaling	57	4.85e-07	5.64e-06	0.45000	3.49e-01	2.84e-01	4.97e-06	2.09e-04
TNFR1-induced proapoptotic signaling	13	3.68e-02	1.16e-01	0.44800	2.72e-01	3.56e-01	8.91e-02	2.62e-02
Metabolism of polyamines	55	8.30e-07	9.17e-06	0.44800	3.66e-01	2.58e-01	2.60e-06	9.49e-04
Respiratory electron transport	90	1.43e-10	4.51e-09	0.44800	2.82e-01	3.47e-01	3.65e-06	1.20e-08
Formation of the ternary complex, and subsequently, the 43S complex	46	5.65e-06	5.39e-05	0.44700	4.00e-01	1.99e-01	2.61e-06	1.94e-02
Regulation of Apoptosis	51	2.59e-06	2.56e-05	0.44700	3.58e-01	2.67e-01	9.59e-06	9.76e-04
cGMP effects	15	1.24e-02	4.73e-02	0.44600	-6.24e-02	-4.41e-01	6.76e-01	3.09e-03
Dectin-1 mediated noncanonical NF-kB signaling	60	3.16e-07	3.81e-06	0.44500	3.49e-01	2.76e-01	2.86e-06	2.19e-04
Activation of IRF3/IRF7 mediated by TBK1/IKK epsilon	17	1.10e-02	4.36e-02	0.44400	1.68e-01	4.11e-01	2.30e-01	3.34e-03
Prednisone ADME	10	8.67e-02	2.12e-01	0.44200	-2.99e-01	-3.25e-01	1.02e-01	7.50e-02
Constitutive Signaling by Overexpressed ERBB2	10	6.43e-02	1.70e-01	0.44100	1.10e-01	4.27e-01	5.46e-01	1.94e-02
Apoptotic cleavage of cell adhesion proteins	11	6.23e-02	1.68e-01	0.44100	-3.84e-01	-2.16e-01	2.73e-02	2.14e-01
Assembly of the ORC complex at the origin of replication	10	2.98e-02	9.74e-02	0.44000	-3.85e-01	2.12e-01	3.49e-02	2.46e-01
Aberrant regulation of mitotic exit in cancer due to RB1 defects	20	6.09e-03	2.85e-02	0.43800	1.83e-01	3.98e-01	1.56e-01	2.04e-03
Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC)	108	3.61e-12	1.32e-10	0.43600	3.71e-01	2.30e-01	2.75e-11	3.51e-05
Nonsense-Mediated Decay (NMD)	108	3.61e-12	1.32e-10	0.43600	3.71e-01	2.30e-01	2.75e-11	3.51e-05
Assembly Of The HIV Virion	16	1.12e-02	4.41e-02	0.43600	5.95e-02	4.32e-01	6.80e-01	2.76e-03
MET activates RAS signaling	11	2.14e-02	7.47e-02	0.43500	-2.51e-01	3.55e-01	1.49e-01	4.15e-02
SARS-CoV-1 activates/modulates innate immune responses	37	1.01e-04	8.14e-04	0.43500	1.91e-01	3.90e-01	4.42e-02	3.97e-05
Membrane binding and targetting of GAG proteins	14	2.12e-02	7.43e-02	0.43400	7.01e-02	4.28e-01	6.50e-01	5.52e-03
Synthesis And Processing Of GAG, GAGPOL Polyproteins	14	2.12e-02	7.43e-02	0.43400	7.01e-02	4.28e-01	6.50e-01	5.52e-03
Major pathway of rRNA processing in the nucleolus and cytosol	171	1.52e-18	2.00e-16	0.43400	3.64e-01	2.36e-01	1.88e-16	1.02e-07
PRC2 methylates histones and DNA	13	1.17e-02	4.53e-02	0.43100	-2.34e-01	3.62e-01	1.44e-01	2.37e-02
Influenza Viral RNA Transcription and Replication	129	7.55e-14	4.02e-12	0.43100	3.43e-01	2.62e-01	1.73e-11	2.80e-07
Regulation of expression of SLITs and ROBOs	159	7.86e-17	6.75e-15	0.42800	3.57e-01	2.37e-01	7.67e-15	2.52e-07
NF-kB is activated and signals survival	12	5.55e-02	1.55e-01	0.42700	3.86e-01	1.81e-01	2.05e-02	2.76e-01
Regulation of innate immune responses to cytosolic DNA	14	4.08e-02	1.24e-01	0.42600	3.34e-01	2.64e-01	3.06e-02	8.69e-02
Assembly of the pre-replicative complex	82	6.78e-09	1.34e-07	0.42600	2.49e-01	3.45e-01	9.56e-05	6.48e-08
Aberrant regulation of mitotic cell cycle due to RB1 defects	36	1.41e-04	1.10e-03	0.42500	1.45e-01	4.00e-01	1.33e-01	3.30e-05
Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase	20	8.38e-03	3.68e-02	0.42500	1.80e-01	3.85e-01	1.64e-01	2.87e-03
rRNA processing in the nucleus and cytosol	180	1.55e-18	2.00e-16	0.42400	3.47e-01	2.45e-01	9.86e-16	1.35e-08
Spry regulation of FGF signaling	16	2.49e-02	8.52e-02	0.42400	2.21e-01	3.61e-01	1.26e-01	1.23e-02
Degradation of AXIN	53	5.70e-06	5.41e-05	0.42300	3.47e-01	2.42e-01	1.22e-05	2.27e-03
Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha	62	8.64e-07	9.47e-06	0.42300	3.25e-01	2.71e-01	9.50e-06	2.20e-04
Digestion and absorption	23	5.63e-03	2.65e-02	0.42300	-2.63e-01	-3.31e-01	2.92e-02	5.97e-03
Dectin-2 family	28	1.62e-03	9.48e-03	0.42200	-3.61e-01	-2.18e-01	9.34e-04	4.55e-02
Influenza Infection	148	5.17e-15	3.63e-13	0.42100	3.20e-01	2.74e-01	1.63e-11	8.96e-09
p75NTR recruits signalling complexes	12	6.48e-02	1.70e-01	0.42000	3.64e-01	2.09e-01	2.90e-02	2.11e-01
Respiratory electron transport, ATP synthesis by chemiosmotic coupling, and heat production by uncoupling proteins.	95	9.39e-10	2.17e-08	0.41600	2.50e-01	3.33e-01	2.52e-05	2.01e-08
Cyclin E associated events during G1/S transition	81	2.64e-08	4.34e-07	0.41500	2.91e-01	2.96e-01	6.12e-06	3.97e-06
Signaling by NOTCH4	79	3.74e-08	5.67e-07	0.41400	3.28e-01	2.53e-01	4.62e-07	9.84e-05
Activation of the TFAP2 (AP-2) family of transcription factors	11	8.96e-02	2.18e-01	0.41400	3.47e-01	2.25e-01	4.61e-02	1.96e-01
DNA Replication Pre-Initiation	97	8.51e-10	1.99e-08	0.41300	2.49e-01	3.29e-01	2.20e-05	2.01e-08
ATF6 (ATF6-alpha) activates chaperone genes	10	1.15e-01	2.59e-01	0.41200	2.40e-01	3.35e-01	1.88e-01	6.65e-02
p75NTR signals via NF-kB	15	3.56e-02	1.13e-01	0.41200	3.65e-01	1.92e-01	1.43e-02	1.98e-01
Thyroxine biosynthesis	10	1.14e-01	2.56e-01	0.41200	-3.45e-01	-2.26e-01	5.87e-02	2.16e-01
Diseases of mitotic cell cycle	37	2.29e-04	1.72e-03	0.41000	1.50e-01	3.81e-01	1.13e-01	6.01e-05
SARS-CoV-1-host interactions	90	6.30e-09	1.26e-07	0.40900	2.71e-01	3.07e-01	8.66e-06	4.92e-07
Cyclin A:Cdk2-associated events at S phase entry	83	2.95e-08	4.75e-07	0.40900	2.86e-01	2.92e-01	6.43e-06	4.33e-06
RUNX1 regulates transcription of genes involved in differentiation of HSCs	68	6.69e-07	7.66e-06	0.40900	2.77e-01	3.01e-01	7.82e-05	1.81e-05
Asymmetric localization of PCP proteins	62	2.19e-06	2.19e-05	0.40800	3.23e-01	2.49e-01	1.07e-05	6.80e-04
Ribosomal scanning and start codon recognition	53	8.96e-06	8.25e-05	0.40800	3.67e-01	1.78e-01	3.72e-06	2.52e-02
Golgi Cisternae Pericentriolar Stack Reorganization	14	4.26e-02	1.28e-01	0.40800	1.46e-01	3.81e-01	3.44e-01	1.36e-02
Defective pyroptosis	11	5.32e-02	1.49e-01	0.40800	-3.02e-02	4.07e-01	8.62e-01	1.95e-02
rRNA processing	186	1.24e-17	1.37e-15	0.40700	3.29e-01	2.40e-01	8.99e-15	1.62e-08
Switching of origins to a post-replicative state	90	7.39e-09	1.45e-07	0.40700	2.52e-01	3.19e-01	3.52e-05	1.67e-07
Hedgehog ligand biogenesis	63	2.25e-06	2.24e-05	0.40500	3.14e-01	2.56e-01	1.64e-05	4.34e-04
Androgen biosynthesis	11	6.79e-02	1.75e-01	0.40500	-4.45e-02	-4.02e-01	7.98e-01	2.09e-02
Diseases of programmed cell death	43	1.20e-04	9.43e-04	0.40300	2.04e-01	3.48e-01	2.08e-02	7.81e-05
Activation of NF-kappaB in B cells	64	2.10e-06	2.13e-05	0.40300	3.11e-01	2.56e-01	1.65e-05	3.91e-04
Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S	54	9.17e-06	8.39e-05	0.40300	3.65e-01	1.70e-01	3.40e-06	3.07e-02
Response of Mtb to phagocytosis	22	1.07e-02	4.31e-02	0.40300	3.30e-01	2.31e-01	7.40e-03	6.05e-02
CYP2E1 reactions	11	9.86e-02	2.33e-01	0.40200	-3.52e-01	-1.95e-01	4.31e-02	2.63e-01
Infection with Mycobacterium tuberculosis	25	6.23e-03	2.89e-02	0.40100	3.20e-01	2.41e-01	5.60e-03	3.68e-02
Inactivation of APC/C via direct inhibition of the APC/C complex	21	1.15e-02	4.45e-02	0.40100	1.69e-01	3.63e-01	1.81e-01	3.93e-03
Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components	21	1.15e-02	4.45e-02	0.40100	1.69e-01	3.63e-01	1.81e-01	3.93e-03
Translation initiation complex formation	53	1.46e-05	1.31e-04	0.39800	3.62e-01	1.66e-01	5.17e-06	3.65e-02
Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects	17	2.26e-02	7.77e-02	0.39300	7.68e-02	3.86e-01	5.83e-01	5.89e-03
Defective binding of RB1 mutants to E2F1,(E2F2, E2F3)	17	2.26e-02	7.77e-02	0.39300	7.68e-02	3.86e-01	5.83e-01	5.89e-03
Diseases associated with glycosylation precursor biosynthesis	15	5.04e-02	1.43e-01	0.39300	2.04e-01	3.36e-01	1.72e-01	2.41e-02
Sensory Perception	567	2.08e-48	3.21e-45	0.39200	-2.12e-01	-3.30e-01	4.33e-18	2.23e-41
Cellular response to hypoxia	71	1.23e-06	1.32e-05	0.39100	2.86e-01	2.67e-01	3.09e-05	9.86e-05
Mitochondrial translation termination	87	5.84e-08	8.20e-07	0.39100	2.68e-01	2.85e-01	1.59e-05	4.14e-06
Orc1 removal from chromatin	69	1.89e-06	1.95e-05	0.39100	2.70e-01	2.82e-01	1.02e-04	5.09e-05
Negative regulation of activity of TFAP2 (AP-2) family transcription factors	10	1.29e-01	2.79e-01	0.38900	3.63e-01	1.40e-01	4.69e-02	4.43e-01
Receptor Mediated Mitophagy	10	1.06e-01	2.45e-01	0.38700	4.28e-02	3.85e-01	8.15e-01	3.50e-02
Translation	262	5.15e-22	1.14e-19	0.38700	3.04e-01	2.39e-01	2.18e-17	2.67e-11
Regulation of RAS by GAPs	65	5.12e-06	4.91e-05	0.38600	2.95e-01	2.49e-01	3.83e-05	5.08e-04
Transcriptional regulation of granulopoiesis	31	5.33e-04	3.57e-03	0.38600	-4.87e-02	3.83e-01	6.39e-01	2.27e-04
Mitochondrial translation	93	3.40e-08	5.25e-07	0.38500	2.66e-01	2.78e-01	9.11e-06	3.66e-06
Methylation	14	4.74e-02	1.38e-01	0.38400	3.81e-01	5.35e-02	1.37e-02	7.29e-01
Nuclear events mediated by NFE2L2	76	7.33e-07	8.33e-06	0.38400	2.34e-01	3.04e-01	4.14e-04	4.47e-06
N-glycan trimming in the ER and Calnexin/Calreticulin cycle	34	1.24e-03	7.55e-03	0.38300	1.46e-01	3.54e-01	1.41e-01	3.53e-04
Defective Intrinsic Pathway for Apoptosis	25	1.02e-02	4.16e-02	0.38200	2.73e-01	2.68e-01	1.80e-02	2.05e-02
Mitochondrial translation elongation	87	1.48e-07	1.91e-06	0.38000	2.62e-01	2.76e-01	2.44e-05	8.67e-06
Mitochondrial translation initiation	87	1.57e-07	1.99e-06	0.37900	2.63e-01	2.73e-01	2.15e-05	1.06e-05
TNFR2 non-canonical NF-kB pathway	94	4.07e-08	5.99e-07	0.37900	2.98e-01	2.35e-01	6.03e-07	8.12e-05
DNA Damage Recognition in GG-NER	36	1.51e-03	8.97e-03	0.37900	2.56e-01	2.80e-01	7.81e-03	3.67e-03
Degradation of cysteine and homocysteine	14	5.90e-02	1.62e-01	0.37700	8.60e-02	3.67e-01	5.77e-01	1.74e-02
FCERI mediated NF-kB activation	74	1.87e-06	1.94e-05	0.37600	2.95e-01	2.34e-01	1.16e-05	5.00e-04
Transcriptional regulation of testis differentiation	12	9.03e-02	2.18e-01	0.37600	8.75e-02	3.65e-01	6.00e-01	2.85e-02
Polo-like kinase mediated events	16	4.11e-02	1.25e-01	0.37500	8.70e-02	3.64e-01	5.47e-01	1.16e-02
Pyrimidine salvage	10	8.18e-02	2.04e-01	0.37400	-1.52e-01	3.42e-01	4.07e-01	6.08e-02
Telomere C-strand synthesis initiation	11	1.17e-01	2.62e-01	0.37400	1.06e-01	3.59e-01	5.43e-01	3.95e-02
Termination of O-glycan biosynthesis	25	1.24e-02	4.73e-02	0.37300	-2.97e-01	-2.25e-01	1.01e-02	5.12e-02
Folding of actin by CCT/TriC	10	1.29e-01	2.79e-01	0.37200	3.69e-01	4.88e-02	4.35e-02	7.89e-01
ER-Phagosome pathway	87	2.96e-07	3.60e-06	0.37200	2.70e-01	2.56e-01	1.34e-05	3.76e-05
Pausing and recovery of Tat-mediated HIV elongation	27	9.13e-03	3.86e-02	0.37000	3.04e-01	2.11e-01	6.26e-03	5.83e-02
Tat-mediated HIV elongation arrest and recovery	27	9.13e-03	3.86e-02	0.37000	3.04e-01	2.11e-01	6.26e-03	5.83e-02
ATF4 activates genes in response to endoplasmic reticulum stress	28	4.12e-03	2.04e-02	0.36900	3.62e-01	7.44e-02	9.19e-04	4.96e-01
Erythrocytes take up carbon dioxide and release oxygen	12	1.31e-01	2.82e-01	0.36700	-2.34e-01	-2.82e-01	1.60e-01	9.05e-02
O2/CO2 exchange in erythrocytes	12	1.31e-01	2.82e-01	0.36700	-2.34e-01	-2.82e-01	1.60e-01	9.05e-02
Purine ribonucleoside monophosphate biosynthesis	11	1.05e-01	2.43e-01	0.36700	2.21e-02	3.66e-01	8.99e-01	3.56e-02
Regulation of TNFR1 signaling	37	1.97e-03	1.13e-02	0.36700	2.55e-01	2.63e-01	7.19e-03	5.60e-03
IKK complex recruitment mediated by RIP1	22	1.95e-02	6.92e-02	0.36600	1.47e-01	3.36e-01	2.32e-01	6.44e-03
RHO GTPases activate KTN1	11	6.87e-02	1.77e-01	0.36600	-1.77e-01	3.20e-01	3.08e-01	6.61e-02
Regulation of mRNA stability by proteins that bind AU-rich elements	87	3.68e-07	4.35e-06	0.36600	3.04e-01	2.03e-01	9.30e-07	1.06e-03
NRIF signals cell death from the nucleus	16	6.18e-02	1.67e-01	0.36400	3.24e-01	1.66e-01	2.47e-02	2.51e-01
Regulation of PTEN mRNA translation	25	2.49e-03	1.39e-02	0.36400	-3.24e-01	1.67e-01	5.05e-03	1.49e-01
PERK regulates gene expression	32	2.53e-03	1.39e-02	0.36400	3.52e-01	9.18e-02	5.58e-04	3.69e-01
Class I peroxisomal membrane protein import	19	3.97e-02	1.22e-01	0.36400	3.07e-01	1.96e-01	2.05e-02	1.40e-01
Processing and activation of SUMO	10	1.41e-01	2.97e-01	0.36300	4.54e-02	3.61e-01	8.04e-01	4.84e-02
UCH proteinases	81	1.42e-06	1.51e-05	0.36300	2.89e-01	2.19e-01	6.64e-06	6.49e-04
Calnexin/calreticulin cycle	25	1.33e-02	4.99e-02	0.36300	1.64e-01	3.24e-01	1.56e-01	5.07e-03
G1/S Transition	126	7.44e-10	1.83e-08	0.36300	2.07e-01	2.98e-01	5.79e-05	7.69e-09
SUMOylation of immune response proteins	10	1.91e-01	3.64e-01	0.36100	2.12e-01	2.93e-01	2.47e-01	1.08e-01
Mitochondrial protein import	54	8.60e-05	7.11e-04	0.36100	1.48e-01	3.29e-01	5.94e-02	2.80e-05
Metabolism of amine-derived hormones	17	6.12e-02	1.66e-01	0.36100	-2.84e-01	-2.22e-01	4.25e-02	1.12e-01
mRNA Splicing	184	1.07e-13	5.32e-12	0.36100	2.70e-01	2.39e-01	2.56e-10	2.19e-08
TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest	18	4.77e-02	1.38e-01	0.36000	1.68e-01	3.18e-01	2.16e-01	1.95e-02
DNA Replication	125	1.50e-09	3.27e-08	0.36000	2.22e-01	2.83e-01	1.80e-05	4.64e-08
ATF6 (ATF6-alpha) activates chaperones	11	1.67e-01	3.32e-01	0.35900	2.23e-01	2.81e-01	2.00e-01	1.06e-01
RUNX3 regulates p14-ARF	10	1.68e-01	3.34e-01	0.35800	1.05e-01	3.43e-01	5.65e-01	6.07e-02
ER Quality Control Compartment (ERQC)	20	3.89e-02	1.20e-01	0.35700	2.04e-01	2.93e-01	1.14e-01	2.32e-02
Complex I biogenesis	49	4.07e-04	2.82e-03	0.35600	2.38e-01	2.66e-01	4.00e-03	1.29e-03
Nuclear import of Rev protein	32	3.36e-03	1.74e-02	0.35600	9.21e-02	3.44e-01	3.67e-01	7.63e-04
Synthesis of bile acids and bile salts via 27-hydroxycholesterol	15	9.18e-02	2.22e-01	0.35600	-2.73e-01	-2.28e-01	6.71e-02	1.26e-01
Unwinding of DNA	12	1.44e-01	3.01e-01	0.35500	1.92e-01	2.99e-01	2.50e-01	7.33e-02
NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10	12	1.24e-01	2.73e-01	0.35500	1.06e-01	3.39e-01	5.25e-01	4.23e-02
Processing of Capped Intron-Containing Pre-mRNA	232	1.94e-16	1.58e-14	0.35400	2.51e-01	2.50e-01	4.36e-11	5.31e-11
RNA Polymerase III Transcription Initiation From Type 3 Promoter	28	1.13e-02	4.45e-02	0.35400	1.94e-01	2.96e-01	7.61e-02	6.68e-03
RNA Polymerase III Transcription Initiation	36	2.89e-03	1.56e-02	0.35300	1.70e-01	3.10e-01	7.70e-02	1.29e-03
Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex	13	9.42e-02	2.26e-01	0.35300	5.92e-02	3.48e-01	7.12e-01	2.98e-02
Translation of Replicase and Assembly of the Replication Transcription Complex 9694676	14	7.24e-02	1.85e-01	0.35300	2.92e-02	3.51e-01	8.50e-01	2.28e-02
tRNA processing in the nucleus	55	1.86e-04	1.41e-03	0.35100	2.04e-01	2.86e-01	8.86e-03	2.47e-04
HIV elongation arrest and recovery	29	9.69e-03	3.99e-02	0.35100	3.07e-01	1.71e-01	4.27e-03	1.11e-01
Pausing and recovery of HIV elongation	29	9.69e-03	3.99e-02	0.35100	3.07e-01	1.71e-01	4.27e-03	1.11e-01
Mitotic G1 phase and G1/S transition	144	1.47e-10	4.54e-09	0.35100	1.86e-01	2.97e-01	1.14e-04	7.19e-10
Translesion Synthesis by POLH	19	4.89e-02	1.40e-01	0.35000	1.75e-01	3.04e-01	1.87e-01	2.19e-02
TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway	16	8.36e-02	2.07e-01	0.34900	2.86e-01	2.01e-01	4.77e-02	1.64e-01
Hormone ligand-binding receptors	13	1.03e-01	2.41e-01	0.34900	-7.37e-02	-3.41e-01	6.46e-01	3.31e-02
Base-Excision Repair, AP Site Formation	18	3.49e-02	1.12e-01	0.34900	1.64e-02	3.49e-01	9.04e-01	1.04e-02
Synthesis of DNA	118	1.41e-08	2.47e-07	0.34900	2.14e-01	2.75e-01	5.68e-05	2.36e-07
RNA Polymerase III Transcription Initiation From Type 1 Promoter	28	1.35e-02	5.05e-02	0.34900	2.11e-01	2.78e-01	5.36e-02	1.09e-02
Downstream signaling events of B Cell Receptor (BCR)	78	6.92e-06	6.48e-05	0.34900	2.62e-01	2.30e-01	6.13e-05	4.53e-04
Beta defensins	28	2.01e-03	1.14e-02	0.34800	2.96e-01	-1.83e-01	6.66e-03	9.44e-02
RNA Polymerase III Transcription Initiation From Type 2 Promoter	27	1.62e-02	5.93e-02	0.34800	2.15e-01	2.74e-01	5.33e-02	1.39e-02
Hedgehog ‘on’ state	83	3.59e-06	3.49e-05	0.34700	2.60e-01	2.30e-01	4.13e-05	2.91e-04
TNF signaling	45	1.10e-03	6.85e-03	0.34700	2.26e-01	2.63e-01	8.63e-03	2.23e-03
Inhibition of DNA recombination at telomere	20	4.56e-02	1.34e-01	0.34700	2.93e-01	1.87e-01	2.34e-02	1.49e-01
Nitric oxide stimulates guanylate cyclase	22	2.08e-02	7.36e-02	0.34700	-5.56e-02	-3.43e-01	6.52e-01	5.41e-03
Bicarbonate transporters	10	2.04e-01	3.83e-01	0.34700	-1.47e-01	-3.14e-01	4.20e-01	8.59e-02
TRAF3-dependent IRF activation pathway	15	9.54e-02	2.27e-01	0.34600	1.57e-01	3.08e-01	2.94e-01	3.88e-02
Metalloprotease DUBs	19	3.12e-02	1.01e-01	0.34500	1.67e-02	3.45e-01	9.00e-01	9.20e-03
Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants	19	5.82e-02	1.60e-01	0.34500	2.59e-01	2.28e-01	5.07e-02	8.46e-02
Signaling by Ligand-Responsive EGFR Variants in Cancer	19	5.82e-02	1.60e-01	0.34500	2.59e-01	2.28e-01	5.07e-02	8.46e-02
mRNA Splicing - Major Pathway	174	6.13e-12	2.16e-10	0.34500	2.56e-01	2.31e-01	5.63e-09	1.41e-07
Cellular response to starvation	147	3.04e-10	8.55e-09	0.34400	2.72e-01	2.12e-01	1.26e-08	9.45e-06
mRNA Splicing - Minor Pathway	51	3.69e-04	2.60e-03	0.34400	3.06e-01	1.56e-01	1.52e-04	5.37e-02
Collagen chain trimerization	42	8.62e-04	5.43e-03	0.34400	-7.76e-02	-3.35e-01	3.84e-01	1.74e-04
Antigen processing-Cross presentation	100	3.85e-07	4.51e-06	0.34400	2.56e-01	2.29e-01	9.86e-06	7.27e-05
Cleavage of the damaged pyrimidine	16	6.58e-02	1.71e-01	0.34300	6.57e-02	3.37e-01	6.49e-01	1.97e-02
Depyrimidination	16	6.58e-02	1.71e-01	0.34300	6.57e-02	3.37e-01	6.49e-01	1.97e-02
Recognition and association of DNA glycosylase with site containing an affected pyrimidine	16	6.58e-02	1.71e-01	0.34300	6.57e-02	3.37e-01	6.49e-01	1.97e-02
Lysosome Vesicle Biogenesis	33	2.93e-03	1.58e-02	0.34300	3.15e-02	3.42e-01	7.54e-01	6.82e-04
MyD88 deficiency (TLR2/4)	16	3.73e-02	1.17e-01	0.34300	-1.12e-01	3.24e-01	4.40e-01	2.47e-02
SUMOylation of transcription factors	20	4.96e-02	1.42e-01	0.34200	1.81e-01	2.90e-01	1.61e-01	2.47e-02
Fatty acids	15	5.43e-02	1.51e-01	0.34100	3.34e-01	-6.49e-02	2.49e-02	6.64e-01
TRAF6-mediated induction of TAK1 complex within TLR4 complex	15	9.33e-02	2.25e-01	0.34100	1.16e-01	3.20e-01	4.37e-01	3.17e-02
rRNA modification in the nucleus and cytosol	55	2.97e-04	2.14e-03	0.34000	1.87e-01	2.84e-01	1.66e-02	2.65e-04
Glucocorticoid biosynthesis	10	1.47e-01	3.05e-01	0.33900	6.06e-02	-3.34e-01	7.40e-01	6.74e-02
Signaling by ROBO receptors	203	1.73e-13	8.38e-12	0.33800	2.78e-01	1.93e-01	8.03e-12	2.18e-06
G2/M Checkpoints	129	8.08e-09	1.52e-07	0.33800	1.94e-01	2.77e-01	1.44e-04	5.67e-08
Alpha-protein kinase 1 signaling pathway	10	2.40e-01	4.29e-01	0.33700	2.53e-01	2.23e-01	1.66e-01	2.23e-01
IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation	14	1.24e-01	2.73e-01	0.33700	1.54e-01	3.00e-01	3.17e-01	5.22e-02
Cyclin D associated events in G1	46	1.20e-03	7.35e-03	0.33700	1.74e-01	2.89e-01	4.16e-02	6.98e-04
G1 Phase	46	1.20e-03	7.35e-03	0.33700	1.74e-01	2.89e-01	4.16e-02	6.98e-04
Transcriptional regulation by RUNX3	93	1.93e-06	1.97e-05	0.33600	2.59e-01	2.14e-01	1.57e-05	3.69e-04
Regulation of TP53 Activity through Methylation	18	7.81e-02	1.97e-01	0.33500	2.10e-01	2.61e-01	1.23e-01	5.49e-02
Response of EIF2AK1 (HRI) to heme deficiency	14	1.40e-01	2.95e-01	0.33500	2.31e-01	2.43e-01	1.35e-01	1.16e-01
Nuclear events stimulated by ALK signaling in cancer	18	6.94e-02	1.78e-01	0.33500	1.42e-01	3.03e-01	2.97e-01	2.61e-02
Degradation of beta-catenin by the destruction complex	81	1.24e-05	1.11e-04	0.33400	2.49e-01	2.23e-01	1.09e-04	5.27e-04
Diseases associated with N-glycosylation of proteins	19	4.92e-02	1.41e-01	0.33400	7.58e-02	3.25e-01	5.68e-01	1.42e-02
NEP/NS2 Interacts with the Cellular Export Machinery	30	9.05e-03	3.85e-02	0.33300	8.24e-02	3.23e-01	4.34e-01	2.20e-03
Aspartate and asparagine metabolism	11	2.12e-01	3.94e-01	0.33300	-2.74e-01	-1.89e-01	1.16e-01	2.77e-01
Regulation of signaling by NODAL	10	1.28e-01	2.78e-01	0.33200	2.44e-01	-2.25e-01	1.81e-01	2.18e-01
Reactions specific to the complex N-glycan synthesis pathway	10	2.49e-01	4.39e-01	0.33200	-2.61e-01	-2.04e-01	1.52e-01	2.63e-01
Regulation of BACH1 activity	15	1.25e-01	2.74e-01	0.33200	2.11e-01	2.56e-01	1.58e-01	8.57e-02
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	16	6.15e-02	1.66e-01	0.33200	-1.32e-02	3.31e-01	9.27e-01	2.17e-02
Downstream TCR signaling	92	1.82e-06	1.90e-05	0.33200	2.95e-01	1.52e-01	1.00e-06	1.19e-02
Export of Viral Ribonucleoproteins from Nucleus	31	9.52e-03	3.95e-02	0.33100	1.08e-01	3.13e-01	3.00e-01	2.55e-03
MET activates PTK2 signaling	18	8.00e-02	2.00e-01	0.33100	-2.81e-01	-1.75e-01	3.92e-02	2.00e-01
Processing of Intronless Pre-mRNAs	19	4.91e-02	1.41e-01	0.32900	5.20e-02	3.25e-01	6.94e-01	1.41e-02
NGF-stimulated transcription	39	4.56e-03	2.20e-02	0.32900	1.81e-01	2.75e-01	5.09e-02	2.96e-03
Interactions of Rev with host cellular proteins	35	4.72e-03	2.26e-02	0.32900	7.91e-02	3.19e-01	4.18e-01	1.08e-03
Regulation of RUNX2 expression and activity	71	6.64e-05	5.58e-04	0.32900	2.51e-01	2.13e-01	2.60e-04	1.95e-03
Keratinization	213	4.28e-14	2.45e-12	0.32800	-1.20e-01	-3.05e-01	2.52e-03	1.44e-14
Transport of Mature mRNAs Derived from Intronless Transcripts	41	1.79e-03	1.04e-02	0.32800	6.51e-02	3.21e-01	4.71e-01	3.75e-04
G1/S-Specific Transcription	28	1.48e-02	5.46e-02	0.32800	8.65e-02	3.16e-01	4.28e-01	3.81e-03
Activation of the phototransduction cascade	11	2.21e-01	4.05e-01	0.32700	-2.77e-01	-1.74e-01	1.12e-01	3.19e-01
Budding and maturation of HIV virion	28	1.28e-02	4.86e-02	0.32700	5.43e-02	3.22e-01	6.19e-01	3.17e-03
KEAP1-NFE2L2 pathway	103	9.13e-07	9.94e-06	0.32700	1.90e-01	2.66e-01	8.58e-04	3.15e-06
NS1 Mediated Effects on Host Pathways	39	3.75e-03	1.88e-02	0.32600	1.21e-01	3.03e-01	1.92e-01	1.06e-03
Transport of Mature mRNA Derived from an Intronless Transcript	40	2.21e-03	1.25e-02	0.32600	6.44e-02	3.19e-01	4.81e-01	4.71e-04
Transcriptional Regulation by E2F6	32	3.20e-03	1.70e-02	0.32500	-7.47e-02	3.17e-01	4.65e-01	1.92e-03
Metabolism of RNA	639	8.56e-37	3.31e-34	0.32500	2.39e-01	2.20e-01	3.89e-25	1.44e-21
Signaling by FLT3 ITD and TKD mutants	16	1.04e-01	2.41e-01	0.32500	1.29e-01	2.98e-01	3.70e-01	3.88e-02
Abortive elongation of HIV-1 transcript in the absence of Tat	23	4.58e-02	1.34e-01	0.32500	2.66e-01	1.86e-01	2.71e-02	1.23e-01
Host Interactions of HIV factors	122	9.88e-08	1.33e-06	0.32400	1.99e-01	2.56e-01	1.50e-04	1.01e-06
PCP/CE pathway	90	7.35e-06	6.85e-05	0.32400	2.31e-01	2.27e-01	1.52e-04	1.91e-04
Regulation of RUNX1 Expression and Activity	25	9.31e-03	3.88e-02	0.32400	-2.97e-01	1.30e-01	1.02e-02	2.62e-01
ERKs are inactivated	13	1.81e-01	3.51e-01	0.32400	2.39e-01	2.18e-01	1.36e-01	1.73e-01
Endosomal/Vacuolar pathway	12	1.58e-01	3.22e-01	0.32300	3.20e-01	4.72e-02	5.51e-02	7.77e-01
Regulation of PTEN stability and activity	66	1.87e-04	1.42e-03	0.32200	2.33e-01	2.23e-01	1.08e-03	1.71e-03
Caspase activation via Death Receptors in the presence of ligand	16	1.21e-01	2.68e-01	0.32200	2.61e-01	1.88e-01	7.02e-02	1.92e-01
Regulation of TLR by endogenous ligand	17	3.82e-02	1.19e-01	0.32200	-1.99e-01	2.52e-01	1.55e-01	7.15e-02
NoRC negatively regulates rRNA expression	43	3.09e-03	1.66e-02	0.32100	1.51e-01	2.83e-01	8.74e-02	1.29e-03
RNA Polymerase III Chain Elongation	18	9.87e-02	2.33e-01	0.32000	2.41e-01	2.11e-01	7.72e-02	1.21e-01
Regulation of NF-kappa B signaling	17	1.08e-01	2.47e-01	0.32000	2.67e-01	1.77e-01	5.71e-02	2.07e-01
E3 ubiquitin ligases ubiquitinate target proteins	43	3.62e-03	1.83e-02	0.32000	1.74e-01	2.68e-01	4.82e-02	2.34e-03
Nucleotide salvage	21	2.78e-02	9.21e-02	0.32000	-5.96e-02	3.14e-01	6.36e-01	1.27e-02
TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)	16	8.35e-02	2.07e-01	0.31900	2.00e-02	3.19e-01	8.90e-01	2.72e-02
Butyrophilin (BTN) family interactions	12	1.37e-01	2.92e-01	0.31900	3.17e-01	-3.61e-02	5.72e-02	8.29e-01
ABC transporter disorders	75	5.82e-05	4.95e-04	0.31800	2.71e-01	1.68e-01	5.06e-05	1.19e-02
Signaling by CSF3 (G-CSF)	28	2.62e-02	8.78e-02	0.31800	1.65e-01	2.72e-01	1.30e-01	1.28e-02
Protein ubiquitination	61	3.53e-04	2.50e-03	0.31800	1.61e-01	2.74e-01	2.97e-02	2.12e-04
Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer’s disease models	22	6.30e-02	1.69e-01	0.31700	2.17e-01	2.30e-01	7.74e-02	6.16e-02
Neurodegenerative Diseases	22	6.30e-02	1.69e-01	0.31700	2.17e-01	2.30e-01	7.74e-02	6.16e-02
SUMOylation of SUMOylation proteins	33	1.06e-02	4.28e-02	0.31600	9.87e-02	3.01e-01	3.26e-01	2.81e-03
FLT3 signaling in disease	28	2.22e-02	7.68e-02	0.31600	1.10e-01	2.97e-01	3.14e-01	6.59e-03
SARS-CoV-2 modulates autophagy	11	1.88e-01	3.61e-01	0.31600	1.97e-02	3.15e-01	9.10e-01	7.01e-02
RNA Pol II CTD phosphorylation and interaction with CE	26	3.81e-02	1.18e-01	0.31500	2.55e-01	1.85e-01	2.46e-02	1.02e-01
RNA Pol II CTD phosphorylation and interaction with CE during HIV infection	26	3.81e-02	1.18e-01	0.31500	2.55e-01	1.85e-01	2.46e-02	1.02e-01
B-WICH complex positively regulates rRNA expression	29	2.73e-02	9.10e-02	0.31500	2.24e-01	2.21e-01	3.67e-02	3.92e-02
TNFR1-induced NFkappaB signaling pathway	22	6.49e-02	1.70e-01	0.31500	2.09e-01	2.35e-01	8.94e-02	5.62e-02
SARS-CoV-1 Infection	134	5.60e-08	8.02e-07	0.31400	1.83e-01	2.55e-01	2.43e-04	3.45e-07
Transport of the SLBP Dependant Mature mRNA	34	9.75e-03	4.01e-02	0.31400	9.32e-02	2.99e-01	3.47e-01	2.51e-03
Selective autophagy	59	6.13e-04	3.98e-03	0.31300	1.69e-01	2.64e-01	2.49e-02	4.58e-04
E2F mediated regulation of DNA replication	20	2.62e-02	8.78e-02	0.31200	-2.18e-01	2.24e-01	9.20e-02	8.26e-02
IRAK4 deficiency (TLR2/4)	17	5.40e-02	1.51e-01	0.31200	-1.10e-01	2.92e-01	4.30e-01	3.71e-02
Transport of Ribonucleoproteins into the Host Nucleus	30	1.64e-02	5.99e-02	0.31200	8.07e-02	3.02e-01	4.44e-01	4.25e-03
Vpr-mediated nuclear import of PICs	32	8.93e-03	3.82e-02	0.31100	1.95e-02	3.11e-01	8.48e-01	2.33e-03
Transport of the SLBP independent Mature mRNA	33	1.20e-02	4.62e-02	0.31100	9.32e-02	2.97e-01	3.54e-01	3.15e-03
Cleavage of the damaged purine	11	1.44e-01	3.01e-01	0.31000	-1.62e-01	2.64e-01	3.51e-01	1.29e-01
Depurination	11	1.44e-01	3.01e-01	0.31000	-1.62e-01	2.64e-01	3.51e-01	1.29e-01
Recognition and association of DNA glycosylase with site containing an affected purine	11	1.44e-01	3.01e-01	0.31000	-1.62e-01	2.64e-01	3.51e-01	1.29e-01
Translation of Replicase and Assembly of the Replication Transcription Complex 9679504	13	1.34e-01	2.87e-01	0.30900	-3.20e-02	3.07e-01	8.42e-01	5.51e-02
Rev-mediated nuclear export of HIV RNA	33	1.09e-02	4.36e-02	0.30900	6.36e-02	3.02e-01	5.27e-01	2.65e-03
Postmitotic nuclear pore complex (NPC) reformation	26	4.04e-02	1.23e-01	0.30900	1.54e-01	2.68e-01	1.74e-01	1.81e-02
SUMOylation of DNA replication proteins	44	3.26e-03	1.72e-02	0.30900	1.02e-01	2.91e-01	2.40e-01	8.30e-04
CLEC7A (Dectin-1) signaling	96	1.10e-05	9.98e-05	0.30800	2.14e-01	2.22e-01	2.94e-04	1.66e-04
Interactions of Vpr with host cellular proteins	33	9.21e-03	3.86e-02	0.30800	3.13e-02	3.06e-01	7.56e-01	2.31e-03
Formation of HIV-1 elongation complex containing HIV-1 Tat	38	1.10e-02	4.36e-02	0.30800	2.18e-01	2.17e-01	1.99e-02	2.05e-02
HIV Transcription Elongation	38	1.10e-02	4.36e-02	0.30800	2.18e-01	2.17e-01	1.99e-02	2.05e-02
Tat-mediated elongation of the HIV-1 transcript	38	1.10e-02	4.36e-02	0.30800	2.18e-01	2.17e-01	1.99e-02	2.05e-02
FGFR1c ligand binding and activation	11	2.71e-01	4.62e-01	0.30800	2.22e-01	2.13e-01	2.03e-01	2.21e-01
Signaling by activated point mutants of FGFR1	11	2.71e-01	4.62e-01	0.30800	2.22e-01	2.13e-01	2.03e-01	2.21e-01
Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA	17	1.08e-01	2.47e-01	0.30700	2.94e-01	9.12e-02	3.61e-02	5.15e-01
Nuclear Pore Complex (NPC) Disassembly	34	8.37e-03	3.68e-02	0.30700	3.47e-02	3.05e-01	7.26e-01	2.06e-03
Negative epigenetic regulation of rRNA expression	45	3.97e-03	1.97e-02	0.30700	1.46e-01	2.70e-01	9.03e-02	1.70e-03
Energy dependent regulation of mTOR by LKB1-AMPK	28	1.24e-02	4.73e-02	0.30700	-5.41e-02	3.02e-01	6.20e-01	5.67e-03
Viral Messenger RNA Synthesis	42	6.64e-03	2.99e-02	0.30700	1.77e-01	2.50e-01	4.70e-02	4.98e-03
Interaction between L1 and Ankyrins	28	1.59e-02	5.84e-02	0.30600	7.87e-03	-3.06e-01	9.43e-01	5.01e-03
Formation of apoptosome	10	1.81e-01	3.51e-01	0.30600	2.66e-01	-1.51e-01	1.45e-01	4.08e-01
Regulation of the apoptosome activity	10	1.81e-01	3.51e-01	0.30600	2.66e-01	-1.51e-01	1.45e-01	4.08e-01
HIV Transcription Initiation	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
RNA Polymerase II HIV Promoter Escape	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
RNA Polymerase II Promoter Escape	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
RNA Polymerase II Transcription Initiation	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
RNA Polymerase II Transcription Initiation And Promoter Clearance	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
RNA Polymerase II Transcription Pre-Initiation And Promoter Opening	43	6.64e-03	2.99e-02	0.30500	2.19e-01	2.13e-01	1.31e-02	1.57e-02
Formation of TC-NER Pre-Incision Complex	51	2.61e-03	1.43e-02	0.30500	2.28e-01	2.02e-01	4.79e-03	1.25e-02
Assembly of active LPL and LIPC lipase complexes	17	5.28e-02	1.49e-01	0.30500	2.26e-01	-2.04e-01	1.06e-01	1.45e-01
Negative regulation of FGFR1 signaling	32	2.45e-02	8.42e-02	0.30400	2.14e-01	2.16e-01	3.59e-02	3.45e-02
S Phase	157	1.20e-08	2.13e-07	0.30400	1.85e-01	2.41e-01	6.42e-05	1.75e-07
SUMOylation of ubiquitinylation proteins	37	7.92e-03	3.51e-02	0.30400	7.09e-02	2.95e-01	4.55e-01	1.89e-03
The citric acid (TCA) cycle and respiratory electron transport	143	5.58e-08	8.02e-07	0.30300	1.64e-01	2.54e-01	7.08e-04	1.47e-07
NOTCH3 Activation and Transmission of Signal to the Nucleus	25	3.68e-02	1.16e-01	0.30100	2.97e-01	5.29e-02	1.02e-02	6.47e-01
Transport of Mature mRNA derived from an Intron-Containing Transcript	67	4.89e-04	3.33e-03	0.30100	1.93e-01	2.31e-01	6.34e-03	1.06e-03
Nucleotide biosynthesis	14	1.54e-01	3.18e-01	0.30000	3.95e-02	2.98e-01	7.98e-01	5.36e-02
TP53 Regulates Transcription of Death Receptors and Ligands	12	2.56e-01	4.46e-01	0.30000	1.86e-01	2.35e-01	2.64e-01	1.58e-01
VLDLR internalisation and degradation	16	1.65e-01	3.30e-01	0.30000	2.01e-01	2.22e-01	1.64e-01	1.24e-01
tRNA Aminoacylation	24	4.39e-02	1.31e-01	0.30000	5.38e-02	2.95e-01	6.48e-01	1.24e-02
Positive epigenetic regulation of rRNA expression	43	7.06e-03	3.17e-02	0.30000	1.59e-01	2.54e-01	7.14e-02	3.94e-03
Glutamate and glutamine metabolism	12	1.77e-01	3.48e-01	0.29900	-2.86e-02	2.97e-01	8.64e-01	7.45e-02
TRAF6 mediated NF-kB activation	24	6.05e-02	1.65e-01	0.29800	1.35e-01	2.66e-01	2.53e-01	2.39e-02
Negative regulation of FGFR3 signaling	28	4.21e-02	1.27e-01	0.29800	1.70e-01	2.45e-01	1.20e-01	2.48e-02
HIV Infection	216	3.08e-11	1.03e-09	0.29800	1.75e-01	2.42e-01	9.35e-06	8.93e-10
Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells	15	1.85e-01	3.57e-01	0.29800	1.77e-01	2.40e-01	2.34e-01	1.08e-01
Formation of Senescence-Associated Heterochromatin Foci (SAHF)	11	1.77e-01	3.48e-01	0.29800	-1.15e-01	2.75e-01	5.10e-01	1.15e-01
Initiation of Nuclear Envelope (NE) Reformation	18	9.45e-02	2.26e-01	0.29700	3.70e-02	2.95e-01	7.86e-01	3.03e-02
RNA Polymerase I Transcription Termination	27	5.13e-02	1.46e-01	0.29600	2.14e-01	2.05e-01	5.44e-02	6.52e-02
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	16	1.52e-01	3.14e-01	0.29500	1.09e-01	2.75e-01	4.51e-01	5.72e-02
Ketone body metabolism	10	3.35e-01	5.40e-01	0.29500	-2.26e-01	-1.89e-01	2.16e-01	3.01e-01
mRNA 3’-end processing	53	3.15e-03	1.69e-02	0.29500	2.01e-01	2.16e-01	1.15e-02	6.60e-03
IRE1alpha activates chaperones	49	2.76e-03	1.50e-02	0.29400	8.60e-02	2.82e-01	2.97e-01	6.46e-04
NOTCH4 Activation and Transmission of Signal to the Nucleus	11	2.14e-01	3.96e-01	0.29400	2.93e-01	-2.87e-02	9.24e-02	8.69e-01
Transport of Mature Transcript to Cytoplasm	76	2.36e-04	1.75e-03	0.29400	1.69e-01	2.41e-01	1.09e-02	2.78e-04
Synthesis, secretion, and inactivation of Glucose-dependent Insulinotropic Polypeptide (GIP)	12	2.65e-01	4.56e-01	0.29400	2.47e-01	1.59e-01	1.38e-01	3.41e-01
HIV Life Cycle	139	1.29e-07	1.68e-06	0.29400	1.23e-01	2.67e-01	1.20e-02	5.46e-08
Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC)	30	2.97e-02	9.74e-02	0.29400	1.03e-01	2.75e-01	3.31e-01	9.06e-03
Regulation of Glucokinase by Glucokinase Regulatory Protein	30	2.97e-02	9.74e-02	0.29400	1.03e-01	2.75e-01	3.31e-01	9.06e-03
Heme degradation	16	1.31e-01	2.82e-01	0.29400	-4.10e-02	-2.91e-01	7.77e-01	4.40e-02
KSRP (KHSRP) binds and destabilizes mRNA	17	8.68e-02	2.12e-01	0.29300	2.88e-01	-5.46e-02	3.96e-02	6.97e-01
Formation of Incision Complex in GG-NER	40	9.96e-03	4.09e-02	0.29300	1.13e-01	2.70e-01	2.15e-01	3.07e-03
TP53 Regulates Transcription of DNA Repair Genes	57	1.93e-03	1.12e-02	0.29300	2.45e-01	1.62e-01	1.40e-03	3.46e-02
Xenobiotics	24	7.56e-02	1.92e-01	0.29300	-2.00e-01	-2.14e-01	9.04e-02	6.91e-02
Transcriptional regulation by small RNAs	46	5.99e-03	2.82e-02	0.29300	1.43e-01	2.55e-01	9.24e-02	2.72e-03
Formation of HIV elongation complex in the absence of HIV Tat	40	1.34e-02	5.02e-02	0.29300	2.24e-01	1.88e-01	1.40e-02	3.95e-02
Passive transport by Aquaporins	13	2.33e-01	4.20e-01	0.29300	-1.36e-01	-2.59e-01	3.95e-01	1.06e-01
XBP1(S) activates chaperone genes	47	3.75e-03	1.88e-02	0.29200	8.07e-02	2.80e-01	3.38e-01	8.76e-04
Attenuation phase	25	6.39e-02	1.70e-01	0.29100	2.53e-01	1.44e-01	2.84e-02	2.12e-01
TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest	14	1.58e-01	3.22e-01	0.29100	3.03e-03	2.91e-01	9.84e-01	5.91e-02
STING mediated induction of host immune responses	13	2.46e-01	4.35e-01	0.29100	2.39e-01	1.67e-01	1.36e-01	2.98e-01
Negative regulation of MAPK pathway	41	9.54e-03	3.95e-02	0.29100	1.12e-01	2.68e-01	2.13e-01	2.93e-03
RNA Polymerase II Pre-transcription Events	73	4.44e-04	3.07e-03	0.29100	2.05e-01	2.06e-01	2.46e-03	2.30e-03
mRNA Capping	28	5.16e-02	1.46e-01	0.29000	2.18e-01	1.93e-01	4.63e-02	7.78e-02
Adherens junctions interactions	26	6.15e-02	1.66e-01	0.29000	-1.60e-01	-2.42e-01	1.59e-01	3.28e-02
Eicosanoid ligand-binding receptors	14	1.16e-01	2.60e-01	0.28900	-1.59e-01	2.42e-01	3.02e-01	1.17e-01
Transcription of the HIV genome	62	1.55e-03	9.14e-03	0.28900	2.05e-01	2.03e-01	5.14e-03	5.68e-03
Separation of Sister Chromatids	161	5.74e-08	8.15e-07	0.28800	1.96e-01	2.11e-01	1.75e-05	3.71e-06
Formation of the Early Elongation Complex	32	3.61e-02	1.14e-01	0.28800	2.11e-01	1.96e-01	3.92e-02	5.48e-02
Formation of the HIV-1 Early Elongation Complex	32	3.61e-02	1.14e-01	0.28800	2.11e-01	1.96e-01	3.92e-02	5.48e-02
TBC/RABGAPs	42	7.16e-03	3.19e-02	0.28700	6.20e-02	2.80e-01	4.87e-01	1.68e-03
Transcription of E2F targets under negative control by DREAM complex	19	1.32e-01	2.84e-01	0.28700	1.41e-01	2.49e-01	2.86e-01	5.99e-02
ISG15 antiviral mechanism	71	6.19e-04	4.00e-03	0.28600	1.60e-01	2.37e-01	2.00e-02	5.46e-04
Purine catabolism	17	1.38e-01	2.94e-01	0.28600	2.78e-01	6.43e-02	4.68e-02	6.46e-01
Cellular response to chemical stress	187	4.14e-09	8.54e-08	0.28600	1.62e-01	2.35e-01	1.37e-04	2.75e-08
Formation of RNA Pol II elongation complex	53	4.49e-03	2.17e-02	0.28500	2.14e-01	1.88e-01	6.91e-03	1.79e-02
RNA Polymerase II Transcription Elongation	53	4.49e-03	2.17e-02	0.28500	2.14e-01	1.88e-01	6.91e-03	1.79e-02
mRNA decay by 3’ to 5’ exoribonuclease	16	1.43e-01	3.00e-01	0.28500	2.83e-01	2.77e-02	4.97e-02	8.48e-01
MAPK6/MAPK4 signaling	89	1.11e-04	8.83e-04	0.28500	2.28e-01	1.70e-01	1.93e-04	5.62e-03
Negative regulation of FLT3	15	2.18e-01	4.01e-01	0.28400	2.18e-01	1.82e-01	1.44e-01	2.22e-01
RNA Polymerase III Abortive And Retractive Initiation	41	1.31e-02	4.94e-02	0.28300	1.26e-01	2.54e-01	1.63e-01	4.87e-03
RNA Polymerase III Transcription	41	1.31e-02	4.94e-02	0.28300	1.26e-01	2.54e-01	1.63e-01	4.87e-03
G0 and Early G1	27	5.22e-02	1.48e-01	0.28300	9.54e-02	2.67e-01	3.91e-01	1.65e-02
Purine salvage	12	2.69e-01	4.60e-01	0.28300	9.32e-02	2.67e-01	5.76e-01	1.09e-01
TP53 Regulates Metabolic Genes	83	9.69e-05	7.89e-04	0.28200	7.67e-02	2.72e-01	2.27e-01	1.85e-05
Antiviral mechanism by IFN-stimulated genes	78	3.83e-04	2.67e-03	0.28200	1.67e-01	2.28e-01	1.08e-02	5.01e-04
Cytosolic sensors of pathogen-associated DNA	60	2.51e-03	1.39e-02	0.28200	2.03e-01	1.96e-01	6.45e-03	8.63e-03
Regulated Necrosis	53	4.33e-03	2.13e-02	0.28200	1.45e-01	2.42e-01	6.83e-02	2.26e-03
Downregulation of ERBB2:ERBB3 signaling	13	2.55e-01	4.46e-01	0.28200	1.19e-01	2.55e-01	4.56e-01	1.11e-01
Epigenetic regulation of gene expression	83	8.78e-05	7.22e-04	0.28200	6.56e-02	2.74e-01	3.01e-01	1.57e-05
Processing of Capped Intronless Pre-mRNA	28	4.14e-02	1.25e-01	0.28200	5.90e-02	2.75e-01	5.89e-01	1.16e-02
Interleukin-1 signaling	109	2.07e-05	1.82e-04	0.28100	2.05e-01	1.93e-01	2.16e-04	5.05e-04
TCR signaling	112	7.91e-06	7.33e-05	0.28100	2.56e-01	1.16e-01	2.74e-06	3.39e-02
Cell Cycle Checkpoints	248	1.47e-11	5.04e-10	0.28100	1.49e-01	2.38e-01	5.04e-05	1.01e-10
Inactivation of CSF3 (G-CSF) signaling	23	1.04e-01	2.41e-01	0.28000	1.85e-01	2.11e-01	1.25e-01	8.02e-02
Nuclear Events (kinase and transcription factor activation)	60	2.14e-03	1.21e-02	0.28000	1.30e-01	2.48e-01	8.13e-02	8.85e-04
Processing of DNA double-strand break ends	61	2.01e-03	1.14e-02	0.28000	1.35e-01	2.45e-01	6.82e-02	9.18e-04
Mitotic Metaphase and Anaphase	222	3.62e-10	9.83e-09	0.27900	1.66e-01	2.25e-01	2.09e-05	7.79e-09
Elevation of cytosolic Ca2+ levels	16	9.92e-02	2.34e-01	0.27900	-2.13e-01	1.80e-01	1.40e-01	2.14e-01
Diseases associated with the TLR signaling cascade	29	2.21e-02	7.65e-02	0.27900	-6.38e-02	2.71e-01	5.52e-01	1.15e-02
Diseases of Immune System	29	2.21e-02	7.65e-02	0.27900	-6.38e-02	2.71e-01	5.52e-01	1.15e-02
HCMV Late Events	54	2.36e-03	1.32e-02	0.27900	5.24e-02	2.74e-01	5.05e-01	5.05e-04
Activation of SMO	17	1.83e-01	3.55e-01	0.27800	1.45e-01	2.38e-01	3.01e-01	8.97e-02
Late Phase of HIV Life Cycle	126	2.82e-06	2.78e-05	0.27800	1.24e-01	2.49e-01	1.58e-02	1.37e-06
Metabolism of non-coding RNA	50	4.91e-03	2.33e-02	0.27800	8.45e-02	2.64e-01	3.01e-01	1.21e-03
snRNP Assembly	50	4.91e-03	2.33e-02	0.27800	8.45e-02	2.64e-01	3.01e-01	1.21e-03
Collagen biosynthesis and modifying enzymes	65	1.47e-03	8.79e-03	0.27800	-1.31e-01	-2.45e-01	6.79e-02	6.42e-04
RNA Polymerase II Transcription Termination	62	2.52e-03	1.39e-02	0.27700	1.82e-01	2.09e-01	1.30e-02	4.39e-03
Platelet Adhesion to exposed collagen	13	2.23e-01	4.07e-01	0.27700	-2.76e-01	-2.36e-02	8.54e-02	8.83e-01
Mitotic Anaphase	221	5.85e-10	1.51e-08	0.27700	1.63e-01	2.23e-01	2.79e-05	1.06e-08
Laminin interactions	23	1.08e-01	2.47e-01	0.27600	-2.21e-01	-1.65e-01	6.60e-02	1.70e-01
IRF3-mediated induction of type I IFN	11	3.37e-01	5.42e-01	0.27600	2.41e-01	1.35e-01	1.67e-01	4.37e-01
Signaling by FGFR2 IIIa TM	19	1.58e-01	3.22e-01	0.27600	2.29e-01	1.54e-01	8.40e-02	2.45e-01
Na+/Cl- dependent neurotransmitter transporters	18	8.02e-02	2.01e-01	0.27600	2.28e-01	-1.55e-01	9.40e-02	2.54e-01
Unfolded Protein Response (UPR)	90	1.95e-04	1.47e-03	0.27500	1.86e-01	2.03e-01	2.27e-03	8.64e-04
Chemokine receptors bind chemokines	56	4.83e-04	3.31e-03	0.27500	2.46e-01	-1.23e-01	1.46e-03	1.10e-01
mTORC1-mediated signalling	23	7.61e-02	1.93e-01	0.27500	3.50e-02	2.73e-01	7.71e-01	2.36e-02
DNA Double Strand Break Response	42	1.83e-02	6.58e-02	0.27500	1.69e-01	2.17e-01	5.87e-02	1.49e-02
RNA polymerase II transcribes snRNA genes	77	5.50e-04	3.66e-03	0.27500	1.36e-01	2.38e-01	3.83e-02	2.98e-04
Nucleotide-like (purinergic) receptors	13	2.62e-01	4.53e-01	0.27400	-2.59e-01	-8.97e-02	1.05e-01	5.76e-01
WNT5A-dependent internalization of FZD4	15	2.44e-01	4.33e-01	0.27400	1.92e-01	1.95e-01	1.98e-01	1.90e-01
Regulation of TP53 Activity through Phosphorylation	88	2.35e-04	1.74e-03	0.27400	1.60e-01	2.22e-01	9.49e-03	3.09e-04
FGFR2 alternative splicing	26	8.58e-02	2.12e-01	0.27300	2.17e-01	1.67e-01	5.56e-02	1.41e-01
Interleukin-10 signaling	45	1.24e-02	4.73e-02	0.27300	2.42e-01	1.28e-01	5.03e-03	1.38e-01
p38MAPK events	13	1.82e-01	3.53e-01	0.27300	-9.28e-02	2.57e-01	5.63e-01	1.08e-01
Fanconi Anemia Pathway	36	3.19e-02	1.04e-01	0.27300	1.44e-01	2.32e-01	1.35e-01	1.60e-02
Hedgehog ‘off’ state	97	9.89e-05	8.00e-04	0.27300	2.29e-01	1.48e-01	9.48e-05	1.17e-02
Acetylcholine regulates insulin secretion	10	2.55e-01	4.46e-01	0.27200	-2.18e-01	1.62e-01	2.32e-01	3.75e-01
Regulation of IFNA/IFNB signaling	22	1.06e-01	2.44e-01	0.27100	-7.98e-02	-2.59e-01	5.17e-01	3.53e-02
FOXO-mediated transcription of cell death genes	15	2.31e-01	4.19e-01	0.27100	2.48e-01	1.09e-01	9.64e-02	4.65e-01
Phospholipase C-mediated cascade: FGFR1	16	2.11e-01	3.92e-01	0.27100	2.46e-01	1.12e-01	8.82e-02	4.36e-01
MTOR signalling	40	8.49e-03	3.71e-02	0.27100	-3.16e-02	2.69e-01	7.30e-01	3.27e-03
Nuclear Envelope Breakdown	50	3.52e-03	1.79e-02	0.27000	1.82e-03	2.70e-01	9.82e-01	9.65e-04
Oncogene Induced Senescence	35	3.49e-02	1.12e-01	0.26900	1.16e-01	2.43e-01	2.36e-01	1.27e-02
RAF-independent MAPK1/3 activation	22	1.28e-01	2.78e-01	0.26900	2.30e-01	1.40e-01	6.19e-02	2.54e-01
Tryptophan catabolism	12	3.12e-01	5.14e-01	0.26900	-2.48e-01	-1.04e-01	1.37e-01	5.33e-01
Cargo concentration in the ER	32	2.13e-02	7.46e-02	0.26700	-5.47e-02	2.62e-01	5.92e-01	1.03e-02
VEGFR2 mediated vascular permeability	26	4.24e-02	1.27e-01	0.26700	-2.59e-01	6.53e-02	2.22e-02	5.65e-01
Protein localization	147	1.74e-06	1.83e-05	0.26700	1.54e-01	2.18e-01	1.27e-03	4.85e-06
FGFR1 ligand binding and activation	15	2.47e-01	4.36e-01	0.26600	2.40e-01	1.15e-01	1.08e-01	4.40e-01
Regulation of TP53 Activity through Association with Co-factors	14	1.87e-01	3.60e-01	0.26600	-2.59e-01	6.02e-02	9.34e-02	6.97e-01
RNA Polymerase I Promoter Escape	28	8.36e-02	2.07e-01	0.26600	1.99e-01	1.77e-01	6.89e-02	1.06e-01
SUMOylation of chromatin organization proteins	54	2.34e-03	1.31e-02	0.26500	-1.90e-02	2.64e-01	8.09e-01	7.86e-04
RUNX3 regulates NOTCH signaling	13	3.07e-01	5.08e-01	0.26500	2.30e-01	1.31e-01	1.51e-01	4.12e-01
Trafficking and processing of endosomal TLR	11	3.55e-01	5.60e-01	0.26500	1.00e-01	2.45e-01	5.65e-01	1.60e-01
NOTCH2 intracellular domain regulates transcription	11	3.82e-01	5.87e-01	0.26400	1.81e-01	1.93e-01	2.99e-01	2.68e-01
Cytochrome c-mediated apoptotic response	12	2.13e-01	3.96e-01	0.26400	2.16e-01	-1.51e-01	1.94e-01	3.64e-01
Ub-specific processing proteases	153	1.51e-06	1.60e-05	0.26400	1.61e-01	2.09e-01	5.65e-04	8.07e-06
HSF1 activation	27	9.34e-02	2.25e-01	0.26400	2.06e-01	1.65e-01	6.34e-02	1.39e-01
SUMOylation of RNA binding proteins	45	1.05e-02	4.23e-02	0.26400	4.49e-02	2.60e-01	6.02e-01	2.53e-03
Signaling by NOTCH3	48	1.04e-02	4.22e-02	0.26300	2.50e-01	8.36e-02	2.77e-03	3.16e-01
Mitotic G2-G2/M phases	177	2.21e-07	2.74e-06	0.26300	1.62e-01	2.06e-01	1.90e-04	2.12e-06
Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks	41	2.88e-02	9.50e-02	0.26200	1.70e-01	2.00e-01	6.00e-02	2.66e-02
Constitutive Signaling by NOTCH1 HD Domain Mutants	15	2.18e-01	4.01e-01	0.26200	2.60e-01	3.61e-02	8.16e-02	8.08e-01
Signaling by NOTCH1 HD Domain Mutants in Cancer	15	2.18e-01	4.01e-01	0.26200	2.60e-01	3.61e-02	8.16e-02	8.08e-01
Signaling by WNT in cancer	32	1.72e-02	6.23e-02	0.26200	-1.59e-01	2.08e-01	1.21e-01	4.14e-02
MET activates RAP1 and RAC1	11	2.50e-01	4.39e-01	0.26200	-2.19e-01	1.43e-01	2.07e-01	4.13e-01
HDL remodeling	10	3.97e-01	5.99e-01	0.26200	-9.68e-02	-2.43e-01	5.96e-01	1.83e-01
Endosomal Sorting Complex Required For Transport (ESCRT)	31	4.43e-02	1.32e-01	0.26200	3.86e-02	2.59e-01	7.10e-01	1.26e-02
SHC-mediated cascade:FGFR3	17	1.97e-01	3.75e-01	0.26100	6.99e-02	2.52e-01	6.18e-01	7.25e-02
G2/M Transition	175	3.27e-07	3.89e-06	0.26100	1.61e-01	2.05e-01	2.41e-04	2.74e-06
Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA	17	1.69e-01	3.35e-01	0.26000	2.60e-01	3.41e-03	6.37e-02	9.81e-01
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	35	4.65e-02	1.36e-01	0.25900	1.24e-01	2.28e-01	2.05e-01	1.95e-02
Negative regulators of DDX58/IFIH1 signaling	34	4.51e-02	1.33e-01	0.25900	9.00e-02	2.43e-01	3.64e-01	1.42e-02
tRNA processing	98	2.39e-04	1.76e-03	0.25900	1.47e-01	2.13e-01	1.20e-02	2.62e-04
SHC-mediated cascade:FGFR1	21	1.70e-01	3.36e-01	0.25900	1.56e-01	2.06e-01	2.15e-01	1.02e-01
FGFR2c ligand binding and activation	12	3.66e-01	5.72e-01	0.25800	1.60e-01	2.02e-01	3.38e-01	2.25e-01
Signaling by FGFR2	72	2.55e-03	1.40e-02	0.25800	1.85e-01	1.79e-01	6.62e-03	8.57e-03
Transcriptional regulation of pluripotent stem cells	30	2.52e-02	8.60e-02	0.25700	-1.62e-01	2.00e-01	1.25e-01	5.82e-02
DNA Damage/Telomere Stress Induced Senescence	28	6.39e-02	1.70e-01	0.25700	3.01e-02	2.55e-01	7.83e-01	1.94e-02
Transcriptional Regulation by VENTX	41	1.57e-02	5.75e-02	0.25600	2.67e-03	2.56e-01	9.76e-01	4.61e-03
ZBP1(DAI) mediated induction of type I IFNs	20	1.95e-01	3.72e-01	0.25500	1.92e-01	1.68e-01	1.38e-01	1.92e-01
Organic anion transporters	10	3.02e-01	5.01e-01	0.25500	1.38e-01	-2.15e-01	4.50e-01	2.40e-01
TAK1-dependent IKK and NF-kappa-B activation	41	3.59e-02	1.14e-01	0.25300	1.54e-01	2.01e-01	8.80e-02	2.57e-02
Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol	24	1.24e-01	2.73e-01	0.25300	-2.37e-01	-9.04e-02	4.48e-02	4.43e-01
NOTCH3 Intracellular Domain Regulates Transcription	24	1.41e-01	2.98e-01	0.25300	2.08e-01	1.45e-01	7.82e-02	2.20e-01
Detoxification of Reactive Oxygen Species	35	6.05e-02	1.65e-01	0.25300	1.81e-01	1.77e-01	6.35e-02	7.06e-02
Phase 0 - rapid depolarisation	31	3.48e-02	1.12e-01	0.25300	5.71e-02	-2.46e-01	5.82e-01	1.76e-02
Negative regulation of FGFR4 signaling	30	8.83e-02	2.15e-01	0.25300	1.48e-01	2.05e-01	1.60e-01	5.23e-02
Regulation of glycolysis by fructose 2,6-bisphosphate metabolism	11	3.51e-01	5.57e-01	0.25300	2.78e-02	2.51e-01	8.73e-01	1.49e-01
HDR through MMEJ (alt-NHEJ)	11	3.63e-01	5.69e-01	0.25200	4.79e-02	2.48e-01	7.83e-01	1.55e-01
Cell recruitment (pro-inflammatory response)	25	1.12e-01	2.54e-01	0.25200	7.88e-02	2.40e-01	4.95e-01	3.81e-02
Purinergic signaling in leishmaniasis infection	25	1.12e-01	2.54e-01	0.25200	7.88e-02	2.40e-01	4.95e-01	3.81e-02
Branched-chain amino acid catabolism	20	1.55e-01	3.19e-01	0.25200	3.82e-02	2.49e-01	7.67e-01	5.37e-02
Deposition of new CENPA-containing nucleosomes at the centromere	26	1.04e-01	2.41e-01	0.25200	8.07e-02	2.39e-01	4.76e-01	3.52e-02
Nucleosome assembly	26	1.04e-01	2.41e-01	0.25200	8.07e-02	2.39e-01	4.76e-01	3.52e-02
Fertilization	26	7.98e-02	2.00e-01	0.25200	-9.25e-03	-2.51e-01	9.35e-01	2.65e-02
POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation	12	2.58e-01	4.49e-01	0.25200	-2.30e-01	1.02e-01	1.68e-01	5.42e-01
Signaling by EGFR in Cancer	25	1.28e-01	2.78e-01	0.25100	1.17e-01	2.22e-01	3.12e-01	5.47e-02
Synthesis of PIPs at the late endosome membrane	10	3.11e-01	5.12e-01	0.25000	-1.87e-01	1.66e-01	3.06e-01	3.62e-01
Ovarian tumor domain proteases	36	4.03e-02	1.23e-01	0.25000	5.50e-02	2.44e-01	5.68e-01	1.13e-02
G2/M DNA damage checkpoint	58	7.17e-03	3.19e-02	0.25000	8.37e-02	2.35e-01	2.70e-01	1.92e-03
Activation of PPARGC1A (PGC-1alpha) by phosphorylation	10	4.22e-01	6.25e-01	0.24900	7.34e-02	2.38e-01	6.88e-01	1.92e-01
DNA Damage Bypass	46	1.92e-02	6.84e-02	0.24900	7.13e-02	2.38e-01	4.03e-01	5.16e-03
Acyl chain remodelling of PI	16	1.75e-01	3.46e-01	0.24800	8.89e-02	-2.32e-01	5.38e-01	1.08e-01
Mitochondrial tRNA aminoacylation	18	2.22e-01	4.05e-01	0.24800	8.50e-02	2.33e-01	5.32e-01	8.72e-02
The NLRP3 inflammasome	16	2.49e-01	4.39e-01	0.24800	6.07e-02	2.40e-01	6.74e-01	9.62e-02
Biosynthesis of specialized proresolving mediators (SPMs)	19	1.16e-01	2.60e-01	0.24800	-1.45e-01	2.00e-01	2.73e-01	1.30e-01
Induction of Cell-Cell Fusion	12	3.88e-01	5.92e-01	0.24800	-1.29e-01	-2.12e-01	4.41e-01	2.04e-01
NOTCH4 Intracellular Domain Regulates Transcription	19	2.32e-01	4.19e-01	0.24800	1.64e-01	1.86e-01	2.16e-01	1.61e-01
Inhibition of replication initiation of damaged DNA by RB1/E2F1	11	3.67e-01	5.72e-01	0.24700	2.73e-02	2.46e-01	8.75e-01	1.58e-01
RHOJ GTPase cycle	51	8.98e-03	3.83e-02	0.24700	-2.46e-01	-1.58e-02	2.34e-03	8.45e-01
Toll Like Receptor 3 (TLR3) Cascade	99	3.73e-04	2.61e-03	0.24600	1.07e-01	2.22e-01	6.58e-02	1.37e-04
Apoptotic factor-mediated response	17	2.38e-01	4.27e-01	0.24600	2.36e-01	6.90e-02	9.16e-02	6.22e-01
Signaling by FGFR3	39	4.73e-02	1.38e-01	0.24600	1.23e-01	2.13e-01	1.84e-01	2.13e-02
Free fatty acids regulate insulin secretion	10	3.85e-01	5.89e-01	0.24600	-2.46e-01	7.55e-03	1.78e-01	9.67e-01
Recognition of DNA damage by PCNA-containing replication complex	29	9.95e-02	2.34e-01	0.24500	1.04e-01	2.22e-01	3.31e-01	3.85e-02
PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases	14	2.17e-01	4.01e-01	0.24400	-2.09e-01	1.26e-01	1.76e-01	4.13e-01
Diseases associated with visual transduction	11	4.40e-01	6.39e-01	0.24400	-1.76e-01	-1.69e-01	3.13e-01	3.31e-01
Diseases of the neuronal system	11	4.40e-01	6.39e-01	0.24400	-1.76e-01	-1.69e-01	3.13e-01	3.31e-01
Retinoid cycle disease events	11	4.40e-01	6.39e-01	0.24400	-1.76e-01	-1.69e-01	3.13e-01	3.31e-01
Recycling of bile acids and salts	18	2.60e-01	4.51e-01	0.24300	-1.43e-01	-1.97e-01	2.94e-01	1.49e-01
Negative regulation of FGFR2 signaling	33	8.62e-02	2.12e-01	0.24300	1.53e-01	1.88e-01	1.27e-01	6.11e-02
HSF1-dependent transactivation	35	6.52e-02	1.70e-01	0.24200	2.21e-01	9.95e-02	2.37e-02	3.08e-01
FCGR activation	12	2.75e-01	4.66e-01	0.24200	1.29e-01	-2.05e-01	4.38e-01	2.19e-01
TP53 Regulates Transcription of Cell Death Genes	42	2.78e-02	9.21e-02	0.24200	4.15e-02	2.39e-01	6.42e-01	7.45e-03
Cellular Senescence	130	1.58e-05	1.40e-04	0.24200	3.93e-02	2.39e-01	4.39e-01	2.60e-06
Paracetamol ADME	27	1.21e-01	2.68e-01	0.24100	-2.22e-01	-9.38e-02	4.54e-02	3.99e-01
Cyclin A/B1/B2 associated events during G2/M transition	24	1.51e-01	3.12e-01	0.24100	8.43e-02	2.26e-01	4.75e-01	5.55e-02
Chylomicron remodeling	10	4.23e-01	6.25e-01	0.24000	-2.52e-02	-2.39e-01	8.90e-01	1.91e-01
RHO GTPases Activate WASPs and WAVEs	34	8.46e-02	2.09e-01	0.23900	1.94e-01	1.40e-01	5.03e-02	1.57e-01
Metabolism of cofactors	19	2.17e-01	4.01e-01	0.23800	5.58e-02	2.31e-01	6.74e-01	8.07e-02
RNA Polymerase I Transcription	47	2.99e-02	9.77e-02	0.23800	1.03e-01	2.14e-01	2.21e-01	1.10e-02
ALK mutants bind TKIs	12	3.33e-01	5.39e-01	0.23800	-2.37e-01	2.38e-02	1.56e-01	8.86e-01
HDACs deacetylate histones	29	9.01e-02	2.18e-01	0.23700	3.30e-02	2.35e-01	7.59e-01	2.85e-02
Mitotic Telophase/Cytokinesis	10	3.76e-01	5.80e-01	0.23700	-7.56e-02	2.24e-01	6.79e-01	2.20e-01
RNA Polymerase I Promoter Clearance	46	3.42e-02	1.10e-01	0.23700	1.06e-01	2.11e-01	2.12e-01	1.31e-02
Regulation of FZD by ubiquitination	21	1.95e-01	3.72e-01	0.23600	6.50e-02	2.27e-01	6.06e-01	7.18e-02
Regulation of PTEN gene transcription	59	6.15e-03	2.86e-02	0.23600	2.83e-03	2.36e-01	9.70e-01	1.71e-03
Mitotic Prophase	78	1.29e-03	7.79e-03	0.23600	7.41e-03	2.36e-01	9.10e-01	3.21e-04
activated TAK1 mediates p38 MAPK activation	16	2.55e-01	4.46e-01	0.23600	7.77e-03	2.35e-01	9.57e-01	1.03e-01
Cell Cycle, Mitotic	476	1.52e-15	1.12e-13	0.23500	1.04e-01	2.11e-01	9.16e-05	2.76e-15
Signaling by NOTCH2	32	1.01e-01	2.36e-01	0.23500	2.04e-01	1.17e-01	4.53e-02	2.53e-01
HCMV Infection	79	1.33e-03	8.02e-03	0.23500	1.50e-02	2.35e-01	8.18e-01	3.11e-04
M Phase	335	4.01e-11	1.29e-09	0.23500	1.07e-01	2.09e-01	7.23e-04	4.62e-11
Defensins	36	2.79e-02	9.23e-02	0.23500	2.10e-01	-1.06e-01	2.95e-02	2.72e-01
Thromboxane signalling through TP receptor	24	1.02e-01	2.38e-01	0.23500	-6.77e-02	2.25e-01	5.66e-01	5.68e-02
Cellular responses to stress	682	7.37e-21	1.42e-18	0.23400	1.34e-01	1.92e-01	1.94e-09	1.16e-17
Global Genome Nucleotide Excision Repair (GG-NER)	81	3.44e-03	1.76e-02	0.23400	1.22e-01	1.99e-01	5.69e-02	1.95e-03
Signaling by BMP	27	9.72e-02	2.31e-01	0.23300	1.04e-02	-2.33e-01	9.26e-01	3.60e-02
Translocation of ZAP-70 to Immunological synapse	17	1.78e-01	3.49e-01	0.23300	1.72e-01	-1.58e-01	2.20e-01	2.60e-01
HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand	37	6.45e-02	1.70e-01	0.23300	2.19e-01	7.99e-02	2.10e-02	4.00e-01
Neutrophil degranulation	458	2.19e-17	2.25e-15	0.23300	-3.03e-03	2.33e-01	9.11e-01	1.07e-17
MyD88-independent TLR4 cascade	103	5.27e-04	3.54e-03	0.23300	8.22e-02	2.18e-01	1.50e-01	1.33e-04
TRIF(TICAM1)-mediated TLR4 signaling	103	5.27e-04	3.54e-03	0.23300	8.22e-02	2.18e-01	1.50e-01	1.33e-04
FGFR2 mutant receptor activation	32	1.06e-01	2.44e-01	0.23300	2.02e-01	1.15e-01	4.75e-02	2.60e-01
Pre-NOTCH Processing in Golgi	18	1.65e-01	3.31e-01	0.23300	-1.33e-01	1.91e-01	3.28e-01	1.61e-01
ABC-family proteins mediated transport	98	1.19e-03	7.35e-03	0.23300	1.92e-01	1.32e-01	1.05e-03	2.38e-02
Signaling by FGFR4	40	6.31e-02	1.69e-01	0.23200	1.26e-01	1.95e-01	1.67e-01	3.27e-02
Plasma lipoprotein remodeling	32	6.11e-02	1.66e-01	0.23200	2.30e-02	-2.31e-01	8.22e-01	2.36e-02
Diseases associated with O-glycosylation of proteins	66	1.17e-02	4.52e-02	0.23200	-1.57e-01	-1.71e-01	2.74e-02	1.63e-02
Activation of HOX genes during differentiation	61	9.24e-03	3.86e-02	0.23200	4.87e-02	2.26e-01	5.11e-01	2.21e-03
Activation of anterior HOX genes in hindbrain development during early embryogenesis	61	9.24e-03	3.86e-02	0.23200	4.87e-02	2.26e-01	5.11e-01	2.21e-03
Signal amplification	33	3.94e-02	1.22e-01	0.23100	-1.21e-01	1.97e-01	2.28e-01	5.02e-02
Cellular responses to stimuli	696	1.11e-20	1.91e-18	0.23100	1.34e-01	1.88e-01	1.72e-09	2.04e-17
Cytosolic sulfonation of small molecules	21	1.26e-01	2.75e-01	0.23000	-1.74e-01	1.50e-01	1.66e-01	2.33e-01
Maturation of nucleoprotein 9683610	11	3.47e-01	5.53e-01	0.23000	1.13e-01	-2.00e-01	5.18e-01	2.50e-01
COPII-mediated vesicle transport	66	4.46e-03	2.17e-02	0.23000	-8.74e-05	2.30e-01	9.99e-01	1.26e-03
Nucleotide Excision Repair	107	8.65e-04	5.43e-03	0.22900	1.50e-01	1.73e-01	7.21e-03	1.93e-03
Cytoprotection by HMOX1	58	1.53e-02	5.62e-02	0.22900	7.24e-02	2.17e-01	3.40e-01	4.18e-03
Nuclear Envelope (NE) Reassembly	73	6.09e-03	2.85e-02	0.22900	9.16e-02	2.10e-01	1.76e-01	1.92e-03
Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein	74	4.77e-03	2.28e-02	0.22900	7.02e-02	2.18e-01	2.97e-01	1.18e-03
Telomere Extension By Telomerase	22	2.17e-01	4.01e-01	0.22900	9.44e-02	2.08e-01	4.43e-01	9.10e-02
Transcriptional Regulation by TP53	346	3.78e-11	1.24e-09	0.22800	8.58e-02	2.12e-01	6.06e-03	1.24e-11
Chromosome Maintenance	86	3.31e-03	1.74e-02	0.22800	1.22e-01	1.93e-01	5.09e-02	2.02e-03
Macroautophagy	111	3.09e-04	2.21e-03	0.22800	5.77e-02	2.20e-01	2.94e-01	6.03e-05
Nephrin family interactions	21	2.38e-01	4.27e-01	0.22800	-9.87e-02	-2.05e-01	4.34e-01	1.04e-01
SUMOylation of intracellular receptors	29	6.16e-02	1.66e-01	0.22800	-1.41e-01	1.79e-01	1.89e-01	9.59e-02
RIP-mediated NFkB activation via ZBP1	16	3.53e-01	5.58e-01	0.22700	1.41e-01	1.78e-01	3.28e-01	2.17e-01
Biosynthesis of DHA-derived SPMs	17	2.03e-01	3.81e-01	0.22700	-1.13e-01	1.97e-01	4.19e-01	1.60e-01
Transcriptional regulation by RUNX2	116	5.84e-04	3.84e-03	0.22700	1.57e-01	1.63e-01	3.43e-03	2.36e-03
MET promotes cell motility	29	1.42e-01	2.98e-01	0.22700	-2.02e-01	-1.03e-01	5.96e-02	3.39e-01
HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA)	93	1.66e-03	9.68e-03	0.22600	8.47e-02	2.10e-01	1.58e-01	4.64e-04
RHOV GTPase cycle	36	5.72e-02	1.58e-01	0.22600	-2.26e-01	-1.68e-03	1.88e-02	9.86e-01
Autophagy	125	1.09e-04	8.75e-04	0.22600	4.71e-02	2.21e-01	3.63e-01	1.95e-05
FRS-mediated FGFR1 signaling	23	2.30e-01	4.18e-01	0.22600	1.58e-01	1.61e-01	1.89e-01	1.81e-01
Dual Incision in GG-NER	39	6.71e-02	1.73e-01	0.22600	7.85e-02	2.12e-01	3.96e-01	2.21e-02
mitochondrial fatty acid beta-oxidation of saturated fatty acids	11	3.84e-01	5.89e-01	0.22600	-5.56e-02	2.19e-01	7.49e-01	2.09e-01
MET receptor recycling	10	3.87e-01	5.91e-01	0.22600	-1.55e-01	1.64e-01	3.97e-01	3.68e-01
Cell Cycle	601	6.69e-18	7.96e-16	0.22500	9.60e-02	2.04e-01	5.63e-05	1.09e-17
Homology Directed Repair	99	1.27e-03	7.69e-03	0.22500	9.19e-02	2.06e-01	1.14e-01	4.02e-04
Activation of the pre-replicative complex	31	9.37e-02	2.25e-01	0.22500	1.92e-02	2.24e-01	8.53e-01	3.06e-02
Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation	10	5.14e-01	7.05e-01	0.22500	1.01e-01	2.01e-01	5.81e-01	2.70e-01
RHOBTB1 GTPase cycle	22	2.40e-01	4.29e-01	0.22500	1.20e-01	1.90e-01	3.29e-01	1.23e-01
Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template	38	7.26e-02	1.86e-01	0.22500	7.59e-02	2.12e-01	4.18e-01	2.38e-02
Transcriptional regulation of white adipocyte differentiation	81	3.68e-03	1.85e-02	0.22400	7.03e-02	2.13e-01	2.74e-01	9.08e-04
Condensation of Prophase Chromosomes	12	3.73e-01	5.77e-01	0.22400	-2.73e-02	2.23e-01	8.70e-01	1.82e-01
Translesion synthesis by POLI	17	3.42e-01	5.48e-01	0.22400	1.70e-01	1.47e-01	2.26e-01	2.95e-01
Signaling by the B Cell Receptor (BCR)	105	1.38e-03	8.28e-03	0.22400	1.59e-01	1.58e-01	4.81e-03	5.22e-03
Activation of ATR in response to replication stress	37	7.87e-02	1.98e-01	0.22400	7.25e-02	2.12e-01	4.45e-01	2.57e-02
Metabolism of amino acids and derivatives	344	4.55e-10	1.21e-08	0.22400	1.79e-01	1.34e-01	1.06e-08	2.00e-05
DNA Repair	276	1.62e-08	2.82e-07	0.22300	9.87e-02	2.00e-01	4.74e-03	9.87e-09
Telomere Maintenance	62	2.10e-02	7.40e-02	0.22300	1.45e-01	1.69e-01	4.78e-02	2.13e-02
ERBB2 Activates PTK6 Signaling	13	3.02e-01	5.01e-01	0.22300	1.42e-01	-1.72e-01	3.77e-01	2.84e-01
Cellular response to heat stress	95	2.71e-03	1.48e-02	0.22200	1.38e-01	1.74e-01	2.00e-02	3.31e-03
MAP3K8 (TPL2)-dependent MAPK1/3 activation	15	3.92e-01	5.95e-01	0.22200	1.35e-01	1.76e-01	3.65e-01	2.37e-01
RAB geranylgeranylation	57	2.48e-02	8.51e-02	0.22200	9.43e-02	2.00e-01	2.18e-01	8.84e-03
Chaperone Mediated Autophagy	19	2.58e-01	4.49e-01	0.22100	2.18e-01	3.85e-02	9.98e-02	7.71e-01
NOTCH1 Intracellular Domain Regulates Transcription	44	4.15e-02	1.25e-01	0.22100	2.71e-02	2.19e-01	7.56e-01	1.19e-02
Signaling by FLT3 fusion proteins	19	2.00e-01	3.77e-01	0.22000	-7.15e-02	2.08e-01	5.90e-01	1.16e-01
PTEN Regulation	150	2.93e-05	2.56e-04	0.22000	4.36e-02	2.16e-01	3.56e-01	4.90e-06
Activated NTRK2 signals through FRS2 and FRS3	11	4.96e-01	6.93e-01	0.22000	9.78e-02	1.97e-01	5.74e-01	2.57e-01
Uptake and function of anthrax toxins	11	3.98e-01	5.99e-01	0.22000	-2.10e-01	6.48e-02	2.27e-01	7.10e-01
Impaired BRCA2 binding to RAD51	33	1.27e-01	2.77e-01	0.22000	1.10e-01	1.90e-01	2.72e-01	5.86e-02
Miscellaneous substrates	12	3.49e-01	5.55e-01	0.22000	1.94e-01	-1.04e-01	2.45e-01	5.33e-01
Deubiquitination	226	8.14e-07	9.10e-06	0.22000	1.11e-01	1.90e-01	4.16e-03	8.29e-07
Chondroitin sulfate biosynthesis	18	2.03e-01	3.81e-01	0.22000	-1.21e-01	1.83e-01	3.74e-01	1.78e-01
Tie2 Signaling	18	1.99e-01	3.77e-01	0.21900	-1.64e-01	1.46e-01	2.29e-01	2.84e-01
Inflammasomes	21	2.73e-01	4.65e-01	0.21900	1.14e-01	1.87e-01	3.67e-01	1.38e-01
Neddylation	228	1.12e-06	1.21e-05	0.21900	1.32e-01	1.75e-01	5.83e-04	5.49e-06
Regulation of HSF1-mediated heat shock response	78	8.90e-03	3.82e-02	0.21900	1.30e-01	1.76e-01	4.70e-02	7.17e-03
FGFR2 ligand binding and activation	19	2.98e-01	4.96e-01	0.21900	2.00e-01	8.93e-02	1.32e-01	5.00e-01
NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux	43	3.66e-02	1.15e-01	0.21800	-2.17e-01	2.01e-02	1.36e-02	8.20e-01
Signaling by Hedgehog	133	3.69e-04	2.60e-03	0.21800	1.62e-01	1.46e-01	1.26e-03	3.60e-03
alpha-linolenic (omega3) and linoleic (omega6) acid metabolism	12	3.87e-01	5.91e-01	0.21800	-3.95e-02	2.14e-01	8.13e-01	1.99e-01
alpha-linolenic acid (ALA) metabolism	12	3.87e-01	5.91e-01	0.21800	-3.95e-02	2.14e-01	8.13e-01	1.99e-01
Collagen formation	88	4.41e-03	2.16e-02	0.21800	-1.02e-01	-1.92e-01	9.82e-02	1.82e-03
CD28 dependent Vav1 pathway	11	4.68e-01	6.69e-01	0.21700	2.14e-01	3.62e-02	2.18e-01	8.35e-01
RHO GTPases activate IQGAPs	11	4.44e-01	6.42e-01	0.21700	-2.17e-01	1.97e-03	2.12e-01	9.91e-01
Synthesis of bile acids and bile salts	34	1.16e-01	2.60e-01	0.21700	-2.01e-01	-8.20e-02	4.25e-02	4.08e-01
Initial triggering of complement	21	1.61e-01	3.24e-01	0.21700	1.28e-01	-1.75e-01	3.11e-01	1.64e-01
RORA activates gene expression	17	2.25e-01	4.10e-01	0.21700	-1.64e-01	1.42e-01	2.42e-01	3.10e-01
HDR through Single Strand Annealing (SSA)	36	1.08e-01	2.47e-01	0.21700	9.53e-02	1.95e-01	3.23e-01	4.31e-02
Interleukin-2 signaling	11	4.36e-01	6.36e-01	0.21700	2.16e-01	-1.78e-02	2.15e-01	9.19e-01
Interleukin-12 signaling	43	6.68e-02	1.73e-01	0.21600	8.22e-02	2.00e-01	3.51e-01	2.31e-02
Collagen degradation	39	1.01e-01	2.37e-01	0.21600	-1.40e-01	-1.65e-01	1.29e-01	7.54e-02
RNA Polymerase I Transcription Initiation	42	7.75e-02	1.96e-01	0.21600	1.01e-01	1.91e-01	2.58e-01	3.22e-02
Regulation of TP53 Expression and Degradation	37	1.07e-01	2.45e-01	0.21600	1.05e-01	1.88e-01	2.67e-01	4.74e-02
Thrombin signalling through proteinase activated receptors (PARs)	32	8.64e-02	2.12e-01	0.21500	-3.43e-02	2.12e-01	7.37e-01	3.76e-02
Binding and Uptake of Ligands by Scavenger Receptors	41	8.92e-02	2.17e-01	0.21500	-1.19e-01	-1.79e-01	1.88e-01	4.71e-02
NOTCH2 Activation and Transmission of Signal to the Nucleus	22	2.55e-01	4.46e-01	0.21500	1.99e-01	8.19e-02	1.07e-01	5.06e-01
Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways	49	4.03e-02	1.23e-01	0.21500	4.95e-02	2.09e-01	5.49e-01	1.13e-02
Interconversion of nucleotide di- and triphosphates	29	1.18e-01	2.63e-01	0.21500	-1.40e-02	2.14e-01	8.96e-01	4.57e-02
Translesion synthesis by REV1	16	3.95e-01	5.96e-01	0.21400	1.29e-01	1.71e-01	3.72e-01	2.35e-01
RHO GTPases Activate NADPH Oxidases	22	1.57e-01	3.21e-01	0.21300	-1.33e-01	1.66e-01	2.79e-01	1.78e-01
Glycogen storage diseases	14	4.48e-01	6.46e-01	0.21200	1.22e-01	1.74e-01	4.29e-01	2.60e-01
FGFR1 mutant receptor activation	30	1.65e-01	3.31e-01	0.21200	8.56e-02	1.94e-01	4.17e-01	6.55e-02
Polymerase switching on the C-strand of the telomere	24	2.07e-01	3.87e-01	0.21200	3.60e-02	2.09e-01	7.60e-01	7.61e-02
Prefoldin mediated transfer of substrate to CCT/TriC	27	1.62e-01	3.26e-01	0.21200	2.11e-01	2.08e-02	5.77e-02	8.51e-01
Phospholipase C-mediated cascade; FGFR3	12	5.09e-01	7.02e-01	0.21200	1.54e-01	1.46e-01	3.56e-01	3.81e-01
Regulation of commissural axon pathfinding by SLIT and ROBO	10	5.45e-01	7.28e-01	0.21100	-7.24e-02	-1.98e-01	6.92e-01	2.77e-01
Translesion synthesis by POLK	17	3.76e-01	5.80e-01	0.21100	1.06e-01	1.82e-01	4.48e-01	1.94e-01
Depolymerisation of the Nuclear Lamina	14	3.49e-01	5.55e-01	0.21100	-4.80e-02	2.05e-01	7.56e-01	1.84e-01
Defective HDR through Homologous Recombination (HRR) due to BRCA1 loss-of-function	23	2.79e-01	4.69e-01	0.21000	1.38e-01	1.58e-01	2.51e-01	1.88e-01
Defective HDR through Homologous Recombination (HRR) due to PALB2 loss of function	23	2.79e-01	4.69e-01	0.21000	1.38e-01	1.58e-01	2.51e-01	1.88e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function	23	2.79e-01	4.69e-01	0.21000	1.38e-01	1.58e-01	2.51e-01	1.88e-01
Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function	23	2.79e-01	4.69e-01	0.21000	1.38e-01	1.58e-01	2.51e-01	1.88e-01
Impaired BRCA2 binding to PALB2	23	2.79e-01	4.69e-01	0.21000	1.38e-01	1.58e-01	2.51e-01	1.88e-01
TP53 Regulates Transcription of Cell Cycle Genes	49	4.40e-02	1.31e-01	0.21000	3.87e-02	2.06e-01	6.39e-01	1.24e-02
Regulation of TP53 Degradation	36	1.21e-01	2.68e-01	0.21000	8.49e-02	1.92e-01	3.78e-01	4.63e-02
PD-1 signaling	21	1.79e-01	3.50e-01	0.21000	1.63e-01	-1.33e-01	1.97e-01	2.93e-01
Intrinsic Pathway of Fibrin Clot Formation	21	3.06e-01	5.07e-01	0.20900	-1.11e-01	-1.78e-01	3.78e-01	1.59e-01
RHOBTB2 GTPase cycle	22	2.66e-01	4.57e-01	0.20900	1.99e-01	6.50e-02	1.07e-01	5.97e-01
FRS-mediated FGFR3 signaling	19	3.28e-01	5.33e-01	0.20900	8.12e-02	1.93e-01	5.40e-01	1.46e-01
Ribavirin ADME	11	5.05e-01	6.99e-01	0.20900	4.88e-02	2.03e-01	7.79e-01	2.43e-01
SHC1 events in EGFR signaling	14	3.28e-01	5.33e-01	0.20900	-1.04e-01	1.81e-01	5.02e-01	2.40e-01
Drug ADME	104	3.29e-03	1.74e-02	0.20900	-1.24e-01	-1.68e-01	2.85e-02	3.12e-03
O-linked glycosylation of mucins	62	1.89e-02	6.79e-02	0.20800	-2.06e-01	-2.87e-02	4.92e-03	6.96e-01
DNA Double-Strand Break Repair	129	6.90e-04	4.41e-03	0.20700	8.98e-02	1.87e-01	7.79e-02	2.48e-04
Transcription-Coupled Nucleotide Excision Repair (TC-NER)	76	1.69e-02	6.14e-02	0.20700	1.37e-01	1.55e-01	3.89e-02	1.93e-02
Early SARS-CoV-2 Infection Events	34	1.18e-01	2.63e-01	0.20700	2.96e-02	2.05e-01	7.65e-01	3.90e-02
Generation of second messenger molecules	30	9.34e-02	2.25e-01	0.20700	1.23e-01	-1.66e-01	2.42e-01	1.16e-01
Glutathione conjugation	36	1.36e-01	2.91e-01	0.20600	1.01e-01	1.80e-01	2.96e-01	6.12e-02
SUMOylation of DNA methylation proteins	16	2.82e-01	4.72e-01	0.20600	-1.57e-01	1.34e-01	2.78e-01	3.54e-01
Recycling pathway of L1	23	1.62e-01	3.26e-01	0.20600	-1.54e-01	1.37e-01	2.00e-01	2.56e-01
Negative regulation of TCF-dependent signaling by WNT ligand antagonists	15	3.13e-01	5.14e-01	0.20600	-1.04e-01	1.78e-01	4.84e-01	2.34e-01
Lysine catabolism	12	5.27e-01	7.12e-01	0.20600	-1.27e-01	-1.62e-01	4.48e-01	3.31e-01
Signalling to RAS	20	2.44e-01	4.33e-01	0.20600	-3.79e-02	2.02e-01	7.69e-01	1.18e-01
Signaling by FGFR1	49	7.48e-02	1.91e-01	0.20600	1.43e-01	1.48e-01	8.36e-02	7.33e-02
JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1	15	3.22e-01	5.25e-01	0.20500	-8.59e-02	1.87e-01	5.65e-01	2.11e-01
O-glycosylation of TSR domain-containing proteins	37	1.04e-01	2.41e-01	0.20500	-3.75e-02	-2.02e-01	6.93e-01	3.34e-02
Regulation of gene expression by Hypoxia-inducible Factor	11	5.15e-01	7.05e-01	0.20500	4.22e-02	2.01e-01	8.08e-01	2.49e-01
FGFR3 mutant receptor activation	11	5.61e-01	7.37e-01	0.20500	1.36e-01	1.53e-01	4.33e-01	3.81e-01
Signaling by activated point mutants of FGFR3	11	5.61e-01	7.37e-01	0.20500	1.36e-01	1.53e-01	4.33e-01	3.81e-01
Oxidative Stress Induced Senescence	66	1.01e-02	4.13e-02	0.20400	-3.82e-02	2.01e-01	5.91e-01	4.80e-03
Phosphorylation of CD3 and TCR zeta chains	20	2.31e-01	4.19e-01	0.20300	1.89e-01	-7.52e-02	1.43e-01	5.61e-01
Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	34	1.55e-01	3.18e-01	0.20300	8.32e-02	1.85e-01	4.01e-01	6.13e-02
Defective B3GALTL causes PpS	36	1.25e-01	2.73e-01	0.20300	-5.07e-02	-1.96e-01	5.99e-01	4.17e-02
SUMOylation of DNA damage response and repair proteins	71	1.07e-02	4.31e-02	0.20300	-7.85e-05	2.03e-01	9.99e-01	3.15e-03
WNT ligand biogenesis and trafficking	25	2.77e-01	4.69e-01	0.20200	1.46e-01	1.40e-01	2.07e-01	2.25e-01
MAP kinase activation	58	3.79e-02	1.18e-01	0.20200	6.18e-02	1.93e-01	4.15e-01	1.11e-02
Citric acid cycle (TCA cycle)	21	3.41e-01	5.48e-01	0.20200	1.41e-01	1.45e-01	2.62e-01	2.51e-01
Bile acid and bile salt metabolism	45	1.00e-01	2.35e-01	0.20200	-1.40e-01	-1.46e-01	1.04e-01	9.08e-02
Cell-cell junction organization	56	5.28e-02	1.49e-01	0.20200	-1.04e-01	-1.73e-01	1.78e-01	2.50e-02
HCMV Early Events	55	3.32e-02	1.08e-01	0.20200	1.14e-02	2.01e-01	8.84e-01	9.78e-03
Ethanol oxidation	12	4.33e-01	6.35e-01	0.20100	5.45e-02	-1.94e-01	7.44e-01	2.45e-01
Mitotic Spindle Checkpoint	106	3.88e-03	1.93e-02	0.20100	9.89e-02	1.75e-01	7.84e-02	1.81e-03
Synthesis of Leukotrienes (LT) and Eoxins (EX)	21	2.99e-01	4.97e-01	0.20100	1.96e-01	4.68e-02	1.21e-01	7.11e-01
Cytosolic iron-sulfur cluster assembly	10	5.58e-01	7.36e-01	0.20100	1.97e-01	3.87e-02	2.80e-01	8.32e-01
Interleukin-1 family signaling	145	6.64e-04	4.28e-03	0.20100	1.50e-01	1.34e-01	1.84e-03	5.31e-03
Peptide hormone biosynthesis	11	5.55e-01	7.35e-01	0.20100	-1.83e-01	-8.40e-02	2.95e-01	6.30e-01
Gap-filling DNA repair synthesis and ligation in TC-NER	62	4.36e-02	1.31e-01	0.20100	1.50e-01	1.33e-01	4.04e-02	7.04e-02
Killing mechanisms	11	5.71e-01	7.45e-01	0.20100	1.21e-01	1.60e-01	4.86e-01	3.59e-01
WNT5:FZD7-mediated leishmania damping	11	5.71e-01	7.45e-01	0.20100	1.21e-01	1.60e-01	4.86e-01	3.59e-01
HDR through Homologous Recombination (HRR)	64	3.50e-02	1.12e-01	0.20100	9.44e-02	1.77e-01	1.92e-01	1.43e-02
TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain	13	4.36e-01	6.37e-01	0.20000	-1.06e-02	2.00e-01	9.47e-01	2.12e-01
ADP signalling through P2Y purinoceptor 1	25	1.59e-01	3.23e-01	0.20000	-1.07e-01	1.69e-01	3.54e-01	1.43e-01
Signal regulatory protein family interactions	13	4.12e-01	6.14e-01	0.20000	-4.98e-02	1.94e-01	7.56e-01	2.27e-01
RHOU GTPase cycle	37	9.97e-02	2.34e-01	0.20000	-2.00e-01	4.00e-05	3.53e-02	1.00e+00
Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA)	25	2.80e-01	4.70e-01	0.20000	1.11e-01	1.66e-01	3.36e-01	1.51e-01
Erythropoietin activates RAS	14	4.17e-01	6.21e-01	0.20000	-1.74e-03	2.00e-01	9.91e-01	1.96e-01
Signaling by FGFR	85	1.40e-02	5.19e-02	0.20000	1.58e-01	1.22e-01	1.16e-02	5.26e-02
Apoptosis	164	2.80e-04	2.03e-03	0.20000	1.26e-01	1.55e-01	5.51e-03	6.06e-04
Activation of Matrix Metalloproteinases	31	2.08e-01	3.88e-01	0.20000	-1.14e-01	-1.64e-01	2.73e-01	1.14e-01
Glycolysis	68	2.64e-02	8.82e-02	0.19900	7.43e-02	1.85e-01	2.90e-01	8.32e-03
Germ layer formation at gastrulation	16	4.16e-01	6.20e-01	0.19900	-1.90e-01	-6.12e-02	1.89e-01	6.72e-01
Fc epsilon receptor (FCERI) signaling	126	1.97e-03	1.13e-02	0.19900	1.39e-01	1.43e-01	7.10e-03	5.68e-03
Toll Like Receptor 9 (TLR9) Cascade	100	4.61e-03	2.22e-02	0.19900	6.77e-02	1.87e-01	2.42e-01	1.22e-03
NR1H2 and NR1H3-mediated signaling	53	4.49e-02	1.33e-01	0.19900	-1.97e-01	-2.50e-02	1.30e-02	7.53e-01
Toll-like Receptor Cascades	154	1.68e-04	1.28e-03	0.19900	3.95e-02	1.95e-01	3.97e-01	3.05e-05
Assembly of collagen fibrils and other multimeric structures	56	4.02e-02	1.23e-01	0.19800	-3.26e-02	-1.96e-01	6.73e-01	1.13e-02
Peroxisomal protein import	62	4.66e-02	1.36e-01	0.19800	1.54e-01	1.25e-01	3.57e-02	8.94e-02
RHOBTB GTPase Cycle	34	1.87e-01	3.60e-01	0.19800	1.49e-01	1.30e-01	1.32e-01	1.89e-01
Calcitonin-like ligand receptors	10	6.10e-01	7.74e-01	0.19800	-1.24e-01	-1.54e-01	4.97e-01	3.98e-01
Beta-catenin phosphorylation cascade	16	3.55e-01	5.60e-01	0.19800	-3.10e-02	1.96e-01	8.30e-01	1.76e-01
DCC mediated attractive signaling	14	4.94e-01	6.93e-01	0.19800	-1.01e-01	-1.70e-01	5.15e-01	2.70e-01
RNA Polymerase III Transcription Termination	23	3.24e-01	5.28e-01	0.19800	1.46e-01	1.33e-01	2.25e-01	2.69e-01
Synthesis of PIPs at the plasma membrane	48	4.56e-02	1.34e-01	0.19800	-1.95e-01	3.00e-02	1.92e-02	7.19e-01
NOD1/2 Signaling Pathway	29	1.60e-01	3.24e-01	0.19800	-1.95e-02	1.97e-01	8.56e-01	6.69e-02
Programmed Cell Death	192	6.86e-05	5.73e-04	0.19800	1.02e-01	1.69e-01	1.47e-02	5.26e-05
N-glycan antennae elongation in the medial/trans-Golgi	26	2.00e-01	3.78e-01	0.19700	-1.97e-01	1.04e-02	8.22e-02	9.27e-01
Zinc influx into cells by the SLC39 gene family	10	6.11e-01	7.74e-01	0.19700	1.61e-01	1.13e-01	3.77e-01	5.35e-01
SARS-CoV-2-host interactions	183	1.16e-04	9.23e-04	0.19700	1.03e-01	1.68e-01	1.60e-02	9.11e-05
Formation of Fibrin Clot (Clotting Cascade)	37	1.66e-01	3.31e-01	0.19700	-1.49e-01	-1.29e-01	1.17e-01	1.75e-01
Downregulation of ERBB2 signaling	28	2.54e-01	4.45e-01	0.19700	1.57e-01	1.18e-01	1.50e-01	2.78e-01
Triglyceride biosynthesis	13	4.09e-01	6.11e-01	0.19600	7.76e-02	-1.80e-01	6.28e-01	2.60e-01
Translocation of SLC2A4 (GLUT4) to the plasma membrane	51	2.75e-02	9.13e-02	0.19600	-1.03e-01	1.67e-01	2.04e-01	3.89e-02
PI-3K cascade:FGFR1	21	3.24e-01	5.28e-01	0.19600	1.88e-01	5.54e-02	1.35e-01	6.61e-01
CREB1 phosphorylation through the activation of Adenylate Cyclase	11	4.77e-01	6.78e-01	0.19600	-6.50e-02	1.85e-01	7.09e-01	2.88e-01
LGI-ADAM interactions	14	5.11e-01	7.03e-01	0.19500	1.25e-01	1.50e-01	4.18e-01	3.31e-01
Signaling by PDGFR in disease	20	2.44e-01	4.33e-01	0.19500	-1.55e-01	1.18e-01	2.30e-01	3.60e-01
Toll Like Receptor 4 (TLR4) Cascade	135	6.88e-04	4.41e-03	0.19500	4.18e-02	1.90e-01	4.02e-01	1.36e-04
TNFs bind their physiological receptors	25	2.79e-01	4.70e-01	0.19500	1.81e-01	7.23e-02	1.18e-01	5.32e-01
Synthesis of Prostaglandins (PG) and Thromboxanes (TX)	14	4.96e-01	6.93e-01	0.19400	7.85e-02	1.77e-01	6.11e-01	2.50e-01
Regulation of NPAS4 gene expression	13	5.01e-01	6.97e-01	0.19300	-1.88e-01	-4.27e-02	2.40e-01	7.90e-01
Dual incision in TC-NER	63	5.32e-02	1.49e-01	0.19300	1.36e-01	1.37e-01	6.20e-02	6.01e-02
Synthesis of substrates in N-glycan biosythesis	60	4.75e-02	1.38e-01	0.19300	6.37e-02	1.82e-01	3.94e-01	1.47e-02
SHC-mediated cascade:FGFR4	19	3.68e-01	5.73e-01	0.19300	4.60e-02	1.87e-01	7.29e-01	1.58e-01
MyD88:MAL(TIRAP) cascade initiated on plasma membrane	106	3.36e-03	1.74e-02	0.19200	3.23e-02	1.90e-01	5.65e-01	7.41e-04
Toll Like Receptor 2 (TLR2) Cascade	106	3.36e-03	1.74e-02	0.19200	3.23e-02	1.90e-01	5.65e-01	7.41e-04
Toll Like Receptor TLR1:TLR2 Cascade	106	3.36e-03	1.74e-02	0.19200	3.23e-02	1.90e-01	5.65e-01	7.41e-04
Toll Like Receptor TLR6:TLR2 Cascade	106	3.36e-03	1.74e-02	0.19200	3.23e-02	1.90e-01	5.65e-01	7.41e-04
Interleukin-15 signaling	13	5.48e-01	7.30e-01	0.19200	1.26e-01	1.45e-01	4.33e-01	3.65e-01
Antimicrobial peptides	78	6.50e-03	2.99e-02	0.19100	1.78e-01	-6.96e-02	6.47e-03	2.88e-01
SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs	11	5.42e-01	7.25e-01	0.19100	1.21e-02	1.91e-01	9.45e-01	2.73e-01
AKT phosphorylates targets in the cytosol	14	5.24e-01	7.09e-01	0.19100	1.15e-01	1.53e-01	4.57e-01	3.23e-01
MyD88 dependent cascade initiated on endosome	96	8.60e-03	3.71e-02	0.19100	6.45e-02	1.80e-01	2.75e-01	2.35e-03
Toll Like Receptor 7/8 (TLR7/8) Cascade	96	8.60e-03	3.71e-02	0.19100	6.45e-02	1.80e-01	2.75e-01	2.35e-03
MyD88 cascade initiated on plasma membrane	91	1.15e-02	4.45e-02	0.19100	6.79e-02	1.78e-01	2.63e-01	3.31e-03
Toll Like Receptor 10 (TLR10) Cascade	91	1.15e-02	4.45e-02	0.19100	6.79e-02	1.78e-01	2.63e-01	3.31e-03
Toll Like Receptor 5 (TLR5) Cascade	91	1.15e-02	4.45e-02	0.19100	6.79e-02	1.78e-01	2.63e-01	3.31e-03
Maturation of nucleoprotein 9694631	15	3.63e-01	5.69e-01	0.19000	1.35e-01	-1.35e-01	3.67e-01	3.67e-01
RHOQ GTPase cycle	57	4.59e-02	1.34e-01	0.19000	-1.89e-01	-1.84e-02	1.35e-02	8.10e-01
Presynaptic phase of homologous DNA pairing and strand exchange	38	1.79e-01	3.49e-01	0.19000	1.17e-01	1.49e-01	2.11e-01	1.12e-01
Interleukin-20 family signaling	24	2.60e-01	4.51e-01	0.18900	3.02e-03	-1.89e-01	9.80e-01	1.09e-01
Protein methylation	16	4.37e-01	6.37e-01	0.18900	3.46e-02	1.86e-01	8.11e-01	1.98e-01
HuR (ELAVL1) binds and stabilizes mRNA	10	5.20e-01	7.08e-01	0.18900	-9.94e-02	1.61e-01	5.86e-01	3.79e-01
Disorders of Developmental Biology	11	5.22e-01	7.08e-01	0.18900	-3.01e-02	1.87e-01	8.63e-01	2.84e-01
Disorders of Nervous System Development	11	5.22e-01	7.08e-01	0.18900	-3.01e-02	1.87e-01	8.63e-01	2.84e-01
Loss of function of MECP2 in Rett syndrome	11	5.22e-01	7.08e-01	0.18900	-3.01e-02	1.87e-01	8.63e-01	2.84e-01
Pervasive developmental disorders	11	5.22e-01	7.08e-01	0.18900	-3.01e-02	1.87e-01	8.63e-01	2.84e-01
ERK/MAPK targets	20	3.44e-01	5.50e-01	0.18900	2.02e-02	1.88e-01	8.75e-01	1.46e-01
BBSome-mediated cargo-targeting to cilium	23	3.43e-01	5.48e-01	0.18900	1.67e-01	8.90e-02	1.66e-01	4.60e-01
Mitochondrial biogenesis	69	2.61e-02	8.77e-02	0.18900	2.23e-02	1.87e-01	7.49e-01	7.10e-03
Nonhomologous End-Joining (NHEJ)	32	2.27e-01	4.12e-01	0.18900	8.95e-02	1.66e-01	3.81e-01	1.04e-01
Signaling by NTRK1 (TRKA)	114	4.43e-03	2.16e-02	0.18900	7.24e-02	1.74e-01	1.81e-01	1.31e-03
MAP2K and MAPK activation	36	1.46e-01	3.05e-01	0.18800	1.54e-02	1.88e-01	8.73e-01	5.15e-02
TCF dependent signaling in response to WNT	168	5.83e-04	3.84e-03	0.18800	1.18e-01	1.46e-01	8.09e-03	1.07e-03
Aggrephagy	23	3.59e-01	5.65e-01	0.18800	1.49e-01	1.15e-01	2.17e-01	3.41e-01
Homologous DNA Pairing and Strand Exchange	41	1.63e-01	3.27e-01	0.18800	1.23e-01	1.42e-01	1.74e-01	1.15e-01
PI3K events in ERBB4 signaling	10	5.23e-01	7.09e-01	0.18800	1.01e-01	-1.58e-01	5.80e-01	3.86e-01
Sensory processing of sound by inner hair cells of the cochlea	62	4.82e-02	1.39e-01	0.18800	-5.39e-02	-1.80e-01	4.63e-01	1.43e-02
Insertion of tail-anchored proteins into the endoplasmic reticulum membrane	18	3.31e-01	5.36e-01	0.18700	-6.19e-02	1.77e-01	6.49e-01	1.94e-01
Defective homologous recombination repair (HRR) due to BRCA2 loss of function	39	1.80e-01	3.51e-01	0.18700	1.26e-01	1.38e-01	1.73e-01	1.35e-01
Diseases of DNA Double-Strand Break Repair	39	1.80e-01	3.51e-01	0.18700	1.26e-01	1.38e-01	1.73e-01	1.35e-01
Sensory processing of sound by outer hair cells of the cochlea	49	1.14e-01	2.56e-01	0.18700	-1.08e-01	-1.52e-01	1.89e-01	6.48e-02
SUMOylation	164	2.33e-04	1.74e-03	0.18700	2.89e-02	1.85e-01	5.23e-01	4.38e-05
MECP2 regulates neuronal receptors and channels	17	3.93e-01	5.95e-01	0.18700	-1.87e-01	4.21e-03	1.82e-01	9.76e-01
Advanced glycosylation endproduct receptor signaling	13	5.39e-01	7.22e-01	0.18700	1.75e-01	6.36e-02	2.73e-01	6.91e-01
Infectious disease	830	2.32e-16	1.79e-14	0.18600	9.75e-02	1.59e-01	1.70e-06	5.82e-15
Pre-NOTCH Expression and Processing	61	2.54e-02	8.65e-02	0.18600	-5.80e-02	1.77e-01	4.33e-01	1.68e-02
Potential therapeutics for SARS	92	7.87e-03	3.50e-02	0.18600	1.02e-02	1.86e-01	8.66e-01	2.06e-03
Regulation of beta-cell development	41	1.67e-01	3.32e-01	0.18600	1.12e-01	1.49e-01	2.16e-01	9.97e-02
Gene expression (Transcription)	1420	4.17e-28	1.29e-25	0.18600	6.57e-02	1.74e-01	3.03e-05	2.45e-28
CRMPs in Sema3A signaling	15	3.93e-01	5.95e-01	0.18500	9.01e-02	-1.62e-01	5.46e-01	2.79e-01
Signaling by Leptin	11	6.18e-01	7.82e-01	0.18500	1.56e-01	9.99e-02	3.72e-01	5.66e-01
TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation	95	1.18e-02	4.56e-02	0.18500	6.01e-02	1.75e-01	3.12e-01	3.22e-03
Regulation of TP53 Activity	154	7.95e-04	5.04e-03	0.18400	5.86e-02	1.75e-01	2.09e-01	1.84e-04
Sensory processing of sound	69	4.50e-02	1.33e-01	0.18400	-7.60e-02	-1.68e-01	2.75e-01	1.60e-02
mRNA decay by 5’ to 3’ exoribonuclease	15	4.88e-01	6.88e-01	0.18300	4.20e-02	1.79e-01	7.78e-01	2.31e-01
GRB2 events in EGFR signaling	13	4.43e-01	6.42e-01	0.18300	-1.32e-01	1.27e-01	4.11e-01	4.26e-01
Organic cation transport	10	5.36e-01	7.19e-01	0.18300	-1.34e-01	1.24e-01	4.62e-01	4.96e-01
Diseases of DNA repair	49	1.20e-01	2.67e-01	0.18200	8.79e-02	1.60e-01	2.87e-01	5.28e-02
Presynaptic depolarization and calcium channel opening	12	5.98e-01	7.66e-01	0.18200	-9.41e-02	-1.56e-01	5.73e-01	3.49e-01
Base Excision Repair	45	9.97e-02	2.34e-01	0.18200	2.35e-03	1.82e-01	9.78e-01	3.48e-02
RNA Polymerase II Transcription	1284	3.82e-24	9.85e-22	0.18200	7.19e-02	1.67e-01	1.36e-05	5.63e-24
Downstream signaling of activated FGFR3	24	3.62e-01	5.68e-01	0.18200	9.61e-02	1.54e-01	4.15e-01	1.91e-01
Notch-HLH transcription pathway	24	2.32e-01	4.19e-01	0.18200	-1.07e-01	1.47e-01	3.66e-01	2.13e-01
DNA strand elongation	31	2.69e-01	4.61e-01	0.18100	9.34e-02	1.55e-01	3.68e-01	1.34e-01
Heme signaling	45	1.11e-01	2.53e-01	0.18100	-1.80e-01	-2.15e-02	3.67e-02	8.03e-01
PI3K events in ERBB2 signaling	16	3.77e-01	5.80e-01	0.18100	1.18e-01	-1.37e-01	4.15e-01	3.41e-01
Signaling by FGFR1 in disease	37	1.75e-01	3.45e-01	0.18100	3.52e-02	1.77e-01	7.11e-01	6.17e-02
Amine ligand-binding receptors	41	1.24e-01	2.73e-01	0.18100	-1.81e-01	-7.69e-05	4.51e-02	9.99e-01
Extension of Telomeres	48	1.16e-01	2.60e-01	0.18100	5.70e-02	1.72e-01	4.95e-01	3.97e-02
Gastrulation	21	3.55e-01	5.60e-01	0.18100	-1.80e-01	-1.34e-02	1.53e-01	9.15e-01
SUMO E3 ligases SUMOylate target proteins	158	5.66e-04	3.76e-03	0.18000	2.84e-02	1.78e-01	5.38e-01	1.11e-04
Negative regulation of MET activity	20	3.48e-01	5.55e-01	0.18000	-2.09e-02	1.79e-01	8.71e-01	1.67e-01
Signaling by NOTCH	182	5.90e-04	3.86e-03	0.18000	1.02e-01	1.48e-01	1.76e-02	5.70e-04
Transport of organic anions	10	6.63e-01	8.21e-01	0.18000	-1.47e-01	-1.03e-01	4.20e-01	5.74e-01
Termination of translesion DNA synthesis	31	2.76e-01	4.68e-01	0.17900	8.98e-02	1.55e-01	3.87e-01	1.35e-01
GPVI-mediated activation cascade	32	1.97e-01	3.75e-01	0.17900	-7.26e-03	1.79e-01	9.43e-01	7.99e-02
TP53 Regulates Transcription of Genes Involved in Cytochrome C Release	19	4.15e-01	6.18e-01	0.17900	3.35e-02	1.76e-01	8.00e-01	1.85e-01
trans-Golgi Network Vesicle Budding	67	2.60e-02	8.75e-02	0.17900	-4.45e-02	1.73e-01	5.29e-01	1.42e-02
SARS-CoV Infections	387	6.27e-08	8.74e-07	0.17900	6.24e-02	1.68e-01	3.48e-02	1.44e-08
Signaling by ERBB2 ECD mutants	15	5.48e-01	7.30e-01	0.17900	1.23e-01	1.30e-01	4.11e-01	3.83e-01
SHC-mediated cascade:FGFR2	22	3.91e-01	5.94e-01	0.17800	6.77e-02	1.65e-01	5.82e-01	1.80e-01
N-Glycan antennae elongation	15	4.12e-01	6.14e-01	0.17800	-1.26e-01	1.26e-01	3.98e-01	3.99e-01
Highly calcium permeable postsynaptic nicotinic acetylcholine receptors	11	5.59e-01	7.37e-01	0.17800	1.75e-01	-3.27e-02	3.15e-01	8.51e-01
mRNA Editing	10	6.00e-01	7.66e-01	0.17800	1.65e-02	-1.77e-01	9.28e-01	3.33e-01
Pentose phosphate pathway	12	5.01e-01	6.97e-01	0.17700	-9.55e-02	1.49e-01	5.67e-01	3.71e-01
Metabolism of porphyrins	27	2.67e-01	4.58e-01	0.17700	1.78e-03	-1.77e-01	9.87e-01	1.12e-01
Constitutive Signaling by EGFRvIII	15	5.56e-01	7.35e-01	0.17700	1.30e-01	1.20e-01	3.84e-01	4.22e-01
Signaling by EGFRvIII in Cancer	15	5.56e-01	7.35e-01	0.17700	1.30e-01	1.20e-01	3.84e-01	4.22e-01
InlB-mediated entry of Listeria monocytogenes into host cell	14	5.80e-01	7.50e-01	0.17600	1.22e-01	1.28e-01	4.31e-01	4.08e-01
YAP1- and WWTR1 (TAZ)-stimulated gene expression	15	4.93e-01	6.93e-01	0.17600	1.76e-01	1.20e-02	2.38e-01	9.36e-01
Disassembly of the destruction complex and recruitment of AXIN to the membrane	30	2.65e-01	4.56e-01	0.17600	3.84e-02	1.72e-01	7.16e-01	1.03e-01
Plasma lipoprotein assembly	19	4.38e-01	6.38e-01	0.17600	-1.70e-01	-4.66e-02	2.00e-01	7.25e-01
Disorders of transmembrane transporters	167	1.51e-03	8.97e-03	0.17600	1.39e-01	1.08e-01	1.94e-03	1.59e-02
Common Pathway of Fibrin Clot Formation	21	4.34e-01	6.35e-01	0.17600	-1.51e-01	-9.06e-02	2.32e-01	4.73e-01
Extracellular matrix organization	287	1.77e-05	1.57e-04	0.17500	-1.11e-01	-1.35e-01	1.15e-03	8.35e-05
Signaling by cytosolic FGFR1 fusion mutants	17	4.21e-01	6.23e-01	0.17500	-3.07e-02	1.72e-01	8.27e-01	2.19e-01
Formation of tubulin folding intermediates by CCT/TriC	26	3.14e-01	5.15e-01	0.17500	1.72e-01	2.81e-02	1.28e-01	8.04e-01
Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding	32	2.64e-01	4.56e-01	0.17400	1.65e-01	5.76e-02	1.07e-01	5.73e-01
Late endosomal microautophagy	32	2.42e-01	4.31e-01	0.17400	2.69e-02	1.72e-01	7.92e-01	9.22e-02
Signaling by FGFR2 in disease	42	1.98e-01	3.76e-01	0.17400	1.46e-01	9.39e-02	1.02e-01	2.92e-01
Regulation of cholesterol biosynthesis by SREBP (SREBF)	54	9.37e-02	2.25e-01	0.17300	2.73e-02	1.71e-01	7.28e-01	2.97e-02
Interleukin-12 family signaling	53	1.20e-01	2.67e-01	0.17300	6.97e-02	1.59e-01	3.80e-01	4.59e-02
Generic Transcription Pathway	1163	4.23e-20	6.55e-18	0.17300	6.81e-02	1.59e-01	8.49e-05	3.85e-20
Signaling by NODAL	21	3.10e-01	5.11e-01	0.17300	1.25e-01	-1.20e-01	3.23e-01	3.42e-01
Caspase-mediated cleavage of cytoskeletal proteins	12	5.76e-01	7.48e-01	0.17300	5.67e-03	1.73e-01	9.73e-01	3.00e-01
Regulation of TP53 Activity through Acetylation	29	2.31e-01	4.19e-01	0.17300	-4.00e-02	1.68e-01	7.09e-01	1.18e-01
WNT5A-dependent internalization of FZD2, FZD5 and ROR2	13	5.90e-01	7.59e-01	0.17200	5.82e-02	1.62e-01	7.17e-01	3.11e-01
MASTL Facilitates Mitotic Progression	10	5.85e-01	7.56e-01	0.17200	-7.86e-02	1.53e-01	6.67e-01	4.02e-01
Asparagine N-linked glycosylation	278	9.28e-06	8.44e-05	0.17200	3.83e-02	1.67e-01	2.71e-01	1.50e-06
SLBP independent Processing of Histone Pre-mRNAs	10	6.34e-01	7.98e-01	0.17200	3.86e-03	1.72e-01	9.83e-01	3.47e-01
Maturation of spike protein 9694548	35	1.59e-01	3.23e-01	0.17200	-6.78e-02	1.58e-01	4.88e-01	1.06e-01
Peroxisomal lipid metabolism	28	3.56e-01	5.62e-01	0.17100	1.30e-01	1.12e-01	2.35e-01	3.05e-01
Retrograde neurotrophin signalling	14	5.98e-01	7.66e-01	0.17100	1.23e-01	1.20e-01	4.27e-01	4.38e-01
Activated NOTCH1 Transmits Signal to the Nucleus	30	2.70e-01	4.62e-01	0.17100	1.70e-01	1.99e-02	1.07e-01	8.50e-01
Degradation of the extracellular matrix	108	1.65e-02	6.01e-02	0.17100	-7.90e-02	-1.51e-01	1.56e-01	6.56e-03
FLT3 Signaling	38	2.50e-01	4.39e-01	0.17000	1.11e-01	1.30e-01	2.38e-01	1.67e-01
Gap-filling DNA repair synthesis and ligation in GG-NER	25	4.01e-01	6.02e-01	0.17000	9.93e-02	1.38e-01	3.90e-01	2.34e-01
Signaling by NTRKs	133	6.17e-03	2.86e-02	0.17000	6.71e-02	1.56e-01	1.82e-01	1.92e-03
Cholesterol biosynthesis	24	4.20e-01	6.23e-01	0.17000	1.10e-01	1.29e-01	3.51e-01	2.74e-01
CS/DS degradation	12	5.30e-01	7.14e-01	0.16900	-9.70e-02	1.39e-01	5.60e-01	4.05e-01
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	54	1.40e-01	2.95e-01	0.16900	9.05e-02	1.42e-01	2.50e-01	7.00e-02
Constitutive Signaling by NOTCH1 PEST Domain Mutants	54	1.40e-01	2.95e-01	0.16900	9.05e-02	1.42e-01	2.50e-01	7.00e-02
Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer	54	1.40e-01	2.95e-01	0.16900	9.05e-02	1.42e-01	2.50e-01	7.00e-02
Signaling by NOTCH1 PEST Domain Mutants in Cancer	54	1.40e-01	2.95e-01	0.16900	9.05e-02	1.42e-01	2.50e-01	7.00e-02
Signaling by NOTCH1 in Cancer	54	1.40e-01	2.95e-01	0.16900	9.05e-02	1.42e-01	2.50e-01	7.00e-02
Deactivation of the beta-catenin transactivating complex	39	2.33e-01	4.20e-01	0.16700	6.68e-02	1.53e-01	4.71e-01	9.72e-02
Role of LAT2/NTAL/LAB on calcium mobilization	13	5.76e-01	7.48e-01	0.16700	-1.67e-01	-1.21e-02	2.98e-01	9.40e-01
Synthesis of glycosylphosphatidylinositol (GPI)	17	4.45e-01	6.43e-01	0.16700	-4.42e-02	1.61e-01	7.52e-01	2.51e-01
Chylomicron assembly	10	7.01e-01	8.42e-01	0.16700	-9.02e-02	-1.40e-01	6.21e-01	4.43e-01
O-linked glycosylation	107	2.17e-02	7.55e-02	0.16600	-1.46e-01	-7.91e-02	9.03e-03	1.57e-01
NCAM1 interactions	36	1.72e-01	3.39e-01	0.16600	6.53e-02	-1.52e-01	4.97e-01	1.13e-01
TFAP2 (AP-2) family regulates transcription of growth factors and their receptors	12	5.62e-01	7.37e-01	0.16600	-5.49e-02	1.56e-01	7.42e-01	3.48e-01
Resolution of Abasic Sites (AP sites)	37	2.17e-01	4.01e-01	0.16600	1.45e-02	1.65e-01	8.79e-01	8.25e-02
Regulated proteolysis of p75NTR	11	6.10e-01	7.74e-01	0.16500	1.64e-01	-2.25e-02	3.46e-01	8.97e-01
VEGFA-VEGFR2 Pathway	93	9.17e-03	3.86e-02	0.16500	-1.33e-01	9.82e-02	2.65e-02	1.02e-01
Caspase activation via extrinsic apoptotic signalling pathway	25	4.24e-01	6.25e-01	0.16500	1.28e-01	1.04e-01	2.67e-01	3.68e-01
Sulfur amino acid metabolism	27	3.74e-01	5.78e-01	0.16500	6.31e-02	1.52e-01	5.71e-01	1.71e-01
Aflatoxin activation and detoxification	19	3.93e-01	5.95e-01	0.16500	7.81e-02	-1.45e-01	5.56e-01	2.74e-01
Metabolism of nucleotides	95	1.92e-02	6.84e-02	0.16500	4.34e-03	1.64e-01	9.42e-01	5.58e-03
SUMOylation of transcription cofactors	43	1.68e-01	3.33e-01	0.16500	6.21e-03	1.64e-01	9.44e-01	6.21e-02
Glucagon signaling in metabolic regulation	33	2.08e-01	3.87e-01	0.16400	-6.03e-02	1.53e-01	5.49e-01	1.29e-01
Interleukin-17 signaling	66	6.41e-02	1.70e-01	0.16300	-6.07e-04	1.63e-01	9.93e-01	2.16e-02
Non-integrin membrane-ECM interactions	40	2.59e-01	4.50e-01	0.16300	-1.36e-01	-8.93e-02	1.37e-01	3.28e-01
Regulation of PLK1 Activity at G2/M Transition	83	4.47e-02	1.33e-01	0.16200	3.75e-02	1.58e-01	5.55e-01	1.27e-02
Transcriptional activation of mitochondrial biogenesis	51	1.58e-01	3.22e-01	0.16200	5.25e-02	1.54e-01	5.16e-01	5.75e-02
Beta-catenin independent WNT signaling	144	8.90e-03	3.82e-02	0.16200	1.12e-01	1.17e-01	2.00e-02	1.53e-02
RHOF GTPase cycle	40	2.67e-01	4.58e-01	0.16200	-1.03e-01	-1.25e-01	2.59e-01	1.71e-01
FGFR2b ligand binding and activation	10	6.37e-01	8.00e-01	0.16200	1.56e-01	-4.48e-02	3.94e-01	8.06e-01
MAPK targets/ Nuclear events mediated by MAP kinases	29	3.40e-01	5.46e-01	0.16200	3.67e-02	1.58e-01	7.32e-01	1.42e-01
Myogenesis	29	2.89e-01	4.82e-01	0.16100	-1.60e-01	2.25e-02	1.36e-01	8.34e-01
Glutathione synthesis and recycling	12	6.08e-01	7.73e-01	0.16100	-8.95e-03	1.61e-01	9.57e-01	3.34e-01
Activation of AMPK downstream of NMDARs	10	6.90e-01	8.33e-01	0.16100	3.54e-02	1.57e-01	8.46e-01	3.89e-01
Activation of gene expression by SREBF (SREBP)	42	1.84e-01	3.56e-01	0.16100	2.16e-03	1.61e-01	9.81e-01	7.07e-02
Telomere C-strand (Lagging Strand) Synthesis	32	2.81e-01	4.71e-01	0.16100	7.64e-03	1.61e-01	9.40e-01	1.15e-01
Resolution of D-loop Structures through Holliday Junction Intermediates	30	3.68e-01	5.73e-01	0.16100	8.25e-02	1.38e-01	4.34e-01	1.90e-01
Reversible hydration of carbon dioxide	11	6.83e-01	8.30e-01	0.16000	6.07e-02	1.48e-01	7.28e-01	3.94e-01
Antigen processing: Ubiquitination & Proteasome degradation	293	4.77e-05	4.07e-04	0.16000	6.02e-02	1.48e-01	7.58e-02	1.29e-05
Glycogen synthesis	13	6.57e-01	8.18e-01	0.15900	8.73e-02	1.33e-01	5.86e-01	4.06e-01
Blood group systems biosynthesis	22	4.94e-01	6.93e-01	0.15900	-1.29e-01	-9.21e-02	2.94e-01	4.55e-01
Lewis blood group biosynthesis	18	5.63e-01	7.37e-01	0.15900	-1.29e-01	-9.24e-02	3.44e-01	4.97e-01
Pregnenolone biosynthesis	10	7.17e-01	8.50e-01	0.15800	6.65e-02	1.44e-01	7.16e-01	4.31e-01
Zinc transporters	17	5.48e-01	7.30e-01	0.15800	1.53e-01	4.07e-02	2.74e-01	7.71e-01
Signaling by FGFR in disease	61	1.47e-01	3.06e-01	0.15800	1.04e-01	1.20e-01	1.62e-01	1.06e-01
Receptor-type tyrosine-protein phosphatases	16	5.15e-01	7.05e-01	0.15800	2.61e-02	-1.56e-01	8.56e-01	2.80e-01
Metabolism of steroid hormones	33	2.46e-01	4.35e-01	0.15800	3.76e-02	-1.54e-01	7.09e-01	1.27e-01
ABC transporters in lipid homeostasis	17	5.66e-01	7.39e-01	0.15800	-6.04e-02	-1.46e-01	6.67e-01	2.97e-01
RHOH GTPase cycle	36	1.89e-01	3.62e-01	0.15800	-1.02e-01	1.20e-01	2.88e-01	2.12e-01
Class I MHC mediated antigen processing & presentation	361	6.27e-06	5.91e-05	0.15800	5.73e-02	1.47e-01	6.14e-02	1.57e-06
SARS-CoV-2 Infection	276	1.45e-04	1.12e-03	0.15700	7.38e-02	1.39e-01	3.48e-02	6.89e-05
Glucose metabolism	87	6.38e-02	1.70e-01	0.15700	8.19e-02	1.34e-01	1.86e-01	3.07e-02
Pre-NOTCH Transcription and Translation	45	1.90e-01	3.64e-01	0.15700	1.53e-02	1.56e-01	8.59e-01	6.98e-02
Signaling by ERBB2 TMD/JMD mutants	21	5.21e-01	7.08e-01	0.15700	1.22e-01	9.86e-02	3.33e-01	4.34e-01
Presynaptic nicotinic acetylcholine receptors	12	6.84e-01	8.31e-01	0.15700	8.23e-02	1.33e-01	6.22e-01	4.24e-01
Resolution of D-Loop Structures	31	3.69e-01	5.73e-01	0.15700	7.03e-02	1.40e-01	4.98e-01	1.78e-01
ECM proteoglycans	55	1.77e-01	3.48e-01	0.15600	-7.84e-02	-1.35e-01	3.14e-01	8.32e-02
Resolution of Sister Chromatid Cohesion	98	4.11e-02	1.25e-01	0.15600	6.01e-02	1.44e-01	3.04e-01	1.37e-02
EGFR downregulation	30	4.00e-01	6.01e-01	0.15600	1.02e-01	1.18e-01	3.35e-01	2.62e-01
Signaling by EGFR	49	2.01e-01	3.78e-01	0.15600	5.70e-02	1.45e-01	4.90e-01	7.88e-02
Cell junction organization	79	8.04e-02	2.01e-01	0.15600	-6.83e-02	-1.40e-01	2.94e-01	3.14e-02
Synthesis of IP2, IP, and Ins in the cytosol	13	6.28e-01	7.94e-01	0.15500	-1.54e-01	-2.04e-02	3.36e-01	8.99e-01
Downstream signaling of activated FGFR1	31	3.83e-01	5.88e-01	0.15500	1.31e-01	8.35e-02	2.07e-01	4.21e-01
Creation of C4 and C2 activators	14	5.74e-01	7.47e-01	0.15500	2.20e-02	-1.54e-01	8.86e-01	3.19e-01
The phototransduction cascade	32	3.74e-01	5.78e-01	0.15500	-8.57e-02	-1.29e-01	4.01e-01	2.05e-01
Cellular hexose transport	21	4.30e-01	6.31e-01	0.15500	1.52e-01	-3.07e-02	2.29e-01	8.08e-01
Retinoid metabolism and transport	42	1.99e-01	3.77e-01	0.15500	1.22e-02	-1.54e-01	8.91e-01	8.38e-02
Transcriptional Regulation by MECP2	60	8.31e-02	2.07e-01	0.15400	-1.46e-01	4.92e-02	5.00e-02	5.09e-01
Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal	89	6.42e-02	1.70e-01	0.15400	7.47e-02	1.35e-01	2.23e-01	2.77e-02
Amplification of signal from the kinetochores	89	6.42e-02	1.70e-01	0.15400	7.47e-02	1.35e-01	2.23e-01	2.77e-02
Dissolution of Fibrin Clot	13	6.72e-01	8.25e-01	0.15400	1.34e-01	7.59e-02	4.04e-01	6.36e-01
DDX58/IFIH1-mediated induction of interferon-alpha/beta	75	8.66e-02	2.12e-01	0.15400	4.60e-02	1.47e-01	4.91e-01	2.81e-02
Mitotic Prometaphase	174	3.22e-03	1.71e-02	0.15400	3.98e-02	1.48e-01	3.65e-01	7.28e-04
tRNA modification in the nucleus and cytosol	38	3.09e-01	5.09e-01	0.15400	6.96e-02	1.37e-01	4.58e-01	1.44e-01
Meiotic synapsis	32	2.47e-01	4.36e-01	0.15300	-1.02e-01	1.15e-01	3.20e-01	2.62e-01
Gene Silencing by RNA	80	5.98e-02	1.64e-01	0.15300	1.20e-02	1.52e-01	8.53e-01	1.84e-02
Apoptotic execution phase	43	1.60e-01	3.24e-01	0.15200	-8.32e-02	1.28e-01	3.45e-01	1.47e-01
Synthesis of bile acids and bile salts via 24-hydroxycholesterol	14	6.60e-01	8.19e-01	0.15200	-8.16e-02	-1.28e-01	5.97e-01	4.06e-01
FRS-mediated FGFR4 signaling	21	5.23e-01	7.09e-01	0.15200	5.84e-02	1.40e-01	6.43e-01	2.67e-01
Signalling to ERKs	34	2.73e-01	4.65e-01	0.15100	-2.68e-02	1.49e-01	7.87e-01	1.32e-01
RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known	37	2.07e-01	3.87e-01	0.15100	-1.03e-01	1.11e-01	2.79e-01	2.43e-01
Interleukin-4 and Interleukin-13 signaling	104	4.96e-02	1.42e-01	0.15100	1.22e-01	8.87e-02	3.10e-02	1.18e-01
Estrogen-dependent gene expression	91	5.92e-02	1.63e-01	0.15100	5.06e-02	1.42e-01	4.04e-01	1.89e-02
Keratan sulfate biosynthesis	28	3.96e-01	5.98e-01	0.15100	-1.49e-01	-2.61e-02	1.74e-01	8.11e-01
Triglyceride metabolism	36	2.95e-01	4.92e-01	0.15000	-1.47e-02	-1.50e-01	8.79e-01	1.20e-01
Acyl chain remodelling of PC	26	3.70e-01	5.74e-01	0.15000	3.40e-02	-1.46e-01	7.64e-01	1.96e-01
Stimuli-sensing channels	96	6.43e-02	1.70e-01	0.15000	-8.52e-02	-1.24e-01	1.49e-01	3.64e-02
Interferon Signaling	191	4.92e-03	2.33e-02	0.14900	1.04e-01	1.07e-01	1.31e-02	1.05e-02
Sphingolipid de novo biosynthesis	41	2.64e-01	4.56e-01	0.14900	-1.47e-01	-2.25e-02	1.03e-01	8.03e-01
Sodium/Calcium exchangers	11	6.37e-01	8.00e-01	0.14800	9.52e-02	-1.14e-01	5.84e-01	5.13e-01
Inactivation, recovery and regulation of the phototransduction cascade	31	4.24e-01	6.25e-01	0.14800	-9.31e-02	-1.15e-01	3.69e-01	2.66e-01
Triglyceride catabolism	23	5.15e-01	7.06e-01	0.14800	-6.69e-02	-1.32e-01	5.79e-01	2.72e-01
Vitamin B5 (pantothenate) metabolism	16	6.42e-01	8.04e-01	0.14800	9.08e-02	1.17e-01	5.30e-01	4.18e-01
Diseases of signal transduction by growth factor receptors and second messengers	410	4.79e-06	4.63e-05	0.14800	4.40e-02	1.41e-01	1.26e-01	8.84e-07
Glyoxylate metabolism and glycine degradation	30	3.59e-01	5.65e-01	0.14800	-1.40e-03	1.48e-01	9.89e-01	1.61e-01
FRS-mediated FGFR2 signaling	24	5.12e-01	7.04e-01	0.14700	7.68e-02	1.26e-01	5.15e-01	2.87e-01
Nicotinamide salvaging	17	5.32e-01	7.17e-01	0.14700	1.41e-01	-4.13e-02	3.15e-01	7.68e-01
Signaling by ALK fusions and activated point mutants	51	1.79e-01	3.49e-01	0.14700	-3.69e-03	1.47e-01	9.64e-01	7.02e-02
Signaling by ALK in cancer	51	1.79e-01	3.49e-01	0.14700	-3.69e-03	1.47e-01	9.64e-01	7.02e-02
Inositol phosphate metabolism	45	2.81e-01	4.71e-01	0.14600	-1.31e-01	-6.47e-02	1.27e-01	4.53e-01
Pyroptosis	26	3.67e-01	5.72e-01	0.14600	-6.70e-02	1.30e-01	5.54e-01	2.52e-01
Signaling by VEGF	101	1.92e-02	6.85e-02	0.14600	-1.22e-01	8.05e-02	3.43e-02	1.62e-01
SARS-CoV-2 activates/modulates innate and adaptive immune responses	110	3.64e-02	1.15e-01	0.14600	3.46e-02	1.42e-01	5.31e-01	1.01e-02
G-protein activation	24	4.00e-01	6.01e-01	0.14600	-6.14e-02	1.32e-01	6.03e-01	2.61e-01
Gap junction degradation	10	7.26e-01	8.54e-01	0.14600	-1.45e-01	-1.29e-02	4.26e-01	9.44e-01
Glutamate Neurotransmitter Release Cycle	23	4.85e-01	6.88e-01	0.14500	1.44e-01	1.72e-02	2.30e-01	8.87e-01
AURKA Activation by TPX2	68	1.36e-01	2.91e-01	0.14500	4.21e-02	1.39e-01	5.48e-01	4.70e-02
Acyl chain remodelling of PS	21	4.91e-01	6.91e-01	0.14500	1.08e-02	-1.45e-01	9.31e-01	2.50e-01
Serotonin receptors	11	7.47e-01	8.63e-01	0.14500	-9.92e-02	-1.06e-01	5.69e-01	5.42e-01
Keratan sulfate degradation	12	7.26e-01	8.54e-01	0.14500	-1.18e-01	-8.40e-02	4.78e-01	6.14e-01
Signaling by Activin	15	5.97e-01	7.66e-01	0.14500	1.44e-01	-1.88e-02	3.35e-01	9.00e-01
PI Metabolism	79	5.38e-02	1.51e-01	0.14500	-1.34e-01	5.36e-02	3.87e-02	4.10e-01
Synthesis of PA	35	3.93e-01	5.95e-01	0.14500	-8.01e-02	-1.20e-01	4.12e-01	2.18e-01
Signaling by ERBB2 in Cancer	25	4.96e-01	6.93e-01	0.14400	1.34e-01	5.45e-02	2.47e-01	6.37e-01
Regulation of MECP2 expression and activity	30	3.19e-01	5.23e-01	0.14400	-1.24e-01	7.33e-02	2.38e-01	4.87e-01
DSCAM interactions	11	7.21e-01	8.54e-01	0.14400	-1.41e-01	-3.19e-02	4.19e-01	8.54e-01
FGFR3 ligand binding and activation	12	7.26e-01	8.54e-01	0.14400	7.73e-02	1.22e-01	6.43e-01	4.65e-01
FGFR3c ligand binding and activation	12	7.26e-01	8.54e-01	0.14400	7.73e-02	1.22e-01	6.43e-01	4.65e-01
Activation of BH3-only proteins	30	3.19e-01	5.23e-01	0.14400	-8.30e-02	1.17e-01	4.32e-01	2.67e-01
Scavenging by Class A Receptors	19	5.80e-01	7.50e-01	0.14300	-3.99e-02	-1.38e-01	7.63e-01	2.99e-01
PIP3 activates AKT signaling	275	3.36e-04	2.39e-03	0.14300	2.97e-02	1.40e-01	3.97e-01	6.35e-05
Interleukin-6 signaling	11	6.59e-01	8.18e-01	0.14300	8.95e-02	-1.11e-01	6.07e-01	5.22e-01
Interleukin-35 Signalling	12	6.96e-01	8.40e-01	0.14300	-1.86e-02	-1.42e-01	9.11e-01	3.95e-01
Acyl chain remodelling of PG	18	5.18e-01	7.08e-01	0.14300	6.12e-02	-1.29e-01	6.53e-01	3.44e-01
TP53 Regulates Transcription of Caspase Activators and Caspases	12	6.35e-01	7.99e-01	0.14300	-9.15e-02	1.10e-01	5.83e-01	5.11e-01
HATs acetylate histones	71	1.48e-01	3.07e-01	0.14200	5.73e-02	1.30e-01	4.04e-01	5.77e-02
Phospholipase C-mediated cascade; FGFR2	17	6.38e-01	8.01e-01	0.14200	1.26e-01	6.49e-02	3.68e-01	6.43e-01
Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters	20	6.00e-01	7.66e-01	0.14200	1.15e-01	8.38e-02	3.75e-01	5.17e-01
PCNA-Dependent Long Patch Base Excision Repair	21	5.62e-01	7.37e-01	0.14200	4.60e-02	1.34e-01	7.15e-01	2.88e-01
EML4 and NUDC in mitotic spindle formation	93	8.67e-02	2.12e-01	0.14100	6.11e-02	1.27e-01	3.08e-01	3.36e-02
Recruitment of NuMA to mitotic centrosomes	75	1.09e-01	2.47e-01	0.14100	1.53e-02	1.40e-01	8.19e-01	3.59e-02
Metabolism of fat-soluble vitamins	46	2.05e-01	3.84e-01	0.14100	4.40e-02	-1.34e-01	6.05e-01	1.16e-01
Insulin processing	26	5.27e-01	7.12e-01	0.14000	-9.94e-02	-9.89e-02	3.80e-01	3.83e-01
RND2 GTPase cycle	42	3.35e-01	5.40e-01	0.14000	-1.28e-01	-5.67e-02	1.51e-01	5.25e-01
Signaling by Erythropoietin	25	5.21e-01	7.08e-01	0.13900	5.38e-02	1.29e-01	6.42e-01	2.65e-01
Leading Strand Synthesis	13	7.29e-01	8.54e-01	0.13900	9.64e-02	1.00e-01	5.47e-01	5.31e-01
Polymerase switching	13	7.29e-01	8.54e-01	0.13900	9.64e-02	1.00e-01	5.47e-01	5.31e-01
Disease	1567	3.14e-17	3.04e-15	0.13900	5.67e-02	1.27e-01	1.66e-04	2.98e-17
SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription	36	4.18e-01	6.21e-01	0.13900	8.83e-02	1.07e-01	3.59e-01	2.66e-01
RAC2 GTPase cycle	80	6.47e-02	1.70e-01	0.13800	-1.26e-01	5.71e-02	5.10e-02	3.77e-01
Removal of the Flap Intermediate from the C-strand	17	5.45e-01	7.28e-01	0.13800	-9.16e-02	1.04e-01	5.13e-01	4.59e-01
Cytokine Signaling in Immune system	670	1.54e-07	1.97e-06	0.13800	9.43e-02	1.01e-01	2.99e-05	7.44e-06
Downstream signaling of activated FGFR2	29	4.98e-01	6.95e-01	0.13800	8.99e-02	1.05e-01	4.02e-01	3.27e-01
Acetylcholine binding and downstream events	14	7.01e-01	8.42e-01	0.13800	1.26e-01	5.74e-02	4.15e-01	7.10e-01
Postsynaptic nicotinic acetylcholine receptors	14	7.01e-01	8.42e-01	0.13800	1.26e-01	5.74e-02	4.15e-01	7.10e-01
Post-translational protein phosphorylation	100	9.00e-02	2.18e-01	0.13800	-1.11e-01	-8.16e-02	5.42e-02	1.58e-01
Synthesis of PC	27	4.33e-01	6.35e-01	0.13800	-1.71e-02	1.37e-01	8.78e-01	2.19e-01
Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)	20	5.81e-01	7.51e-01	0.13800	2.96e-02	1.34e-01	8.19e-01	2.98e-01
Downstream signaling of activated FGFR4	26	5.33e-01	7.18e-01	0.13800	7.65e-02	1.14e-01	4.99e-01	3.13e-01
Signaling by Interleukins	434	3.95e-05	3.41e-04	0.13800	9.39e-02	1.01e-01	7.84e-04	3.18e-04
Miscellaneous transport and binding events	21	5.73e-01	7.46e-01	0.13700	-3.63e-02	-1.33e-01	7.73e-01	2.93e-01
RA biosynthesis pathway	22	4.98e-01	6.95e-01	0.13700	-2.88e-02	1.34e-01	8.15e-01	2.76e-01
Plasma lipoprotein clearance	37	4.09e-01	6.11e-01	0.13700	7.05e-02	1.17e-01	4.58e-01	2.17e-01
RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function	38	2.80e-01	4.70e-01	0.13700	-1.24e-01	5.78e-02	1.86e-01	5.37e-01
Prostacyclin signalling through prostacyclin receptor	19	5.69e-01	7.43e-01	0.13700	-7.26e-03	1.36e-01	9.56e-01	3.03e-01
Interferon alpha/beta signaling	69	1.52e-01	3.15e-01	0.13600	1.35e-01	1.88e-02	5.28e-02	7.87e-01
Cell-Cell communication	112	7.11e-02	1.82e-01	0.13600	-7.42e-02	-1.14e-01	1.75e-01	3.70e-02
Cell-extracellular matrix interactions	14	7.14e-01	8.49e-01	0.13600	1.19e-01	6.48e-02	4.39e-01	6.74e-01
C-type lectin receptors (CLRs)	137	3.97e-02	1.22e-01	0.13600	7.29e-02	1.15e-01	1.40e-01	2.05e-02
Glycosphingolipid metabolism	40	3.34e-01	5.40e-01	0.13600	1.52e-02	1.35e-01	8.68e-01	1.40e-01
Arachidonic acid metabolism	56	2.50e-01	4.39e-01	0.13600	1.26e-01	5.05e-02	1.03e-01	5.14e-01
Signaling by high-kinase activity BRAF mutants	32	3.83e-01	5.88e-01	0.13600	-1.67e-02	1.34e-01	8.70e-01	1.88e-01
Apoptotic cleavage of cellular proteins	35	3.04e-01	5.04e-01	0.13500	-9.59e-02	9.52e-02	3.26e-01	3.30e-01
FCERI mediated MAPK activation	29	3.77e-01	5.80e-01	0.13500	-7.73e-02	1.11e-01	4.71e-01	3.02e-01
Defects of contact activation system (CAS) and kallikrein/kinin system (KKS)	14	7.25e-01	8.54e-01	0.13500	-8.50e-02	-1.05e-01	5.82e-01	4.97e-01
Diseases of hemostasis	14	7.25e-01	8.54e-01	0.13500	-8.50e-02	-1.05e-01	5.82e-01	4.97e-01
Gamma carboxylation, hypusine formation and arylsulfatase activation	34	4.24e-01	6.25e-01	0.13500	3.81e-02	1.29e-01	7.00e-01	1.93e-01
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers	28	5.05e-01	6.99e-01	0.13400	-1.25e-01	-4.95e-02	2.52e-01	6.51e-01
Mucopolysaccharidoses	10	7.42e-01	8.61e-01	0.13400	-1.32e-01	2.25e-02	4.69e-01	9.02e-01
Formation of the cornified envelope	73	1.90e-01	3.64e-01	0.13400	-7.86e-02	-1.09e-01	2.45e-01	1.08e-01
Acyl chain remodelling of PE	24	4.77e-01	6.78e-01	0.13300	4.58e-02	-1.24e-01	6.98e-01	2.91e-01
Processive synthesis on the C-strand of the telomere	19	5.38e-01	7.21e-01	0.13200	-8.60e-02	1.01e-01	5.16e-01	4.47e-01
Metabolism of proteins	1767	5.98e-17	5.44e-15	0.13200	6.66e-02	1.14e-01	2.86e-06	8.85e-16
BMAL1:CLOCK,NPAS2 activates circadian gene expression	27	5.46e-01	7.29e-01	0.13200	-1.12e-01	-6.96e-02	3.13e-01	5.31e-01
Neurotransmitter release cycle	47	2.85e-01	4.77e-01	0.13200	1.32e-01	4.16e-03	1.18e-01	9.61e-01
Resolution of AP sites via the multiple-nucleotide patch replacement pathway	24	5.28e-01	7.12e-01	0.13200	5.44e-03	1.32e-01	9.63e-01	2.64e-01
Growth hormone receptor signaling	24	5.02e-01	6.98e-01	0.13200	2.09e-02	-1.30e-01	8.60e-01	2.70e-01
Regulation of lipid metabolism by PPARalpha	116	4.06e-02	1.24e-01	0.13200	-8.76e-03	1.31e-01	8.70e-01	1.45e-02
Phospholipase C-mediated cascade; FGFR4	14	7.34e-01	8.57e-01	0.13200	1.09e-01	7.34e-02	4.79e-01	6.34e-01
HDMs demethylate histones	18	6.24e-01	7.89e-01	0.13100	7.61e-03	1.31e-01	9.55e-01	3.36e-01
Retrograde transport at the Trans-Golgi-Network	47	3.52e-01	5.57e-01	0.13100	6.55e-02	1.14e-01	4.37e-01	1.78e-01
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	120	2.89e-02	9.50e-02	0.13100	1.26e-01	-3.71e-02	1.73e-02	4.82e-01
ADP signalling through P2Y purinoceptor 12	22	5.06e-01	6.99e-01	0.13100	-5.98e-02	1.17e-01	6.27e-01	3.44e-01
Transcriptional regulation by RUNX1	183	1.23e-02	4.73e-02	0.13100	3.31e-02	1.27e-01	4.40e-01	3.09e-03
Factors involved in megakaryocyte development and platelet production	128	1.74e-02	6.27e-02	0.13100	-1.04e-01	7.97e-02	4.22e-02	1.19e-01
Phase 4 - resting membrane potential	19	6.51e-01	8.15e-01	0.13100	-5.59e-02	-1.18e-01	6.73e-01	3.73e-01
G beta:gamma signalling through PI3Kgamma	25	4.67e-01	6.69e-01	0.13100	-5.29e-02	1.19e-01	6.47e-01	3.01e-01
Centrosome maturation	76	1.55e-01	3.19e-01	0.13000	2.22e-02	1.28e-01	7.37e-01	5.37e-02
Recruitment of mitotic centrosome proteins and complexes	76	1.55e-01	3.19e-01	0.13000	2.22e-02	1.28e-01	7.37e-01	5.37e-02
Amino acids regulate mTORC1	52	2.42e-01	4.31e-01	0.13000	-1.39e-02	1.29e-01	8.63e-01	1.07e-01
Activated point mutants of FGFR2	16	7.05e-01	8.42e-01	0.13000	1.13e-01	6.45e-02	4.36e-01	6.55e-01
GABA synthesis, release, reuptake and degradation	19	5.51e-01	7.31e-01	0.13000	9.39e-02	-8.94e-02	4.78e-01	5.00e-01
Signaling by WNT	263	3.46e-03	1.76e-02	0.13000	6.38e-02	1.13e-01	7.46e-02	1.63e-03
MAPK1/MAPK3 signaling	270	3.46e-03	1.76e-02	0.12900	1.03e-01	7.85e-02	3.56e-03	2.62e-02
PPARA activates gene expression	114	4.52e-02	1.33e-01	0.12900	-1.63e-02	1.28e-01	7.63e-01	1.81e-02
Regulation of localization of FOXO transcription factors	11	7.88e-01	8.87e-01	0.12900	-1.14e-01	-6.02e-02	5.13e-01	7.29e-01
Chromatin modifying enzymes	186	8.56e-03	3.71e-02	0.12900	1.63e-04	1.29e-01	9.97e-01	2.47e-03
Chromatin organization	186	8.56e-03	3.71e-02	0.12900	1.63e-04	1.29e-01	9.97e-01	2.47e-03
RAF/MAP kinase cascade	264	4.33e-03	2.13e-02	0.12800	1.02e-01	7.84e-02	4.42e-03	2.82e-02
Synthesis of IP3 and IP4 in the cytosol	25	5.97e-01	7.66e-01	0.12800	-9.18e-02	-8.96e-02	4.27e-01	4.38e-01
Sealing of the nuclear envelope (NE) by ESCRT-III	31	5.28e-01	7.12e-01	0.12800	8.13e-02	9.88e-02	4.33e-01	3.41e-01
Golgi Associated Vesicle Biogenesis	51	2.16e-01	4.01e-01	0.12800	-6.83e-02	1.08e-01	3.99e-01	1.81e-01
Prolactin receptor signaling	15	7.09e-01	8.45e-01	0.12800	3.32e-02	1.23e-01	8.24e-01	4.08e-01
PI-3K cascade:FGFR3	17	7.00e-01	8.42e-01	0.12700	1.09e-01	6.56e-02	4.35e-01	6.39e-01
APC truncation mutants have impaired AXIN binding	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
AXIN missense mutants destabilize the destruction complex	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
Signaling by AMER1 mutants	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
Signaling by APC mutants	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
Signaling by AXIN mutants	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
Truncations of AMER1 destabilize the destruction complex	13	7.05e-01	8.42e-01	0.12700	-2.19e-02	1.25e-01	8.91e-01	4.34e-01
Regulation of actin dynamics for phagocytic cup formation	59	3.05e-01	5.05e-01	0.12700	9.35e-02	8.56e-02	2.14e-01	2.55e-01
Repression of WNT target genes	13	6.86e-01	8.31e-01	0.12700	5.73e-02	-1.13e-01	7.20e-01	4.80e-01
Neurexins and neuroligins	52	3.46e-01	5.52e-01	0.12600	-6.81e-02	-1.06e-01	3.95e-01	1.85e-01
Loss of Nlp from mitotic centrosomes	65	2.20e-01	4.03e-01	0.12600	1.64e-02	1.25e-01	8.19e-01	8.25e-02
Loss of proteins required for interphase microtubule organization from the centrosome	65	2.20e-01	4.03e-01	0.12600	1.64e-02	1.25e-01	8.19e-01	8.25e-02
PIWI-interacting RNA (piRNA) biogenesis	29	5.37e-01	7.21e-01	0.12500	1.18e-01	3.99e-02	2.70e-01	7.10e-01
Signaling by NOTCH1	69	2.39e-01	4.28e-01	0.12500	5.05e-02	1.14e-01	4.69e-01	1.01e-01
Reduction of cytosolic Ca++ levels	11	7.28e-01	8.54e-01	0.12500	7.44e-02	-1.00e-01	6.69e-01	5.65e-01
Iron uptake and transport	57	3.29e-01	5.34e-01	0.12500	8.39e-02	9.23e-02	2.73e-01	2.28e-01
Axon guidance	503	4.56e-05	3.91e-04	0.12500	1.10e-01	5.84e-02	2.32e-05	2.47e-02
Death Receptor Signalling	134	7.49e-02	1.91e-01	0.12500	8.91e-02	8.70e-02	7.47e-02	8.21e-02
VEGFR2 mediated cell proliferation	19	5.86e-01	7.56e-01	0.12400	-1.07e-01	6.33e-02	4.21e-01	6.33e-01
Intracellular signaling by second messengers	313	1.03e-03	6.43e-03	0.12400	2.31e-02	1.22e-01	4.81e-01	2.08e-04
SHC1 events in ERBB4 signaling	14	7.15e-01	8.50e-01	0.12400	-6.23e-04	1.24e-01	9.97e-01	4.22e-01
Innate Immune System	999	7.71e-10	1.85e-08	0.12400	2.84e-02	1.21e-01	1.28e-01	9.60e-11
CTNNB1 S33 mutants aren’t phosphorylated	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
CTNNB1 S37 mutants aren’t phosphorylated	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
CTNNB1 S45 mutants aren’t phosphorylated	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
CTNNB1 T41 mutants aren’t phosphorylated	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
Signaling by CTNNB1 phospho-site mutants	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
Signaling by GSK3beta mutants	14	6.77e-01	8.25e-01	0.12400	-6.05e-02	1.08e-01	6.95e-01	4.85e-01
RHOB GTPase cycle	66	2.74e-01	4.65e-01	0.12400	-1.06e-01	-6.42e-02	1.38e-01	3.67e-01
Carboxyterminal post-translational modifications of tubulin	40	3.32e-01	5.38e-01	0.12400	1.10e-01	-5.63e-02	2.29e-01	5.38e-01
Post-translational modification: synthesis of GPI-anchored proteins	89	9.64e-02	2.29e-01	0.12300	3.62e-02	-1.18e-01	5.55e-01	5.43e-02
Signaling by ERBB2 KD Mutants	24	6.14e-01	7.78e-01	0.12300	1.13e-01	4.80e-02	3.36e-01	6.84e-01
Phenylalanine and tyrosine metabolism	10	8.06e-01	8.98e-01	0.12300	2.75e-02	1.20e-01	8.80e-01	5.12e-01
G alpha (s) signalling events	153	5.67e-02	1.57e-01	0.12300	-9.06e-02	-8.26e-02	5.29e-02	7.78e-02
MAPK3 (ERK1) activation	10	7.80e-01	8.84e-01	0.12200	1.21e-01	-1.99e-02	5.08e-01	9.13e-01
Circadian Clock	69	1.47e-01	3.06e-01	0.12200	-9.14e-02	8.11e-02	1.89e-01	2.44e-01
Signaling by KIT in disease	20	6.59e-01	8.18e-01	0.12200	3.33e-02	1.17e-01	7.97e-01	3.63e-01
Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants	20	6.59e-01	8.18e-01	0.12200	3.33e-02	1.17e-01	7.97e-01	3.63e-01
Nuclear signaling by ERBB4	32	4.26e-01	6.27e-01	0.12200	5.04e-02	-1.11e-01	6.22e-01	2.76e-01
Downstream signal transduction	29	5.20e-01	7.08e-01	0.12200	7.12e-03	1.22e-01	9.47e-01	2.57e-01
RHO GTPases Activate Formins	114	1.20e-01	2.67e-01	0.12100	7.05e-02	9.87e-02	1.93e-01	6.86e-02
Negative regulation of NMDA receptor-mediated neuronal transmission	20	6.53e-01	8.17e-01	0.12000	-1.77e-02	-1.19e-01	8.91e-01	3.57e-01
Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)	14	7.35e-01	8.57e-01	0.12000	6.70e-03	1.20e-01	9.65e-01	4.37e-01
SARS-CoV-2 targets host intracellular signalling and regulatory pathways	12	7.39e-01	8.60e-01	0.12000	-1.14e-01	3.86e-02	4.95e-01	8.17e-01
Visual phototransduction	93	1.61e-01	3.25e-01	0.11900	-3.69e-02	-1.14e-01	5.38e-01	5.82e-02
Nervous system development	527	5.94e-05	5.02e-04	0.11900	1.08e-01	5.14e-02	2.23e-05	4.30e-02
Signaling by ERBB2	49	4.08e-01	6.10e-01	0.11900	5.91e-02	1.03e-01	4.74e-01	2.11e-01
Translation of Structural Proteins 9694635	55	3.35e-01	5.40e-01	0.11900	3.11e-02	1.15e-01	6.90e-01	1.41e-01
ER to Golgi Anterograde Transport	134	5.59e-02	1.55e-01	0.11900	5.88e-03	1.19e-01	9.06e-01	1.75e-02
Signaling by Retinoic Acid	41	3.69e-01	5.73e-01	0.11900	-3.41e-02	1.14e-01	7.05e-01	2.08e-01
Mismatch Repair	15	7.44e-01	8.62e-01	0.11900	3.16e-02	1.14e-01	8.32e-01	4.43e-01
Signal transduction by L1	20	6.89e-01	8.33e-01	0.11700	1.09e-01	4.33e-02	3.98e-01	7.38e-01
FGFR4 ligand binding and activation	13	7.99e-01	8.94e-01	0.11700	9.11e-02	7.36e-02	5.69e-01	6.46e-01
Striated Muscle Contraction	33	5.55e-01	7.35e-01	0.11700	-5.59e-02	-1.03e-01	5.79e-01	3.06e-01
PKMTs methylate histone lysines	37	3.91e-01	5.94e-01	0.11700	-8.86e-02	7.63e-02	3.51e-01	4.22e-01
PECAM1 interactions	12	7.93e-01	8.89e-01	0.11700	1.13e-01	2.85e-02	4.97e-01	8.64e-01
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)	117	1.26e-01	2.75e-01	0.11700	-5.49e-02	-1.03e-01	3.05e-01	5.41e-02
Association of TriC/CCT with target proteins during biosynthesis	38	5.20e-01	7.08e-01	0.11700	9.29e-02	7.06e-02	3.22e-01	4.51e-01
LDL clearance	19	7.00e-01	8.42e-01	0.11700	1.11e-01	3.52e-02	4.02e-01	7.90e-01
Synthesis of PE	12	7.51e-01	8.66e-01	0.11600	-4.13e-02	1.09e-01	8.04e-01	5.14e-01
Platelet calcium homeostasis	27	5.10e-01	7.03e-01	0.11600	-9.60e-02	6.56e-02	3.88e-01	5.55e-01
Pyruvate metabolism and Citric Acid (TCA) cycle	52	3.69e-01	5.73e-01	0.11600	2.57e-02	1.13e-01	7.49e-01	1.58e-01
G-protein beta:gamma signalling	30	4.72e-01	6.74e-01	0.11600	-7.75e-02	8.62e-02	4.62e-01	4.14e-01
Synthesis of PIPs at the early endosome membrane	15	7.30e-01	8.54e-01	0.11500	-1.15e-01	3.98e-03	4.40e-01	9.79e-01
Chondroitin sulfate/dermatan sulfate metabolism	45	3.65e-01	5.71e-01	0.11500	-2.61e-02	1.12e-01	7.62e-01	1.93e-01
FOXO-mediated transcription	65	3.22e-01	5.25e-01	0.11500	1.04e-01	4.77e-02	1.46e-01	5.06e-01
Pyruvate metabolism	29	4.99e-01	6.96e-01	0.11400	-6.05e-02	9.70e-02	5.72e-01	3.66e-01
Incretin synthesis, secretion, and inactivation	23	6.07e-01	7.73e-01	0.11400	-1.89e-02	1.13e-01	8.75e-01	3.49e-01
Dermatan sulfate biosynthesis	10	7.86e-01	8.86e-01	0.11400	-8.81e-02	7.22e-02	6.29e-01	6.93e-01
Intrinsic Pathway for Apoptosis	52	4.30e-01	6.31e-01	0.11400	7.37e-02	8.66e-02	3.58e-01	2.80e-01
Integrin cell surface interactions	66	3.44e-01	5.50e-01	0.11300	-7.20e-02	-8.77e-02	3.12e-01	2.18e-01
Mitochondrial Fatty Acid Beta-Oxidation	35	4.68e-01	6.69e-01	0.11300	-2.49e-02	1.11e-01	7.99e-01	2.58e-01
Synthesis of very long-chain fatty acyl-CoAs	23	6.77e-01	8.25e-01	0.11300	-4.78e-02	-1.03e-01	6.92e-01	3.94e-01
Syndecan interactions	19	6.39e-01	8.01e-01	0.11300	-9.31e-02	6.43e-02	4.82e-01	6.28e-01
Synthesis, secretion, and deacylation of Ghrelin	19	7.37e-01	8.58e-01	0.11300	7.61e-02	8.36e-02	5.66e-01	5.28e-01
Netrin-1 signaling	49	4.58e-01	6.57e-01	0.11300	-8.72e-02	-7.13e-02	2.91e-01	3.88e-01
Signaling by Hippo	19	7.35e-01	8.57e-01	0.11300	-6.18e-02	-9.41e-02	6.41e-01	4.77e-01
Signaling by NTRK2 (TRKB)	25	6.58e-01	8.18e-01	0.11200	4.82e-02	1.02e-01	6.76e-01	3.79e-01
Synthesis of PIPs at the Golgi membrane	17	6.81e-01	8.29e-01	0.11200	-1.01e-01	4.86e-02	4.70e-01	7.29e-01
GPER1 signaling	44	3.76e-01	5.80e-01	0.11200	-4.29e-02	1.03e-01	6.23e-01	2.35e-01
Regulation of Complement cascade	45	4.91e-01	6.91e-01	0.11200	-6.82e-02	-8.88e-02	4.29e-01	3.03e-01
Effects of PIP2 hydrolysis	26	6.66e-01	8.22e-01	0.11200	-7.87e-02	-7.93e-02	4.87e-01	4.84e-01
Complement cascade	56	4.06e-01	6.08e-01	0.11200	-5.59e-02	-9.66e-02	4.69e-01	2.11e-01
Synaptic adhesion-like molecules	19	7.35e-01	8.57e-01	0.11200	9.84e-02	5.26e-02	4.58e-01	6.92e-01
Translation of Structural Proteins 9683701	29	6.33e-01	7.98e-01	0.11200	9.05e-02	6.52e-02	3.99e-01	5.43e-01
Transport of inorganic cations/anions and amino acids/oligopeptides	101	1.34e-01	2.87e-01	0.11100	1.03e-02	-1.11e-01	8.58e-01	5.43e-02
MAPK family signaling cascades	311	8.24e-03	3.64e-02	0.11100	8.72e-02	6.91e-02	8.14e-03	3.59e-02
SARS-CoV-1 targets host intracellular signalling and regulatory pathways	16	7.12e-01	8.49e-01	0.11100	-3.16e-02	1.06e-01	8.27e-01	4.62e-01
Keratan sulfate/keratin metabolism	33	5.11e-01	7.03e-01	0.11000	-1.08e-01	2.25e-02	2.84e-01	8.23e-01
Cell surface interactions at the vascular wall	127	6.16e-02	1.66e-01	0.11000	-5.80e-02	9.30e-02	2.59e-01	7.01e-02
Elastic fibre formation	40	4.25e-01	6.26e-01	0.11000	-1.00e-01	4.38e-02	2.72e-01	6.32e-01
Signaling by NTRK3 (TRKC)	17	7.47e-01	8.63e-01	0.10900	2.27e-02	1.07e-01	8.71e-01	4.45e-01
Post-translational protein modification	1289	1.22e-09	2.74e-08	0.10900	2.94e-02	1.05e-01	7.48e-02	1.73e-10
PLC beta mediated events	47	4.26e-01	6.26e-01	0.10900	-1.09e-01	-6.10e-03	1.96e-01	9.42e-01
Rab regulation of trafficking	113	1.05e-01	2.42e-01	0.10900	-2.36e-02	1.06e-01	6.65e-01	5.07e-02
ESR-mediated signaling	160	6.45e-02	1.70e-01	0.10800	1.32e-02	1.07e-01	7.72e-01	1.95e-02
Signaling by FGFR3 in disease	21	7.30e-01	8.54e-01	0.10800	5.49e-02	9.27e-02	6.63e-01	4.62e-01
NPAS4 regulates expression of target genes	21	6.57e-01	8.18e-01	0.10700	1.03e-01	-3.19e-02	4.16e-01	8.00e-01
Adaptive Immune System	709	3.55e-05	3.09e-04	0.10700	5.57e-02	9.18e-02	1.12e-02	2.99e-05
Gap junction assembly	18	6.86e-01	8.31e-01	0.10700	5.30e-02	-9.33e-02	6.97e-01	4.93e-01
Basigin interactions	24	6.55e-01	8.18e-01	0.10600	3.63e-04	1.06e-01	9.98e-01	3.67e-01
G-protein mediated events	52	3.93e-01	5.95e-01	0.10600	-1.06e-01	5.61e-03	1.85e-01	9.44e-01
Post-chaperonin tubulin folding pathway	23	7.22e-01	8.54e-01	0.10600	7.31e-02	7.70e-02	5.44e-01	5.22e-01
DARPP-32 events	24	6.83e-01	8.30e-01	0.10600	2.62e-02	1.03e-01	8.24e-01	3.83e-01
NCAM signaling for neurite out-growth	57	3.19e-01	5.23e-01	0.10600	4.63e-02	-9.49e-02	5.45e-01	2.15e-01
Immune System	1870	3.68e-12	1.32e-10	0.10500	3.61e-02	9.91e-02	9.15e-03	8.57e-13
Metabolic disorders of biological oxidation enzymes	32	5.56e-01	7.35e-01	0.10500	1.64e-02	-1.04e-01	8.73e-01	3.08e-01
Tight junction interactions	28	6.74e-01	8.25e-01	0.10500	-5.88e-02	-8.71e-02	5.90e-01	4.25e-01
Signaling by BRAF and RAF1 fusions	60	2.98e-01	4.96e-01	0.10500	-5.54e-02	8.93e-02	4.58e-01	2.32e-01
Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding	38	5.78e-01	7.49e-01	0.10400	4.36e-02	9.49e-02	6.42e-01	3.12e-01
G beta:gamma signalling through BTK	17	7.46e-01	8.63e-01	0.10400	-3.34e-03	1.04e-01	9.81e-01	4.56e-01
Signaling by PDGFRA extracellular domain mutants	12	7.86e-01	8.86e-01	0.10400	-5.88e-02	8.61e-02	7.24e-01	6.05e-01
Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants	12	7.86e-01	8.86e-01	0.10400	-5.88e-02	8.61e-02	7.24e-01	6.05e-01
G beta:gamma signalling through CDC42	19	7.14e-01	8.49e-01	0.10400	-1.25e-02	1.04e-01	9.25e-01	4.35e-01
Protein folding	96	2.64e-01	4.56e-01	0.10300	4.99e-02	9.06e-02	3.98e-01	1.25e-01
RHO GTPases activate PAKs	19	7.75e-01	8.84e-01	0.10300	-7.74e-02	-6.86e-02	5.59e-01	6.05e-01
Signaling by MET	66	2.71e-01	4.62e-01	0.10300	-6.93e-02	7.65e-02	3.30e-01	2.82e-01
Cargo recognition for clathrin-mediated endocytosis	98	2.38e-01	4.27e-01	0.10300	3.18e-02	9.82e-02	5.86e-01	9.29e-02
Interleukin-27 signaling	11	8.31e-01	9.13e-01	0.10300	5.16e-03	-1.03e-01	9.76e-01	5.56e-01
Kinesins	42	4.40e-01	6.39e-01	0.10300	-7.83e-02	6.63e-02	3.80e-01	4.57e-01
RMTs methylate histone arginines	30	5.63e-01	7.37e-01	0.10200	-5.21e-02	8.82e-02	6.21e-01	4.03e-01
Cobalamin (Cbl, vitamin B12) transport and metabolism	20	7.04e-01	8.42e-01	0.10200	2.06e-02	-1.00e-01	8.73e-01	4.38e-01
Transport to the Golgi and subsequent modification	165	5.67e-02	1.57e-01	0.10200	-2.00e-02	1.00e-01	6.57e-01	2.63e-02
MHC class II antigen presentation	104	2.43e-01	4.33e-01	0.10200	4.70e-02	9.06e-02	4.07e-01	1.10e-01
Biotin transport and metabolism	10	8.51e-01	9.25e-01	0.10200	-1.79e-04	1.02e-01	9.99e-01	5.77e-01
Removal of the Flap Intermediate	13	8.41e-01	9.17e-01	0.10200	5.20e-02	8.75e-02	7.46e-01	5.85e-01
RAC3 GTPase cycle	84	2.08e-01	3.87e-01	0.10200	-8.92e-02	4.87e-02	1.57e-01	4.40e-01
Platelet sensitization by LDL	17	7.37e-01	8.58e-01	0.10200	-3.26e-02	9.62e-02	8.16e-01	4.92e-01
RND1 GTPase cycle	41	4.96e-01	6.93e-01	0.10100	-9.97e-02	1.82e-02	2.69e-01	8.41e-01
VxPx cargo-targeting to cilium	20	7.63e-01	8.77e-01	0.10100	-4.28e-02	-9.16e-02	7.40e-01	4.78e-01
Deadenylation of mRNA	25	6.64e-01	8.21e-01	0.10100	-1.01e-01	7.32e-03	3.83e-01	9.49e-01
RAF activation	33	5.60e-01	7.37e-01	0.10100	-3.05e-02	9.60e-02	7.61e-01	3.40e-01
PI-3K cascade:FGFR2	22	7.28e-01	8.54e-01	0.10000	9.81e-02	2.13e-02	4.26e-01	8.63e-01
FCGR3A-mediated phagocytosis	57	4.87e-01	6.88e-01	0.10000	7.82e-02	6.25e-02	3.07e-01	4.14e-01
Leishmania phagocytosis	57	4.87e-01	6.88e-01	0.10000	7.82e-02	6.25e-02	3.07e-01	4.14e-01
Parasite infection	57	4.87e-01	6.88e-01	0.10000	7.82e-02	6.25e-02	3.07e-01	4.14e-01
Long-term potentiation	22	6.84e-01	8.30e-01	0.09990	2.94e-02	-9.55e-02	8.12e-01	4.38e-01
Tandem pore domain potassium channels	12	8.51e-01	9.25e-01	0.09980	-9.27e-02	-3.71e-02	5.78e-01	8.24e-01
Regulation of pyruvate dehydrogenase (PDH) complex	14	7.76e-01	8.84e-01	0.09950	-5.03e-02	8.58e-02	7.44e-01	5.78e-01
Ion channel transport	168	1.15e-01	2.59e-01	0.09940	-4.51e-02	-8.85e-02	3.13e-01	4.76e-02
Metabolism of folate and pterines	16	7.52e-01	8.66e-01	0.09930	-4.59e-02	8.80e-02	7.50e-01	5.42e-01
Signaling by ERBB4	57	4.74e-01	6.76e-01	0.09920	9.08e-02	3.99e-02	2.36e-01	6.02e-01
Amyloid fiber formation	53	4.89e-01	6.89e-01	0.09910	9.41e-02	3.13e-02	2.36e-01	6.93e-01
Membrane Trafficking	585	9.51e-05	7.78e-04	0.09880	-1.61e-02	9.75e-02	5.05e-01	5.39e-05
Glycogen metabolism	22	7.23e-01	8.54e-01	0.09790	3.73e-03	9.79e-02	9.76e-01	4.27e-01
Activation of BAD and translocation to mitochondria	15	7.68e-01	8.82e-01	0.09760	-7.88e-02	5.77e-02	5.97e-01	6.99e-01
Glutamate binding, activation of AMPA receptors and synaptic plasticity	29	6.73e-01	8.25e-01	0.09710	9.55e-02	1.79e-02	3.74e-01	8.68e-01
Trafficking of AMPA receptors	29	6.73e-01	8.25e-01	0.09710	9.55e-02	1.79e-02	3.74e-01	8.68e-01
Interleukin-37 signaling	20	7.05e-01	8.42e-01	0.09700	-5.97e-02	7.64e-02	6.44e-01	5.54e-01
Phase I - Functionalization of compounds	100	1.85e-01	3.57e-01	0.09680	4.35e-02	-8.65e-02	4.52e-01	1.35e-01
Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer	49	5.03e-01	6.99e-01	0.09680	9.37e-03	9.63e-02	9.10e-01	2.43e-01
Processive synthesis on the lagging strand	14	8.35e-01	9.14e-01	0.09670	3.04e-02	9.18e-02	8.44e-01	5.52e-01
Listeria monocytogenes entry into host cells	19	7.90e-01	8.87e-01	0.09660	4.05e-02	8.78e-02	7.60e-01	5.08e-01
ADORA2B mediated anti-inflammatory cytokines production	42	4.87e-01	6.88e-01	0.09640	-5.40e-02	7.99e-02	5.45e-01	3.70e-01
Endogenous sterols	26	7.30e-01	8.54e-01	0.09640	-8.48e-02	-4.58e-02	4.54e-01	6.86e-01
Norepinephrine Neurotransmitter Release Cycle	16	8.28e-01	9.10e-01	0.09630	-5.43e-02	-7.96e-02	7.07e-01	5.82e-01
Cardiac conduction	123	1.97e-01	3.74e-01	0.09610	-1.93e-02	-9.41e-02	7.11e-01	7.13e-02
Glycosaminoglycan metabolism	116	1.49e-01	3.10e-01	0.09610	-8.82e-02	3.81e-02	1.01e-01	4.78e-01
Ion transport by P-type ATPases	51	4.44e-01	6.42e-01	0.09610	2.77e-02	-9.20e-02	7.32e-01	2.56e-01
Activation of the AP-1 family of transcription factors	10	8.52e-01	9.25e-01	0.09590	9.11e-02	-2.98e-02	6.18e-01	8.70e-01
Ephrin signaling	17	8.03e-01	8.98e-01	0.09570	-9.26e-02	-2.41e-02	5.09e-01	8.64e-01
Chaperonin-mediated protein folding	90	3.53e-01	5.58e-01	0.09530	5.24e-02	7.96e-02	3.90e-01	1.92e-01
EPH-ephrin mediated repulsion of cells	48	4.50e-01	6.48e-01	0.09500	-5.47e-02	7.77e-02	5.12e-01	3.52e-01
Muscle contraction	193	7.71e-02	1.95e-01	0.09490	-1.18e-02	-9.42e-02	7.78e-01	2.39e-02
NRAGE signals death through JNK	53	5.50e-01	7.30e-01	0.09480	-7.29e-02	-6.05e-02	3.59e-01	4.46e-01
Sema4D in semaphorin signaling	24	6.90e-01	8.33e-01	0.09460	-2.79e-02	9.04e-02	8.13e-01	4.43e-01
Meiosis	56	3.99e-01	6.01e-01	0.09430	-5.35e-02	7.77e-02	4.88e-01	3.14e-01
ERBB2 Regulates Cell Motility	15	7.80e-01	8.84e-01	0.09430	6.51e-02	-6.82e-02	6.63e-01	6.47e-01
Formation of the beta-catenin:TCF transactivating complex	32	5.99e-01	7.66e-01	0.09410	8.40e-02	-4.25e-02	4.11e-01	6.77e-01
Rap1 signalling	16	8.34e-01	9.14e-01	0.09300	4.16e-02	8.32e-02	7.73e-01	5.65e-01
CD28 co-stimulation	32	6.02e-01	7.67e-01	0.09230	-6.38e-02	6.67e-02	5.32e-01	5.14e-01
Adenylate cyclase activating pathway	10	8.63e-01	9.32e-01	0.09180	3.05e-02	-8.65e-02	8.67e-01	6.36e-01
Acetylcholine Neurotransmitter Release Cycle	16	7.82e-01	8.84e-01	0.09160	4.87e-02	-7.76e-02	7.36e-01	5.91e-01
RND3 GTPase cycle	41	6.00e-01	7.66e-01	0.09110	-9.07e-02	-8.39e-03	3.15e-01	9.26e-01
Neurotoxicity of clostridium toxins	10	8.94e-01	9.46e-01	0.09070	-3.21e-02	-8.49e-02	8.61e-01	6.42e-01
RHO GTPase Effectors	232	7.72e-02	1.95e-01	0.09060	3.22e-02	8.47e-02	3.98e-01	2.61e-02
Intraflagellar transport	36	6.65e-01	8.22e-01	0.09050	8.64e-02	2.68e-02	3.69e-01	7.81e-01
Signaling by Non-Receptor Tyrosine Kinases	55	4.68e-01	6.69e-01	0.09030	-2.10e-02	8.78e-02	7.88e-01	2.60e-01
Signaling by PTK6	55	4.68e-01	6.69e-01	0.09030	-2.10e-02	8.78e-02	7.88e-01	2.60e-01
Heme biosynthesis	13	8.33e-01	9.14e-01	0.09020	2.49e-02	-8.67e-02	8.76e-01	5.88e-01
Oncogenic MAPK signaling	76	3.42e-01	5.48e-01	0.08980	-3.03e-02	8.45e-02	6.47e-01	2.03e-01
IL-6-type cytokine receptor ligand interactions	17	8.13e-01	9.05e-01	0.08950	-6.11e-03	-8.93e-02	9.65e-01	5.24e-01
Organelle biogenesis and maintenance	243	6.78e-02	1.75e-01	0.08940	2.43e-02	8.60e-02	5.14e-01	2.08e-02
RAC1 GTPase cycle	170	1.07e-01	2.46e-01	0.08900	-8.76e-02	1.57e-02	4.86e-02	7.23e-01
Protein-protein interactions at synapses	78	4.45e-01	6.43e-01	0.08900	-4.02e-02	-7.94e-02	5.39e-01	2.25e-01
Azathioprine ADME	22	7.43e-01	8.62e-01	0.08900	-2.22e-02	8.62e-02	8.57e-01	4.84e-01
Ca2+ pathway	62	5.35e-01	7.19e-01	0.08900	-7.39e-02	-4.95e-02	3.14e-01	5.00e-01
Other semaphorin interactions	18	8.04e-01	8.98e-01	0.08870	-8.87e-02	-2.72e-03	5.15e-01	9.84e-01
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	29	6.61e-01	8.19e-01	0.08770	6.89e-02	-5.42e-02	5.21e-01	6.13e-01
Interleukin-7 signaling	21	7.79e-01	8.84e-01	0.08770	8.76e-02	1.90e-03	4.87e-01	9.88e-01
Clathrin-mediated endocytosis	135	2.23e-01	4.07e-01	0.08720	1.31e-02	8.63e-02	7.93e-01	8.34e-02
Sphingolipid metabolism	81	3.22e-01	5.25e-01	0.08690	-6.71e-02	5.52e-02	2.96e-01	3.90e-01
Signaling by Nuclear Receptors	237	4.86e-02	1.40e-01	0.08680	-2.22e-02	8.39e-02	5.57e-01	2.60e-02
Response to metal ions	14	8.62e-01	9.32e-01	0.08640	8.40e-02	2.01e-02	5.86e-01	8.96e-01
Sema4D induced cell migration and growth-cone collapse	20	7.76e-01	8.84e-01	0.08610	-2.14e-02	8.34e-02	8.68e-01	5.18e-01
Unblocking of NMDA receptors, glutamate binding and activation	19	7.82e-01	8.84e-01	0.08590	2.91e-02	-8.08e-02	8.26e-01	5.42e-01
Phospholipid metabolism	192	7.84e-02	1.97e-01	0.08580	-7.57e-02	4.05e-02	7.04e-02	3.33e-01
Leishmania infection	156	2.00e-01	3.78e-01	0.08550	2.05e-02	8.30e-02	6.58e-01	7.33e-02
RAS processing	19	7.83e-01	8.85e-01	0.08530	-7.90e-02	3.21e-02	5.51e-01	8.09e-01
G alpha (i) signalling events	305	6.43e-02	1.70e-01	0.08520	-6.11e-02	-5.94e-02	6.62e-02	7.41e-02
Paradoxical activation of RAF signaling by kinase inactive BRAF	41	6.71e-01	8.25e-01	0.08510	3.23e-02	7.87e-02	7.21e-01	3.83e-01
Signaling by RAS mutants	41	6.71e-01	8.25e-01	0.08510	3.23e-02	7.87e-02	7.21e-01	3.83e-01
Signaling by moderate kinase activity BRAF mutants	41	6.71e-01	8.25e-01	0.08510	3.23e-02	7.87e-02	7.21e-01	3.83e-01
Signaling downstream of RAS mutants	41	6.71e-01	8.25e-01	0.08510	3.23e-02	7.87e-02	7.21e-01	3.83e-01
The role of Nef in HIV-1 replication and disease pathogenesis	27	7.79e-01	8.84e-01	0.08510	7.08e-02	4.72e-02	5.25e-01	6.71e-01
Signaling by SCF-KIT	43	5.62e-01	7.37e-01	0.08510	-5.24e-02	6.70e-02	5.52e-01	4.47e-01
Heparan sulfate/heparin (HS-GAG) metabolism	49	6.06e-01	7.72e-01	0.08490	-8.25e-02	-2.03e-02	3.18e-01	8.06e-01
Metabolism	1963	2.78e-08	4.52e-07	0.08480	3.46e-02	7.75e-02	1.08e-02	1.09e-08
Glycogen breakdown (glycogenolysis)	11	9.02e-01	9.50e-01	0.08440	-7.61e-02	-3.66e-02	6.62e-01	8.34e-01
PKA-mediated phosphorylation of CREB	19	7.77e-01	8.84e-01	0.08440	-6.03e-02	5.91e-02	6.49e-01	6.56e-01
Antigen Presentation: Folding, assembly and peptide loading of class I MHC	29	7.72e-01	8.84e-01	0.08400	5.08e-02	6.69e-02	6.36e-01	5.33e-01
PI-3K cascade:FGFR4	19	8.28e-01	9.10e-01	0.08380	8.12e-02	2.07e-02	5.40e-01	8.76e-01
SHC1 events in ERBB2 signaling	22	8.25e-01	9.09e-01	0.08370	5.80e-02	6.03e-02	6.38e-01	6.24e-01
Transport of nucleosides and free purine and pyrimidine bases across the plasma membrane	10	9.08e-01	9.53e-01	0.08360	2.45e-02	8.00e-02	8.93e-01	6.62e-01
Interferon gamma signaling	89	4.56e-01	6.55e-01	0.08330	4.60e-02	6.94e-02	4.53e-01	2.58e-01
Glucagon-like Peptide-1 (GLP1) regulates insulin secretion	42	6.02e-01	7.67e-01	0.08300	-2.89e-02	7.78e-02	7.46e-01	3.83e-01
Vesicle-mediated transport	623	7.25e-04	4.61e-03	0.08290	-2.40e-02	7.93e-02	3.05e-01	7.02e-04
Role of phospholipids in phagocytosis	23	8.19e-01	9.07e-01	0.08290	-4.92e-02	-6.67e-02	6.83e-01	5.80e-01
Signaling by TGF-beta Receptor Complex	90	3.61e-01	5.68e-01	0.08250	-1.46e-02	8.12e-02	8.10e-01	1.83e-01
CaMK IV-mediated phosphorylation of CREB	10	8.92e-01	9.45e-01	0.08230	8.05e-02	-1.73e-02	6.59e-01	9.25e-01
Defective B3GALT6 causes EDSP2 and SEMDJL1	17	8.54e-01	9.27e-01	0.08210	-2.62e-02	-7.78e-02	8.52e-01	5.79e-01
GPCR downstream signalling	603	6.91e-03	3.10e-02	0.08190	-6.26e-02	-5.29e-02	8.55e-03	2.61e-02
Integrin signaling	27	7.39e-01	8.60e-01	0.08170	-8.02e-02	1.58e-02	4.71e-01	8.87e-01
RHOG GTPase cycle	69	4.79e-01	6.80e-01	0.08130	-8.10e-02	7.79e-03	2.45e-01	9.11e-01
Fcgamma receptor (FCGR) dependent phagocytosis	82	4.85e-01	6.88e-01	0.08130	3.18e-02	7.47e-02	6.18e-01	2.42e-01
TRP channels	24	8.18e-01	9.07e-01	0.08120	-4.58e-02	-6.70e-02	6.98e-01	5.70e-01
HS-GAG biosynthesis	28	7.82e-01	8.84e-01	0.08080	-7.50e-02	-2.99e-02	4.92e-01	7.84e-01
EGR2 and SOX10-mediated initiation of Schwann cell myelination	27	7.58e-01	8.72e-01	0.08010	5.33e-03	-8.00e-02	9.62e-01	4.72e-01
Fatty acid metabolism	167	2.44e-01	4.33e-01	0.07990	3.23e-02	7.30e-02	4.71e-01	1.03e-01
Hemostasis	555	1.58e-03	9.28e-03	0.07980	-5.96e-02	5.31e-02	1.61e-02	3.21e-02
GAB1 signalosome	17	8.26e-01	9.09e-01	0.07910	-3.48e-02	7.10e-02	8.04e-01	6.12e-01
Regulation of gene expression in beta cells	21	8.23e-01	9.09e-01	0.07900	7.84e-02	9.53e-03	5.34e-01	9.40e-01
Serotonin Neurotransmitter Release Cycle	16	8.83e-01	9.42e-01	0.07880	-5.08e-02	-6.02e-02	7.25e-01	6.76e-01
Nicotinate metabolism	29	7.73e-01	8.84e-01	0.07810	7.69e-02	1.33e-02	4.73e-01	9.01e-01
PKA activation in glucagon signalling	17	8.27e-01	9.10e-01	0.07800	-4.16e-02	6.60e-02	7.66e-01	6.38e-01
Defects in vitamin and cofactor metabolism	20	8.36e-01	9.14e-01	0.07800	1.10e-02	7.72e-02	9.32e-01	5.50e-01
COPI-dependent Golgi-to-ER retrograde traffic	81	4.19e-01	6.22e-01	0.07780	-3.05e-02	7.16e-02	6.35e-01	2.65e-01
Peptide hormone metabolism	83	4.51e-01	6.49e-01	0.07770	-7.76e-02	3.90e-03	2.21e-01	9.51e-01
Insulin receptor recycling	26	8.05e-01	8.98e-01	0.07760	2.33e-02	7.41e-02	8.37e-01	5.13e-01
Regulation of KIT signaling	16	8.85e-01	9.43e-01	0.07760	-6.40e-02	-4.38e-02	6.58e-01	7.61e-01
Phase II - Conjugation of compounds	106	4.51e-01	6.48e-01	0.07750	-5.82e-02	-5.12e-02	3.00e-01	3.62e-01
Molecules associated with elastic fibres	29	7.46e-01	8.63e-01	0.07740	-7.56e-02	1.65e-02	4.81e-01	8.78e-01
MicroRNA (miRNA) biogenesis	26	8.25e-01	9.09e-01	0.07680	5.50e-02	5.37e-02	6.27e-01	6.36e-01
CD28 dependent PI3K/Akt signaling	22	8.20e-01	9.07e-01	0.07680	3.33e-03	7.67e-02	9.78e-01	5.33e-01
Peptide ligand-binding receptors	190	1.29e-01	2.79e-01	0.07680	6.35e-02	-4.32e-02	1.31e-01	3.05e-01
Pyrimidine catabolism	12	8.89e-01	9.44e-01	0.07670	-7.54e-02	1.42e-02	6.51e-01	9.32e-01
Downregulation of SMAD2/3:SMAD4 transcriptional activity	29	7.42e-01	8.61e-01	0.07610	-2.97e-02	7.00e-02	7.82e-01	5.14e-01
Crosslinking of collagen fibrils	10	9.02e-01	9.50e-01	0.07600	6.94e-02	-3.10e-02	7.04e-01	8.65e-01
Deadenylation-dependent mRNA decay	56	6.68e-01	8.24e-01	0.07570	4.73e-02	5.91e-02	5.40e-01	4.44e-01
RHO GTPase cycle	420	1.29e-02	4.86e-02	0.07530	-5.95e-02	4.62e-02	3.62e-02	1.04e-01
Cytochrome P450 - arranged by substrate type	64	5.79e-01	7.50e-01	0.07520	-6.08e-03	-7.50e-02	9.33e-01	2.99e-01
Metabolism of carbohydrates	275	8.63e-02	2.12e-01	0.07440	-8.10e-03	7.40e-02	8.17e-01	3.46e-02
Phase 2 - plateau phase	14	8.87e-01	9.44e-01	0.07420	-2.83e-04	-7.42e-02	9.99e-01	6.31e-01
FOXO-mediated transcription of cell cycle genes	16	8.94e-01	9.46e-01	0.07390	3.85e-02	6.31e-02	7.90e-01	6.62e-01
G beta:gamma signalling through PLC beta	20	8.18e-01	9.07e-01	0.07360	-4.40e-02	5.90e-02	7.33e-01	6.48e-01
IGF1R signaling cascade	51	6.89e-01	8.33e-01	0.07360	2.68e-02	6.85e-02	7.41e-01	3.97e-01
Sema3A PAK dependent Axon repulsion	14	8.78e-01	9.39e-01	0.07350	-7.07e-02	1.99e-02	6.47e-01	8.97e-01
Metabolism of nitric oxide: NOS3 activation and regulation	15	8.64e-01	9.32e-01	0.07340	-6.52e-02	3.36e-02	6.62e-01	8.22e-01
RHOC GTPase cycle	69	5.39e-01	7.22e-01	0.07260	-7.05e-02	1.75e-02	3.11e-01	8.02e-01
A tetrasaccharide linker sequence is required for GAG synthesis	23	8.60e-01	9.31e-01	0.07230	-5.41e-02	-4.79e-02	6.53e-01	6.91e-01
Lagging Strand Synthesis	19	8.78e-01	9.39e-01	0.07190	3.12e-02	6.48e-02	8.14e-01	6.25e-01
Signaling by RAF1 mutants	37	7.61e-01	8.75e-01	0.07190	1.53e-02	7.02e-02	8.72e-01	4.60e-01
COPI-mediated anterograde transport	83	5.88e-01	7.57e-01	0.07140	4.56e-02	5.50e-02	4.73e-01	3.86e-01
L1CAM interactions	92	5.59e-01	7.37e-01	0.07110	-4.62e-02	-5.40e-02	4.43e-01	3.71e-01
Signal attenuation	10	9.23e-01	9.56e-01	0.07000	6.95e-02	-8.14e-03	7.04e-01	9.64e-01
Attachment and Entry 9694614	16	8.66e-01	9.32e-01	0.06970	-4.38e-02	5.42e-02	7.62e-01	7.07e-01
Erythropoietin activates Phosphoinositide-3-kinase (PI3K)	12	9.21e-01	9.56e-01	0.06940	-1.59e-02	-6.75e-02	9.24e-01	6.85e-01
EPHA-mediated growth cone collapse	15	9.01e-01	9.50e-01	0.06910	-1.25e-02	-6.79e-02	9.33e-01	6.49e-01
RAB GEFs exchange GTP for GDP on RABs	82	5.04e-01	6.99e-01	0.06860	-6.30e-02	2.70e-02	3.24e-01	6.73e-01
GABA receptor activation	57	6.30e-01	7.94e-01	0.06850	-6.54e-02	2.04e-02	3.93e-01	7.90e-01
Signaling by Rho GTPases, Miro GTPases and RHOBTB3	603	8.55e-03	3.71e-02	0.06840	-1.98e-02	6.54e-02	4.05e-01	5.95e-03
Processing of SMDT1	15	9.16e-01	9.53e-01	0.06820	-4.23e-02	-5.35e-02	7.77e-01	7.20e-01
CLEC7A (Dectin-1) induces NFAT activation	11	9.18e-01	9.53e-01	0.06810	1.43e-02	-6.66e-02	9.35e-01	7.02e-01
Signaling by Insulin receptor	77	6.25e-01	7.90e-01	0.06800	2.89e-02	6.16e-02	6.61e-01	3.50e-01
Class B/2 (Secretin family receptors)	94	4.76e-01	6.78e-01	0.06780	-1.89e-02	6.51e-02	7.51e-01	2.75e-01
Nuclear Receptor transcription pathway	51	6.60e-01	8.19e-01	0.06770	-6.23e-02	2.66e-02	4.42e-01	7.42e-01
Biological oxidations	213	2.39e-01	4.28e-01	0.06760	-8.72e-03	-6.71e-02	8.26e-01	9.14e-02
Aquaporin-mediated transport	51	7.24e-01	8.54e-01	0.06750	-6.48e-02	-1.90e-02	4.24e-01	8.14e-01
Diseases associated with glycosaminoglycan metabolism	38	8.05e-01	8.98e-01	0.06700	-5.55e-02	-3.75e-02	5.54e-01	6.89e-01
SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion	13	9.02e-01	9.50e-01	0.06700	-2.45e-02	6.23e-02	8.78e-01	6.97e-01
Platelet activation, signaling and aggregation	245	1.35e-01	2.90e-01	0.06670	-3.93e-02	5.39e-02	2.89e-01	1.46e-01
SLC-mediated transmembrane transport	238	1.58e-01	3.22e-01	0.06660	2.41e-02	-6.21e-02	5.22e-01	9.85e-02
Signaling by Receptor Tyrosine Kinases	493	3.75e-02	1.17e-01	0.06630	1.84e-03	6.63e-02	9.44e-01	1.15e-02
Transport of bile salts and organic acids, metal ions and amine compounds	84	5.07e-01	7.00e-01	0.06630	3.76e-02	-5.46e-02	5.51e-01	3.87e-01
SLC transporter disorders	92	5.90e-01	7.59e-01	0.06630	3.08e-02	5.87e-02	6.10e-01	3.30e-01
Meiotic recombination	26	8.62e-01	9.32e-01	0.06620	3.17e-02	5.81e-02	7.80e-01	6.08e-01
TRAF6 mediated IRF7 activation	26	8.40e-01	9.17e-01	0.06590	1.64e-03	6.59e-02	9.88e-01	5.61e-01
GPCR ligand binding	443	9.56e-02	2.27e-01	0.06550	-4.95e-02	-4.29e-02	7.36e-02	1.21e-01
Signaling by Rho GTPases	589	1.37e-02	5.10e-02	0.06520	-2.17e-02	6.15e-02	3.66e-01	1.06e-02
Metabolism of Angiotensinogen to Angiotensins	15	9.06e-01	9.52e-01	0.06490	-6.49e-02	1.43e-04	6.63e-01	9.99e-01
Diseases of glycosylation	137	4.47e-01	6.45e-01	0.06480	-6.26e-02	-1.66e-02	2.05e-01	7.37e-01
Regulation of IFNG signaling	14	9.03e-01	9.50e-01	0.06450	-2.15e-02	6.08e-02	8.89e-01	6.94e-01
Defective EXT1 causes exostoses 1, TRPS2 and CHDS	12	9.12e-01	9.53e-01	0.06450	3.48e-02	-5.43e-02	8.35e-01	7.45e-01
Defective EXT2 causes exostoses 2	12	9.12e-01	9.53e-01	0.06450	3.48e-02	-5.43e-02	8.35e-01	7.45e-01
RHO GTPases activate CIT	19	8.70e-01	9.34e-01	0.06450	5.98e-02	-2.41e-02	6.52e-01	8.56e-01
Sialic acid metabolism	33	8.35e-01	9.14e-01	0.06440	2.86e-02	5.77e-02	7.76e-01	5.66e-01
Transferrin endocytosis and recycling	30	8.24e-01	9.09e-01	0.06400	-2.19e-03	6.39e-02	9.83e-01	5.44e-01
Extra-nuclear estrogen signaling	73	5.88e-01	7.57e-01	0.06330	-3.17e-02	5.47e-02	6.39e-01	4.19e-01
Diseases of carbohydrate metabolism	30	8.57e-01	9.29e-01	0.06300	3.13e-02	5.47e-02	7.67e-01	6.04e-01
Metallothioneins bind metals	11	9.29e-01	9.58e-01	0.06250	6.04e-02	-1.60e-02	7.29e-01	9.27e-01
Organic cation/anion/zwitterion transport	15	9.13e-01	9.53e-01	0.06210	8.95e-04	-6.21e-02	9.95e-01	6.77e-01
eNOS activation	11	9.34e-01	9.61e-01	0.06170	-6.10e-02	8.73e-03	7.26e-01	9.60e-01
Vasopressin regulates renal water homeostasis via Aquaporins	42	7.45e-01	8.63e-01	0.06160	-4.96e-02	3.64e-02	5.78e-01	6.83e-01
Cargo trafficking to the periciliary membrane	49	7.52e-01	8.66e-01	0.06150	6.15e-02	2.18e-03	4.56e-01	9.79e-01
Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)	14	9.16e-01	9.53e-01	0.06140	-9.63e-03	6.06e-02	9.50e-01	6.94e-01
CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling	25	8.89e-01	9.44e-01	0.06140	-4.28e-02	-4.40e-02	7.11e-01	7.03e-01
RHO GTPases activate PKNs	34	7.89e-01	8.87e-01	0.06130	-4.77e-02	3.85e-02	6.30e-01	6.98e-01
Beta-oxidation of very long chain fatty acids	10	9.47e-01	9.69e-01	0.06080	6.01e-02	9.01e-03	7.42e-01	9.61e-01
Regulation of signaling by CBL	18	9.18e-01	9.53e-01	0.06070	-3.01e-02	-5.27e-02	8.25e-01	6.98e-01
EPHB-mediated forward signaling	34	8.23e-01	9.09e-01	0.06070	-2.82e-04	6.07e-02	9.98e-01	5.40e-01
ROS and RNS production in phagocytes	35	8.13e-01	9.05e-01	0.06070	-4.94e-03	6.05e-02	9.60e-01	5.36e-01
Hyaluronan uptake and degradation	12	9.27e-01	9.57e-01	0.06050	1.76e-02	-5.78e-02	9.16e-01	7.29e-01
Defective B3GAT3 causes JDSSDHD	17	9.17e-01	9.53e-01	0.06030	-1.61e-02	-5.82e-02	9.09e-01	6.78e-01
CD209 (DC-SIGN) signaling	20	9.10e-01	9.53e-01	0.06020	-5.26e-02	-2.92e-02	6.84e-01	8.21e-01
Anchoring of the basal body to the plasma membrane	92	5.85e-01	7.56e-01	0.06010	-5.67e-03	5.98e-02	9.25e-01	3.21e-01
Signaling by GPCR	670	5.11e-02	1.45e-01	0.06010	-4.68e-02	-3.77e-02	3.82e-02	9.56e-02
Insulin receptor signalling cascade	53	7.88e-01	8.87e-01	0.05980	3.84e-02	4.59e-02	6.29e-01	5.64e-01
Prolonged ERK activation events	14	9.39e-01	9.65e-01	0.05950	-4.95e-02	-3.30e-02	7.48e-01	8.30e-01
Opioid Signalling	88	5.76e-01	7.48e-01	0.05940	-5.46e-02	2.34e-02	3.76e-01	7.05e-01
Integration of energy metabolism	106	5.06e-01	6.99e-01	0.05910	-3.44e-02	4.80e-02	5.40e-01	3.93e-01
G alpha (12/13) signalling events	74	6.43e-01	8.05e-01	0.05890	-5.66e-02	1.64e-02	4.00e-01	8.07e-01
Adrenaline,noradrenaline inhibits insulin secretion	28	8.58e-01	9.30e-01	0.05860	5.86e-02	-2.75e-03	5.92e-01	9.80e-01
Defective B4GALT7 causes EDS, progeroid type	17	9.27e-01	9.57e-01	0.05820	-5.19e-02	-2.63e-02	7.11e-01	8.51e-01
Voltage gated Potassium channels	42	7.69e-01	8.82e-01	0.05820	-4.72e-02	3.40e-02	5.97e-01	7.03e-01
Platelet Aggregation (Plug Formation)	37	7.99e-01	8.94e-01	0.05800	-5.17e-02	2.63e-02	5.86e-01	7.82e-01
Estrogen-dependent nuclear events downstream of ESR-membrane signaling	23	8.92e-01	9.45e-01	0.05720	-5.71e-02	-3.82e-03	6.36e-01	9.75e-01
IRS-related events triggered by IGF1R	50	8.07e-01	8.98e-01	0.05670	2.21e-02	5.22e-02	7.87e-01	5.23e-01
Late SARS-CoV-2 Infection Events	67	7.22e-01	8.54e-01	0.05640	2.47e-03	5.64e-02	9.72e-01	4.25e-01
Gap junction trafficking and regulation	29	8.87e-01	9.44e-01	0.05600	-2.46e-02	-5.04e-02	8.19e-01	6.39e-01
Gap junction trafficking	27	8.75e-01	9.37e-01	0.05590	1.86e-03	-5.59e-02	9.87e-01	6.15e-01
PKA activation	18	9.03e-01	9.50e-01	0.05580	-2.72e-02	4.88e-02	8.42e-01	7.20e-01
IRS-mediated signalling	47	8.19e-01	9.07e-01	0.05560	1.73e-02	5.29e-02	8.38e-01	5.31e-01
Interleukin receptor SHC signaling	24	9.09e-01	9.53e-01	0.05550	-4.84e-02	-2.72e-02	6.82e-01	8.17e-01
Constitutive Signaling by AKT1 E17K in Cancer	25	8.69e-01	9.34e-01	0.05540	-2.83e-02	4.76e-02	8.07e-01	6.80e-01
Intra-Golgi and retrograde Golgi-to-ER traffic	181	4.79e-01	6.80e-01	0.05520	2.09e-02	5.11e-02	6.27e-01	2.36e-01
p130Cas linkage to MAPK signaling for integrins	15	9.38e-01	9.65e-01	0.05500	-1.35e-02	-5.33e-02	9.28e-01	7.21e-01
Interleukin-6 family signaling	24	8.75e-01	9.37e-01	0.05490	4.33e-02	-3.37e-02	7.13e-01	7.75e-01
Smooth Muscle Contraction	43	7.90e-01	8.87e-01	0.05440	4.37e-02	-3.24e-02	6.20e-01	7.13e-01
Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R)	52	8.18e-01	9.07e-01	0.05410	2.33e-02	4.88e-02	7.72e-01	5.42e-01
EPH-Ephrin signaling	90	6.75e-01	8.25e-01	0.05410	5.27e-03	5.38e-02	9.31e-01	3.77e-01
G alpha (q) signalling events	206	4.04e-01	6.06e-01	0.05400	-5.39e-02	-3.56e-03	1.82e-01	9.30e-01
Uptake and actions of bacterial toxins	29	8.64e-01	9.32e-01	0.05400	-5.18e-02	1.53e-02	6.29e-01	8.87e-01
CDC42 GTPase cycle	143	5.12e-01	7.04e-01	0.05380	-5.34e-02	6.14e-03	2.70e-01	8.99e-01
Gluconeogenesis	32	8.80e-01	9.40e-01	0.05340	5.16e-02	1.39e-02	6.13e-01	8.92e-01
DAP12 signaling	28	8.73e-01	9.36e-01	0.05320	-1.42e-02	5.13e-02	8.97e-01	6.38e-01
TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain	21	9.12e-01	9.53e-01	0.05310	4.84e-04	5.31e-02	9.97e-01	6.74e-01
Downregulation of TGF-beta receptor signaling	26	8.93e-01	9.46e-01	0.05300	9.97e-04	5.30e-02	9.93e-01	6.40e-01
Inwardly rectifying K+ channels	35	8.73e-01	9.36e-01	0.05270	-1.41e-02	-5.08e-02	8.85e-01	6.03e-01
Metabolism of water-soluble vitamins and cofactors	118	6.36e-01	8.00e-01	0.05240	1.39e-02	5.05e-02	7.94e-01	3.43e-01
The canonical retinoid cycle in rods (twilight vision)	23	9.24e-01	9.56e-01	0.05230	-3.51e-02	-3.87e-02	7.70e-01	7.48e-01
Signaling by ALK	26	8.85e-01	9.43e-01	0.05210	5.00e-02	-1.48e-02	6.59e-01	8.96e-01
Mitochondrial calcium ion transport	22	8.96e-01	9.47e-01	0.05200	-4.23e-02	3.02e-02	7.31e-01	8.06e-01
Cilium Assembly	174	5.49e-01	7.30e-01	0.05160	2.50e-02	4.52e-02	5.69e-01	3.04e-01
Surfactant metabolism	28	9.11e-01	9.53e-01	0.05140	-4.05e-02	-3.15e-02	7.11e-01	7.73e-01
Plasma lipoprotein assembly, remodeling, and clearance	73	7.05e-01	8.42e-01	0.05080	3.99e-02	-3.15e-02	5.56e-01	6.42e-01
Fatty acyl-CoA biosynthesis	36	8.83e-01	9.42e-01	0.05050	-1.84e-02	-4.71e-02	8.48e-01	6.25e-01
COPI-independent Golgi-to-ER retrograde traffic	34	8.60e-01	9.31e-01	0.04890	2.88e-02	-3.95e-02	7.71e-01	6.90e-01
Defects in cobalamin (B12) metabolism	12	9.64e-01	9.80e-01	0.04880	2.97e-02	3.87e-02	8.58e-01	8.16e-01
Ras activation upon Ca2+ influx through NMDA receptor	19	9.42e-01	9.68e-01	0.04880	-2.22e-02	-4.35e-02	8.67e-01	7.43e-01
Platelet homeostasis	85	7.77e-01	8.84e-01	0.04830	-4.06e-02	-2.61e-02	5.17e-01	6.78e-01
Reproduction	82	7.88e-01	8.87e-01	0.04770	-3.95e-02	-2.68e-02	5.36e-01	6.75e-01
Vitamin D (calciferol) metabolism	12	9.64e-01	9.80e-01	0.04750	-1.84e-02	-4.38e-02	9.12e-01	7.93e-01
Metal ion SLC transporters	25	9.23e-01	9.56e-01	0.04750	1.16e-02	4.60e-02	9.20e-01	6.90e-01
RHO GTPases Activate ROCKs	19	9.44e-01	9.68e-01	0.04630	-4.51e-02	-1.06e-02	7.34e-01	9.36e-01
Ion homeostasis	50	8.71e-01	9.35e-01	0.04620	-2.34e-02	-3.99e-02	7.74e-01	6.26e-01
Anti-inflammatory response favouring Leishmania parasite infection	75	7.80e-01	8.84e-01	0.04600	-4.60e-02	6.54e-04	4.91e-01	9.92e-01
Leishmania parasite growth and survival	75	7.80e-01	8.84e-01	0.04600	-4.60e-02	6.54e-04	4.91e-01	9.92e-01
Constitutive Signaling by Aberrant PI3K in Cancer	77	8.00e-01	8.95e-01	0.04570	4.38e-02	1.29e-02	5.06e-01	8.45e-01
Platelet degranulation	115	7.23e-01	8.54e-01	0.04530	-4.31e-02	-1.38e-02	4.24e-01	7.98e-01
Ca-dependent events	35	9.11e-01	9.53e-01	0.04520	-4.00e-02	-2.11e-02	6.82e-01	8.29e-01
Transport of small molecules	689	9.49e-02	2.26e-01	0.04520	1.21e-02	-4.36e-02	5.87e-01	5.08e-02
Trafficking of GluR2-containing AMPA receptors	15	9.60e-01	9.79e-01	0.04510	-1.91e-02	-4.09e-02	8.98e-01	7.84e-01
Glycerophospholipid biosynthesis	114	6.55e-01	8.18e-01	0.04490	-3.63e-02	2.64e-02	5.04e-01	6.26e-01
Dopamine Neurotransmitter Release Cycle	20	9.44e-01	9.68e-01	0.04400	-6.27e-03	-4.36e-02	9.61e-01	7.36e-01
PI3K Cascade	43	8.99e-01	9.49e-01	0.04400	3.71e-02	2.37e-02	6.74e-01	7.88e-01
Signal Transduction	2409	9.79e-04	6.13e-03	0.04400	-5.80e-03	4.36e-02	6.39e-01	4.17e-04
Assembly and cell surface presentation of NMDA receptors	23	9.24e-01	9.56e-01	0.04390	1.77e-02	-4.02e-02	8.83e-01	7.39e-01
Presynaptic function of Kainate receptors	21	9.33e-01	9.61e-01	0.04340	-1.37e-02	4.12e-02	9.14e-01	7.44e-01
G alpha (z) signalling events	48	8.67e-01	9.33e-01	0.04330	-1.55e-03	4.33e-02	9.85e-01	6.04e-01
RUNX2 regulates osteoblast differentiation	22	9.47e-01	9.69e-01	0.04280	3.96e-02	1.63e-02	7.48e-01	8.94e-01
Potassium Channels	102	7.91e-01	8.88e-01	0.04280	-2.74e-02	-3.28e-02	6.32e-01	5.67e-01
Golgi-to-ER retrograde transport	115	7.17e-01	8.50e-01	0.04090	-1.29e-02	3.88e-02	8.10e-01	4.73e-01
DAG and IP3 signaling	39	9.08e-01	9.53e-01	0.04080	-4.05e-02	-4.90e-03	6.62e-01	9.58e-01
Nucleotide catabolism	35	9.17e-01	9.53e-01	0.04080	4.05e-02	4.14e-03	6.78e-01	9.66e-01
Adenylate cyclase inhibitory pathway	14	9.71e-01	9.82e-01	0.03950	-1.51e-02	-3.64e-02	9.22e-01	8.13e-01
RUNX2 regulates bone development	29	9.32e-01	9.61e-01	0.03930	3.93e-02	-1.02e-03	7.14e-01	9.92e-01
Regulation of insulin secretion	77	8.22e-01	9.09e-01	0.03920	-6.88e-03	3.86e-02	9.17e-01	5.58e-01
PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling	104	8.17e-01	9.07e-01	0.03900	2.08e-02	3.30e-02	7.13e-01	5.61e-01
Other interleukin signaling	24	9.45e-01	9.68e-01	0.03880	6.65e-04	3.88e-02	9.96e-01	7.42e-01
Negative regulation of the PI3K/AKT network	111	7.70e-01	8.83e-01	0.03820	-3.73e-03	3.80e-02	9.46e-01	4.89e-01
Metabolism of lipids	696	1.60e-01	3.24e-01	0.03810	-2.52e-02	2.85e-02	2.55e-01	1.98e-01
Activation of NMDA receptors and postsynaptic events	69	8.39e-01	9.17e-01	0.03730	-1.90e-02	3.21e-02	7.85e-01	6.45e-01
Intra-Golgi traffic	43	9.20e-01	9.55e-01	0.03710	8.67e-03	3.60e-02	9.22e-01	6.83e-01
Glucagon-type ligand receptors	33	9.22e-01	9.56e-01	0.03700	-1.52e-02	3.38e-02	8.80e-01	7.37e-01
Post NMDA receptor activation events	58	8.66e-01	9.32e-01	0.03650	-2.68e-02	2.48e-02	7.24e-01	7.44e-01
PI3K/AKT Signaling in Cancer	103	8.42e-01	9.18e-01	0.03650	2.80e-02	2.34e-02	6.23e-01	6.82e-01
Developmental Biology	1027	1.67e-01	3.32e-01	0.03640	3.44e-02	1.16e-02	6.11e-02	5.26e-01
HS-GAG degradation	18	9.66e-01	9.80e-01	0.03620	3.56e-02	6.46e-03	7.94e-01	9.62e-01
Amino acid transport across the plasma membrane	30	9.43e-01	9.68e-01	0.03580	2.87e-03	3.57e-02	9.78e-01	7.35e-01
Neuronal System	371	5.62e-01	7.37e-01	0.03540	-2.70e-02	-2.28e-02	3.71e-01	4.50e-01
Frs2-mediated activation	12	9.75e-01	9.83e-01	0.03510	3.37e-02	-1.00e-02	8.40e-01	9.52e-01
FGFRL1 modulation of FGFR1 signaling	13	9.77e-01	9.84e-01	0.03430	1.68e-03	3.43e-02	9.92e-01	8.30e-01
Metabolism of vitamins and cofactors	181	7.69e-01	8.82e-01	0.03410	2.43e-02	2.39e-02	5.72e-01	5.79e-01
p75 NTR receptor-mediated signalling	89	8.89e-01	9.44e-01	0.03250	2.46e-02	2.12e-02	6.89e-01	7.29e-01
Response to elevated platelet cytosolic Ca2+	120	8.45e-01	9.21e-01	0.03210	-3.02e-02	-1.07e-02	5.67e-01	8.39e-01
RHOA GTPase cycle	140	7.76e-01	8.84e-01	0.03190	-1.35e-02	2.89e-02	7.83e-01	5.55e-01
Cell death signalling via NRAGE, NRIF and NADE	69	9.26e-01	9.57e-01	0.02990	2.17e-02	2.06e-02	7.55e-01	7.68e-01
Activation of G protein gated Potassium channels	29	9.61e-01	9.79e-01	0.02970	2.97e-02	-1.60e-04	7.82e-01	9.99e-01
G protein gated Potassium channels	29	9.61e-01	9.79e-01	0.02970	2.97e-02	-1.60e-04	7.82e-01	9.99e-01
Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits	29	9.61e-01	9.79e-01	0.02970	2.97e-02	-1.60e-04	7.82e-01	9.99e-01
RET signaling	41	9.53e-01	9.74e-01	0.02960	-2.73e-02	-1.15e-02	7.62e-01	8.99e-01
Metabolism of steroids	148	8.48e-01	9.23e-01	0.02920	-1.28e-02	-2.62e-02	7.88e-01	5.82e-01
Diseases of metabolism	234	7.72e-01	8.84e-01	0.02900	-2.63e-02	-1.21e-02	4.88e-01	7.50e-01
Interleukin-3, Interleukin-5 and GM-CSF signaling	41	9.43e-01	9.68e-01	0.02890	-7.13e-03	2.80e-02	9.37e-01	7.56e-01
Semaphorin interactions	61	9.17e-01	9.53e-01	0.02880	-7.85e-03	2.77e-02	9.16e-01	7.09e-01
CTLA4 inhibitory signaling	21	9.72e-01	9.82e-01	0.02850	-5.70e-03	2.79e-02	9.64e-01	8.25e-01
Signaling by FGFR4 in disease	11	9.84e-01	9.89e-01	0.02820	1.89e-02	-2.10e-02	9.14e-01	9.04e-01
Signaling by TGFB family members	118	8.92e-01	9.45e-01	0.02790	2.05e-02	1.89e-02	7.00e-01	7.23e-01
FCGR3A-mediated IL10 synthesis	37	9.67e-01	9.80e-01	0.02700	-1.71e-02	-2.09e-02	8.57e-01	8.25e-01
Activation of kainate receptors upon glutamate binding	29	9.73e-01	9.82e-01	0.02590	-2.53e-02	-5.83e-03	8.14e-01	9.57e-01
Hyaluronan metabolism	17	9.82e-01	9.87e-01	0.02430	-1.42e-02	1.98e-02	9.19e-01	8.88e-01
GRB2 events in ERBB2 signaling	16	9.87e-01	9.91e-01	0.02410	2.29e-02	7.53e-03	8.74e-01	9.58e-01
Transport of vitamins, nucleosides, and related molecules	38	9.62e-01	9.79e-01	0.02400	-8.91e-03	2.23e-02	9.24e-01	8.12e-01
RHOD GTPase cycle	48	9.65e-01	9.80e-01	0.02370	-2.17e-02	-9.62e-03	7.95e-01	9.08e-01
TGF-beta receptor signaling activates SMADs	45	9.59e-01	9.79e-01	0.02370	-4.29e-03	2.33e-02	9.60e-01	7.87e-01
Neurotransmitter receptors and postsynaptic signal transmission	175	8.34e-01	9.14e-01	0.02370	-1.75e-02	1.60e-02	6.90e-01	7.15e-01
CaM pathway	33	9.70e-01	9.82e-01	0.02290	-2.10e-02	9.13e-03	8.35e-01	9.28e-01
Calmodulin induced events	33	9.70e-01	9.82e-01	0.02290	-2.10e-02	9.13e-03	8.35e-01	9.28e-01
Physiological factors	14	9.92e-01	9.95e-01	0.02050	1.05e-02	1.76e-02	9.46e-01	9.09e-01
Transcriptional Regulation by NPAS4	33	9.78e-01	9.84e-01	0.02020	3.32e-03	-1.99e-02	9.74e-01	8.43e-01
Class A/1 (Rhodopsin-like receptors)	311	8.48e-01	9.23e-01	0.01950	-4.87e-03	-1.88e-02	8.82e-01	5.67e-01
Signaling by PDGF	52	9.76e-01	9.84e-01	0.01940	-1.38e-02	-1.36e-02	8.63e-01	8.66e-01
Activation of GABAB receptors	43	9.71e-01	9.82e-01	0.01930	1.51e-02	-1.20e-02	8.64e-01	8.92e-01
GABA B receptor activation	43	9.71e-01	9.82e-01	0.01930	1.51e-02	-1.20e-02	8.64e-01	8.92e-01
GRB2:SOS provides linkage to MAPK signaling for Integrins	15	9.93e-01	9.95e-01	0.01910	6.96e-03	1.78e-02	9.63e-01	9.05e-01
Costimulation by the CD28 family	65	9.74e-01	9.83e-01	0.01500	6.16e-03	-1.37e-02	9.32e-01	8.49e-01
Interleukin-2 family signaling	40	9.94e-01	9.96e-01	0.01030	-9.44e-03	-4.24e-03	9.18e-01	9.63e-01
Gastrin-CREB signalling pathway via PKC and MAPK	17	9.98e-01	9.98e-01	0.01010	-4.60e-03	-8.97e-03	9.74e-01	9.49e-01
DAP12 interactions	40	9.96e-01	9.97e-01	0.00771	-6.23e-03	4.55e-03	9.46e-01	9.60e-01
Transmission across Chemical Synapses	237	9.85e-01	9.90e-01	0.00682	2.32e-03	6.41e-03	9.51e-01	8.65e-01
FCERI mediated Ca+2 mobilization	27	9.98e-01	9.98e-01	0.00644	-6.16e-03	-1.86e-03	9.56e-01	9.87e-01

---

Detailed Gene set reports

Class C/3 (Metabotropic glutamate/pheromone receptors)

Class C/3 (Metabotropic glutamate/pheromone receptors)

metric	value
setSize	39
pMANOVA	1.81e-10
p.adjustMANOVA	5.47e-09
s.dist	0.677
s.bl	-0.49
s.gu	-0.468
p.bl	1.16e-07
p.gu	4.29e-07

Top 20 genes

Gene	bl	gu
TAS2R43	-20301	-17476
TAS2R39	-21100	-16412
TAS2R1	-20635	-16629
TAS2R3	-21161	-16122
TAS2R42	-21057	-16140
TAS2R20	-21087	-15956
TAS2R30	-20441	-16313
TAS2R50	-21189	-15633
TAS2R10	-21093	-15608
TAS2R9	-20781	-15404
TAS2R8	-20965	-15268
GPRC6A	-20304	-15299
TAS2R19	-17769	-17281
TAS2R14	-20616	-14805
TAS2R41	-18506	-15380
TAS2R7	-20556	-13241
TAS2R16	-17596	-15285
TAS2R60	-15769	-16828
TAS2R4	-13108	-17407
TAS2R5	-18019	-10797

Click HERE to show all gene set members

All member genes

	bl	gu
CASR	-5293	-623
GABBR1	-11390	-8966
GABBR2	-4208	-5543
GPRC6A	-20304	-15299
GRM1	-16224	-11048
GRM2	-5675	-216
GRM3	-7834	-10622
GRM4	-4847	-8801
GRM5	-16036	-7419
GRM6	-10353	-11729
GRM7	-8371	-10844
GRM8	-3496	-12183
TAS1R1	-2580	-10716
TAS1R2	-2297	4050
TAS1R3	-9249	4467
TAS2R1	-20635	-16629
TAS2R10	-21093	-15608
TAS2R13	-18249	4625
TAS2R14	-20616	-14805
TAS2R16	-17596	-15285
TAS2R19	-17769	-17281
TAS2R20	-21087	-15956
TAS2R3	-21161	-16122
TAS2R30	-20441	-16313
TAS2R31	-20094	-4227
TAS2R38	-8087	-11255
TAS2R39	-21100	-16412
TAS2R4	-13108	-17407
TAS2R40	-18098	1554
TAS2R41	-18506	-15380
TAS2R42	-21057	-16140
TAS2R43	-20301	-17476
TAS2R46	-20746	-9370
TAS2R5	-18019	-10797
TAS2R50	-21189	-15633
TAS2R60	-15769	-16828
TAS2R7	-20556	-13241
TAS2R8	-20965	-15268
TAS2R9	-20781	-15404

---

---

TICAM1-dependent activation of IRF3/IRF7

TICAM1-dependent activation of IRF3/IRF7

metric	value
setSize	12
pMANOVA	0.00124
p.adjustMANOVA	0.00755
s.dist	0.667
s.bl	0.45
s.gu	0.492
p.bl	0.00692
p.gu	0.00316

Top 20 genes

Gene	bl	gu
TLR3	3432	5652
UBB	3278	4141
RPS27A	2633	5083

Click HERE to show all gene set members

All member genes

	bl	gu
IKBKE	-3863	-7503
IRF3	-2294	711
IRF7	-2525	3289
RPS27A	2633	5083
TANK	-9140	1964
TBK1	-5736	3411
TICAM1	-1572	432
TLR3	3432	5652
TRAF3	-16727	-3327
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Scavenging of heme from plasma

Scavenging of heme from plasma

metric	value
setSize	12
pMANOVA	0.00197
p.adjustMANOVA	0.0113
s.dist	0.643
s.bl	-0.473
s.gu	-0.436
p.bl	0.00452
p.gu	0.00898

Top 20 genes

Gene	bl	gu
HBA1	-20492	-17033
HBB	-20298	-16008
ALB	-20900	-15234
APOL1	-20613	-12055
HPX	-18409	-11860
JCHAIN	-12281	-17188
AMBP	-11260	-14218
CD163	-16282	-8683
HPR	-14504	-7583
APOA1	-5372	-4007
LRP1	-2496	-3040

Click HERE to show all gene set members

All member genes

	bl	gu
ALB	-20900	-15234
AMBP	-11260	-14218
APOA1	-5372	-4007
APOL1	-20613	-12055
CD163	-16282	-8683
HBA1	-20492	-17033
HBB	-20298	-16008
HP	-14625	1886
HPR	-14504	-7583
HPX	-18409	-11860
JCHAIN	-12281	-17188
LRP1	-2496	-3040

---

---

Eicosanoids

Eicosanoids

metric	value
setSize	12
pMANOVA	0.000296
p.adjustMANOVA	0.00214
s.dist	0.64
s.bl	0.631
s.gu	-0.102
p.bl	0.000152
p.gu	0.541

Top 20 genes

Gene	bl	gu
CYP8B1	2902	-14599
CYP4F2	2357	-13024
CYP4F8	1192	-15481
CYP4F11	626	-11827

Click HERE to show all gene set members

All member genes

	bl	gu
CYP4A11	3815	1402
CYP4A22	3037	4100
CYP4B1	-8587	-13995
CYP4F11	626	-11827
CYP4F12	-883	7280
CYP4F2	2357	-13024
CYP4F22	-1207	-2486
CYP4F3	-43	3401
CYP4F8	1192	-15481
CYP8B1	2902	-14599
PTGIS	-312	-13498
TBXAS1	-10068	-4830

---

---

Pexophagy

Pexophagy

metric	value
setSize	11
pMANOVA	0.00413
p.adjustMANOVA	0.0204
s.dist	0.626
s.bl	0.515
s.gu	0.356
p.bl	0.00311
p.gu	0.0408

Top 20 genes

Gene	bl	gu
UBB	3278	4141
RPS27A	2633	5083

Click HERE to show all gene set members

All member genes

	bl	gu
ATM	1939	-2867
EPAS1	-11215	-9857
MAP1LC3B	-6322	4627
NBR1	2099	-8899
PEX5	-4821	1218
RPS27A	2633	5083
SQSTM1	-4938	-851
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
USP30	-3108	568

---

---

SARS-CoV-1 modulates host translation machinery

SARS-CoV-1 modulates host translation machinery

metric	value
setSize	34
pMANOVA	1.09e-07
p.adjustMANOVA	1.44e-06
s.dist	0.604
s.bl	0.522
s.gu	0.305
p.bl	1.4e-07
p.gu	0.00211

Top 20 genes

Gene	bl	gu
HNRNPA1	3521	6834
RPS27A	2633	5083
RPS19	2541	4237
RPS27	1289	6541
EEF1A1	1152	6931
RPS16	1209	4604
RPS17	1222	3419
RPSA	559	7037
RPS18	709	1936
RPS23	983	1243

Click HERE to show all gene set members

All member genes

	bl	gu
EEF1A1	1152	6931
FAU	339	-8142
HNRNPA1	3521	6834
RPS10	-4517	2368
RPS11	2207	-13804
RPS12	3518	-1497
RPS13	-3760	-14339
RPS14	-8453	7156
RPS15	-5601	3218
RPS15A	-3699	4700
RPS16	1209	4604
RPS17	1222	3419
RPS18	709	1936
RPS19	2541	4237
RPS2	-830	-12504
RPS20	-1591	-5511
RPS21	908	-5285
RPS23	983	1243
RPS24	-5861	5913
RPS25	-3493	-1399
RPS26	-7211	6898
RPS27	1289	6541
RPS27A	2633	5083
RPS27L	859	-7524
RPS28	-13883	-2888
RPS29	1292	-12538
RPS3	-747	1694
RPS3A	-699	-804
RPS5	-9203	-15424
RPS6	-9677	325
RPS7	-4265	-4644
RPS8	-2232	5018
RPS9	-7704	-9762
RPSA	559	7037

---

---

Sensory perception of sweet, bitter, and umami (glutamate) taste

Sensory perception of sweet, bitter, and umami (glutamate) taste

metric	value
setSize	41
pMANOVA	1.17e-08
p.adjustMANOVA	2.1e-07
s.dist	0.594
s.bl	-0.465
s.gu	-0.37
p.bl	2.48e-07
p.gu	4.17e-05

Top 20 genes

Gene	bl	gu
TAS2R43	-20301	-17476
GNAT3	-21044	-16497
TAS2R39	-21100	-16412
TAS2R1	-20635	-16629
TAS2R3	-21161	-16122
TAS2R20	-21087	-15956
TAS2R30	-20441	-16313
TAS2R50	-21189	-15633
TAS2R10	-21093	-15608
TAS2R8	-20965	-15268
TAS2R14	-20616	-14805
TAS2R41	-18506	-15380
TAS2R7	-20556	-13241
TAS2R16	-17596	-15285
TAS2R4	-13108	-17407
SCN1B	-15607	-12626
TAS2R5	-18019	-10797
TAS2R46	-20746	-9370
GRM1	-16224	-11048
SCN9A	-15411	-10728

Click HERE to show all gene set members

All member genes

	bl	gu
CALHM1	-12276	-6058
CALHM3	-12788	-12696
GNAT3	-21044	-16497
GNB1	-16858	-3249
GNB3	-12531	5837
GNG13	-7640	-1360
GRM1	-16224	-11048
GRM4	-4847	-8801
ITPR3	-11478	-12700
PLCB2	-12670	-6069
SCN1B	-15607	-12626
SCN2A	-10570	-11434
SCN2B	-8927	-629
SCN3A	-9666	-9622
SCN4B	-8620	-6101
SCN9A	-15411	-10728
TAS1R1	-2580	-10716
TAS1R2	-2297	4050
TAS1R3	-9249	4467
TAS2R1	-20635	-16629
TAS2R10	-21093	-15608
TAS2R13	-18249	4625
TAS2R14	-20616	-14805
TAS2R16	-17596	-15285
TAS2R20	-21087	-15956
TAS2R3	-21161	-16122
TAS2R30	-20441	-16313
TAS2R31	-20094	-4227
TAS2R38	-8087	-11255
TAS2R39	-21100	-16412
TAS2R4	-13108	-17407
TAS2R40	-18098	1554
TAS2R41	-18506	-15380
TAS2R43	-20301	-17476
TAS2R46	-20746	-9370
TAS2R5	-18019	-10797
TAS2R50	-21189	-15633
TAS2R7	-20556	-13241
TAS2R8	-20965	-15268
TRPM4	-5452	-10967
TRPM5	-3798	-4287

---

---

TICAM1,TRAF6-dependent induction of TAK1 complex

TICAM1,TRAF6-dependent induction of TAK1 complex

metric	value
setSize	10
pMANOVA	0.0146
p.adjustMANOVA	0.0541
s.dist	0.58
s.bl	0.431
s.gu	0.388
p.bl	0.0182
p.gu	0.0336

Top 20 genes

Gene	bl	gu
TLR3	3432	5652
UBB	3278	4141
RPS27A	2633	5083

Click HERE to show all gene set members

All member genes

	bl	gu
MAP3K7	-7575	-9127
RPS27A	2633	5083
TAB1	-9799	6095
TAB2	-9801	-9844
TICAM1	-1572	432
TLR3	3432	5652
TRAF6	-9681	-4945
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Competing endogenous RNAs (ceRNAs) regulate PTEN translation

Competing endogenous RNAs (ceRNAs) regulate PTEN translation

metric	value
setSize	16
pMANOVA	0.000127
p.adjustMANOVA	0.000998
s.dist	0.555
s.bl	-0.482
s.gu	0.274
p.bl	0.000837
p.gu	0.0577

Top 20 genes

Gene	bl	gu
MIR20A	-18057	7439
MIR19A	-16631	7449
MIR19B1	-19684	5354
MIR17	-10078	6477
MOV10	-8488	5987
MIR106B	-20027	2091
AGO3	-14012	625

Click HERE to show all gene set members

All member genes

	bl	gu
AGO1	-20797	-10713
AGO2	-8757	-82
AGO3	-14012	625
AGO4	-19507	-11950
CNOT6L	-13667	-2535
MIR106B	-20027	2091
MIR17	-10078	6477
MIR19A	-16631	7449
MIR19B1	-19684	5354
MIR20A	-18057	7439
MOV10	-8488	5987
PTENP1	-16012	-6105
TNRC6A	-16547	-12111
TNRC6B	-4964	-3964
TNRC6C	-15450	-5248
VAPA	-15857	-3503

---

---

Glucuronidation

Glucuronidation

metric	value
setSize	25
pMANOVA	8.06e-05
p.adjustMANOVA	0.00067
s.dist	0.548
s.bl	-0.378
s.gu	-0.397
p.bl	0.00106
p.gu	0.000587

Top 20 genes

Gene	bl	gu
UGT2B11	-21337	-17278
UGT2B4	-21311	-16951
UGT2B7	-19466	-16802
UGT2B10	-21288	-15316
UGT2B28	-21526	-14687
UGT2A2	-18383	-12817
UGT2A1	-20687	-11233
UGT2A3	-20744	-9744
UGT1A1	-11541	-16565
UGT1A8	-12587	-13229
UGT1A10	-12197	-13428
UGT1A7	-11787	-12600
UGT2B15	-13049	-10893
UGT1A9	-10674	-13288
SLC35D1	-16334	-8051
UGT1A6	-9529	-13378
UGT1A3	-9171	-12535
UGT1A5	-9602	-11810
UGT1A4	-8869	-10588
UGDH	-6353	-3062

Click HERE to show all gene set members

All member genes

	bl	gu
ABHD10	80	3681
SLC35D1	-16334	-8051
UGDH	-6353	-3062
UGP2	-8183	-740
UGT1A1	-11541	-16565
UGT1A10	-12197	-13428
UGT1A3	-9171	-12535
UGT1A4	-8869	-10588
UGT1A5	-9602	-11810
UGT1A6	-9529	-13378
UGT1A7	-11787	-12600
UGT1A8	-12587	-13229
UGT1A9	-10674	-13288
UGT2A1	-20687	-11233
UGT2A2	-18383	-12817
UGT2A3	-20744	-9744
UGT2B10	-21288	-15316
UGT2B11	-21337	-17278
UGT2B15	-13049	-10893
UGT2B17	-20950	1510
UGT2B28	-21526	-14687
UGT2B4	-21311	-16951
UGT2B7	-19466	-16802
UGT3A1	-1170	-4112
UGT3A2	-12605	5872

---

---

SCF(Skp2)-mediated degradation of p27/p21

SCF(Skp2)-mediated degradation of p27/p21

metric	value
setSize	58
pMANOVA	3.6e-10
p.adjustMANOVA	9.83e-09
s.dist	0.547
s.bl	0.412
s.gu	0.359
p.bl	5.52e-08
p.gu	2.26e-06

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
CKS1B	1991	3982
CDK4	1512	5233
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
CCNA1	-7464	-6482
CCNA2	-1152	991
CCND1	-10740	1014
CCNE1	-14977	-3093
CCNE2	-2676	6813
CDK2	-11196	-1157
CDK4	1512	5233
CDKN1A	-4145	5957
CDKN1B	-2910	-188
CKS1B	1991	3982
CUL1	-10922	-3518
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSMF1	-7580	-2334
PTK6	-4516	-13859
RPS27A	2633	5083
SKP1	245	2633
SKP2	-1221	1281
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2

GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2

metric	value
setSize	50
pMANOVA	9.13e-09
p.adjustMANOVA	1.68e-07
s.dist	0.543
s.bl	0.411
s.gu	0.355
p.bl	4.82e-07
p.gu	1.43e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
BTRC	-17678	952
CUL1	-10922	-3518
GSK3B	-6608	-12189
NFE2L2	-3398	4832
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSMF1	-7580	-2334
RBX1	-3011	5968
RPS27A	2633	5083
SKP1	245	2633
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

APC/C:Cdc20 mediated degradation of Cyclin B

APC/C:Cdc20 mediated degradation of Cyclin B

metric	value
setSize	24
pMANOVA	0.000135
p.adjustMANOVA	0.00105
s.dist	0.539
s.bl	0.3
s.gu	0.448
p.bl	0.0108
p.gu	0.000144

Top 20 genes

Gene	bl	gu
UBB	3278	4141
RPS27A	2633	5083
ANAPC10	1568	7316

Click HERE to show all gene set members

All member genes

	bl	gu
ANAPC1	-214	5021
ANAPC10	1568	7316
ANAPC11	-853	1262
ANAPC15	-3568	-5708
ANAPC16	-3038	5076
ANAPC2	-6999	3577
ANAPC4	-12035	-5819
ANAPC5	-13436	3996
ANAPC7	-14	2634
CCNB1	-15483	5329
CDC16	-5235	-1817
CDC20	-4067	100
CDC23	1982	-12630
CDC26	-4616	5368
CDC27	-17169	-12590
CDK1	-1204	1566
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
UBE2C	-148	-1659
UBE2D1	-11102	2093
UBE2E1	-12259	826
UBE2S	-11896	5126

---

---

Peptide chain elongation

Peptide chain elongation

metric	value
setSize	84
pMANOVA	2.22e-14
p.adjustMANOVA	1.43e-12
s.dist	0.538
s.bl	0.466
s.gu	0.269
p.bl	1.47e-13
p.gu	2e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
EEF1A1	1152	6931
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
EEF1A1	1152.0	6931.0
EEF2	-10566.0	-952.0
FAU	339.0	-8142.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
UBA52	-1582.0	2411.0

---

---

PINK1-PRKN Mediated Mitophagy

PINK1-PRKN Mediated Mitophagy

metric	value
setSize	21
pMANOVA	0.000463
p.adjustMANOVA	0.00318
s.dist	0.534
s.bl	0.287
s.gu	0.45
p.bl	0.0227
p.gu	0.000353

Top 20 genes

Gene	bl	gu
UBB	3278	4141
RPS27A	2633	5083
TOMM6	2444	721

Click HERE to show all gene set members

All member genes

	bl	gu
ATG12	-7618	-6545
ATG5	-10356	2224
MAP1LC3A	-16409	2604
MAP1LC3B	-6322	4627
MFN1	-938	4389
MFN2	-8895	2711
MTERF3	418	-4922
PARK2	-5767	-8511
PINK1	-578	4062
RPS27A	2633	5083
SQSTM1	-4938	-851
TOMM20	-6383	-2940
TOMM22	-3837	-1943
TOMM40	-5635	7261
TOMM5	-12296	-2157
TOMM6	2444	721
TOMM7	-4647	4769
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
VDAC1	-17004	1350

---

---

Eukaryotic Translation Termination

Eukaryotic Translation Termination

metric	value
setSize	87
pMANOVA	1.17e-14
p.adjustMANOVA	7.89e-13
s.dist	0.534
s.bl	0.464
s.gu	0.263
p.bl	6.84e-14
p.gu	2.17e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
APEH	-7707.0	2313.0
ETF1	-3072.0	-10743.0
FAU	339.0	-8142.0
GSPT1	-8626.0	1941.0
N6AMT1	948.0	-3848.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
TRMT112	-1282.0	5702.0
UBA52	-1582.0	2411.0

---

---

Ubiquitin Mediated Degradation of Phosphorylated Cdc25A

Ubiquitin Mediated Degradation of Phosphorylated Cdc25A

metric	value
setSize	50
pMANOVA	2.24e-08
p.adjustMANOVA	3.72e-07
s.dist	0.527
s.bl	0.425
s.gu	0.313
p.bl	1.99e-07
p.gu	0.000131

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
CDC25A	-5210	-131
CHEK1	-5848	-3310
CHEK2	-4820	5616
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

p53-Independent DNA Damage Response

p53-Independent DNA Damage Response

metric	value
setSize	50
pMANOVA	2.24e-08
p.adjustMANOVA	3.72e-07
s.dist	0.527
s.bl	0.425
s.gu	0.313
p.bl	1.99e-07
p.gu	0.000131

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
CDC25A	-5210	-131
CHEK1	-5848	-3310
CHEK2	-4820	5616
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

p53-Independent G1/S DNA damage checkpoint

p53-Independent G1/S DNA damage checkpoint

metric	value
setSize	50
pMANOVA	2.24e-08
p.adjustMANOVA	3.72e-07
s.dist	0.527
s.bl	0.425
s.gu	0.313
p.bl	1.99e-07
p.gu	0.000131

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
CDC25A	-5210	-131
CHEK1	-5848	-3310
CHEK2	-4820	5616
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Sensory perception of taste

Sensory perception of taste

metric	value
setSize	47
pMANOVA	9.25e-08
p.adjustMANOVA	1.25e-06
s.dist	0.525
s.bl	-0.365
s.gu	-0.377
p.bl	1.49e-05
p.gu	7.81e-06

Top 20 genes

Gene	bl	gu
TAS2R43	-20301	-17476
GNAT3	-21044	-16497
TAS2R39	-21100	-16412
TAS2R1	-20635	-16629
TAS2R3	-21161	-16122
TAS2R20	-21087	-15956
TAS2R30	-20441	-16313
TAS2R50	-21189	-15633
TAS2R10	-21093	-15608
TAS2R8	-20965	-15268
TAS2R14	-20616	-14805
TAS2R41	-18506	-15380
TAS2R7	-20556	-13241
TAS2R16	-17596	-15285
TAS2R4	-13108	-17407
SCN1B	-15607	-12626
TAS2R5	-18019	-10797
TAS2R46	-20746	-9370
GRM1	-16224	-11048
SCN9A	-15411	-10728

Click HERE to show all gene set members

All member genes

	bl	gu
CALHM1	-12276	-6058
CALHM3	-12788	-12696
GNAT3	-21044	-16497
GNB1	-16858	-3249
GNB3	-12531	5837
GNG13	-7640	-1360
GRM1	-16224	-11048
GRM4	-4847	-8801
ITPR3	-11478	-12700
KCNJ2	-12114	-10127
OTOP1	316	-17156
PLCB2	-12670	-6069
SCN1B	-15607	-12626
SCN2A	-10570	-11434
SCN2B	-8927	-629
SCN3A	-9666	-9622
SCN4B	-8620	-6101
SCN9A	-15411	-10728
SCNN1A	-10170	-11670
SCNN1B	982	-6516
SCNN1D	-6233	-13029
SCNN1G	-178	-3100
TAS1R1	-2580	-10716
TAS1R2	-2297	4050
TAS1R3	-9249	4467
TAS2R1	-20635	-16629
TAS2R10	-21093	-15608
TAS2R13	-18249	4625
TAS2R14	-20616	-14805
TAS2R16	-17596	-15285
TAS2R20	-21087	-15956
TAS2R3	-21161	-16122
TAS2R30	-20441	-16313
TAS2R31	-20094	-4227
TAS2R38	-8087	-11255
TAS2R39	-21100	-16412
TAS2R4	-13108	-17407
TAS2R40	-18098	1554
TAS2R41	-18506	-15380
TAS2R43	-20301	-17476
TAS2R46	-20746	-9370
TAS2R5	-18019	-10797
TAS2R50	-21189	-15633
TAS2R7	-20556	-13241
TAS2R8	-20965	-15268
TRPM4	-5452	-10967
TRPM5	-3798	-4287

---

---

Autodegradation of Cdh1 by Cdh1:APC/C

Autodegradation of Cdh1 by Cdh1:APC/C

metric	value
setSize	62
pMANOVA	5.36e-10
p.adjustMANOVA	1.4e-08
s.dist	0.524
s.bl	0.372
s.gu	0.37
p.bl	4.13e-07
p.gu	4.61e-07

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
ANAPC10	1568	7316
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
ANAPC1	-214	5021
ANAPC10	1568	7316
ANAPC11	-853	1262
ANAPC15	-3568	-5708
ANAPC16	-3038	5076
ANAPC2	-6999	3577
ANAPC4	-12035	-5819
ANAPC5	-13436	3996
ANAPC7	-14	2634
CDC16	-5235	-1817
CDC23	1982	-12630
CDC26	-4616	5368
CDC27	-17169	-12590
FZR1	-15242	5573
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
UBE2C	-148	-1659
UBE2D1	-11102	2093
UBE2E1	-12259	826
UBE2S	-11896	5126

---

---

Hh mutants are degraded by ERAD

Hh mutants are degraded by ERAD

metric	value
setSize	54
pMANOVA	8.26e-09
p.adjustMANOVA	1.54e-07
s.dist	0.523
s.bl	0.408
s.gu	0.328
p.bl	2.13e-07
p.gu	3.1e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
OS9	1966	2664
PSME1	492	7331
PSMA3	835	3842
DERL2	1861	1250

Click HERE to show all gene set members

All member genes

	bl	gu
DERL2	1861	1250
ERLEC1	-2271	-5022
OS9	1966	2664
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
SEL1L	-17085	-4295
SHH	-2084	1951
SYVN1	-9156	5978
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
VCP	-13994	6796

---

---

Eukaryotic Translation Elongation

Eukaryotic Translation Elongation

metric	value
setSize	88
pMANOVA	2.89e-14
p.adjustMANOVA	1.72e-12
s.dist	0.522
s.bl	0.458
s.gu	0.251
p.bl	1.07e-13
p.gu	4.71e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
EEF1A1	1152	6931
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
EEF1A1	1152.0	6931.0
EEF1A2	-9460.0	-10759.0
EEF1B2	3353.0	-277.0
EEF1D	-10136.0	-12713.0
EEF1G	-3883.0	-2325.0
EEF2	-10566.0	-952.0
FAU	339.0	-8142.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
UBA52	-1582.0	2411.0

---

---

Autodegradation of the E3 ubiquitin ligase COP1

Autodegradation of the E3 ubiquitin ligase COP1

metric	value
setSize	50
pMANOVA	3.12e-08
p.adjustMANOVA	4.97e-07
s.dist	0.521
s.bl	0.433
s.gu	0.289
p.bl	1.17e-07
p.gu	0.000403

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
ATM	1939	-2867
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RFWD2	-10106	-7493
RPS27A	2633	5083
TP53	-2599	-2481
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

The role of GTSE1 in G2/M progression after G2 checkpoint

The role of GTSE1 in G2/M progression after G2 checkpoint

metric	value
setSize	58
pMANOVA	2.68e-09
p.adjustMANOVA	5.59e-08
s.dist	0.52
s.bl	0.4
s.gu	0.333
p.bl	1.37e-07
p.gu	1.14e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
GTSE1	477	1088

Click HERE to show all gene set members

All member genes

	bl	gu
CCNB1	-15483	5329
CCNB2	-18433	3729
CDK1	-1204	1566
CDKN1A	-4145	5957
FKBPL	-2933	-11171
GTSE1	477	1088
HSP90AA1	-4051	1448
HSP90AB1	-3343	5407
MAPRE1	-5085	-681
PLK1	-3953	681
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
TP53	-2599	-2481
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Ubiquitin-dependent degradation of Cyclin D

Ubiquitin-dependent degradation of Cyclin D

metric	value
setSize	50
pMANOVA	3.46e-08
p.adjustMANOVA	5.3e-07
s.dist	0.52
s.bl	0.425
s.gu	0.3
p.bl	1.98e-07
p.gu	0.000243

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
CDK4	1512	5233
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
CCND1	-10740	1014
CDK4	1512	5233
GSK3B	-6608	-12189
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Viral mRNA Translation

Viral mRNA Translation

metric	value
setSize	84
pMANOVA	2.28e-13
p.adjustMANOVA	1.01e-11
s.dist	0.519
s.bl	0.445
s.gu	0.267
p.bl	1.75e-12
p.gu	2.29e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
DNAJC3	-17156.0	549.0
FAU	339.0	-8142.0
GRSF1	-15089.0	3351.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
UBA52	-1582.0	2411.0

---

---

Selenocysteine synthesis

Selenocysteine synthesis

metric	value
setSize	87
pMANOVA	8.57e-14
p.adjustMANOVA	4.42e-12
s.dist	0.517
s.bl	0.448
s.gu	0.258
p.bl	4.6e-13
p.gu	3.23e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
EEFSEC	-11516.0	-7253.0
FAU	339.0	-8142.0
PSTK	-7111.0	785.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
SECISBP2	-12271.0	-1329.0
SEPHS2	-2195.0	-4938.0
SEPSECS	-4187.0	1852.0
UBA52	-1582.0	2411.0

---

---

Vpu mediated degradation of CD4

Vpu mediated degradation of CD4

metric	value
setSize	50
pMANOVA	5.45e-08
p.adjustMANOVA	7.95e-07
s.dist	0.515
s.bl	0.405
s.gu	0.318
p.bl	7.14e-07
p.gu	9.93e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
BTRC	-17678	952
CD4	-11176	2140
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
SKP1	245	2633
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

TICAM1, RIP1-mediated IKK complex recruitment

TICAM1, RIP1-mediated IKK complex recruitment

metric	value
setSize	18
pMANOVA	0.00253
p.adjustMANOVA	0.0139
s.dist	0.514
s.bl	0.336
s.gu	0.389
p.bl	0.0135
p.gu	0.00427

Top 20 genes

Gene	bl	gu
TLR3	3432	5652
UBB	3278	4141
RPS27A	2633	5083

Click HERE to show all gene set members

All member genes

	bl	gu
BIRC2	-2998	-235
BIRC3	-2648	3567
CHUK	-14624	-5696
IKBKB	-11002	-9952
RIPK1	-12287	-6219
RIPK3	-7719	6119
RPS27A	2633	5083
TICAM1	-1572	432
TLR3	3432	5652
TRAF6	-9681	-4945
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
UBE2D1	-11102	2093
UBE2D2	-1933	4145
UBE2D3	-4271	-4948
UBE2N	-3018	-6061
UBE2V1	-2949	5852

---

---

Stabilization of p53

Stabilization of p53

metric	value
setSize	55
pMANOVA	1.09e-08
p.adjustMANOVA	1.98e-07
s.dist	0.514
s.bl	0.41
s.gu	0.31
p.bl	1.47e-07
p.gu	6.91e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
ATM	1939	-2867
CDKN2A	-95	2969
CHEK2	-4820	5616
MDM2	-2588	5308
MDM4	-10176	2303
PHF20	-14647	-7011
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RFWD2	-10106	-7493
RPS27A	2633	5083
TP53	-2599	-2481
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

AUF1 (hnRNP D0) binds and destabilizes mRNA

AUF1 (hnRNP D0) binds and destabilizes mRNA

metric	value
setSize	53
pMANOVA	2.15e-08
p.adjustMANOVA	3.69e-07
s.dist	0.512
s.bl	0.422
s.gu	0.289
p.bl	1.04e-07
p.gu	0.000275

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
HNRNPD	1515	4959
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
EIF4G1	-4091	-1993
HNRNPD	1515	4959
HSPA1A	2323	-4622
HSPA8	-1762	-1774
HSPB1	-9948	-5786
PABPC1	-15538	-7224
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Negative regulation of NOTCH4 signaling

Negative regulation of NOTCH4 signaling

metric	value
setSize	52
pMANOVA	3.98e-08
p.adjustMANOVA	5.91e-07
s.dist	0.51
s.bl	0.394
s.gu	0.324
p.bl	8.64e-07
p.gu	5.24e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
AKT1	-15503	-4591
CUL1	-10922	-3518
FBXW7	-16999	-11774
NOTCH4	-5925	-2761
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSMF1	-7580	-2334
RBX1	-3011	5968
RPS27A	2633	5083
SKP1	245	2633
TACC3	-5651	-166
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
YWHAZ	-1840	-7978

---

---

SCF-beta-TrCP mediated degradation of Emi1

SCF-beta-TrCP mediated degradation of Emi1

metric	value
setSize	53
pMANOVA	3.18e-08
p.adjustMANOVA	5.01e-07
s.dist	0.509
s.bl	0.392
s.gu	0.325
p.bl	7.97e-07
p.gu	4.25e-05

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
BTRC	-17678	952
CDC20	-4067	100
CUL1	-10922	-3518
FBXO5	-566	2391
FZR1	-15242	5573
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
SKP1	245	2633
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Regulation of activated PAK-2p34 by proteasome mediated degradation

Regulation of activated PAK-2p34 by proteasome mediated degradation

metric	value
setSize	48
pMANOVA	1.59e-07
p.adjustMANOVA	2e-06
s.dist	0.507
s.bl	0.411
s.gu	0.296
p.bl	8.06e-07
p.gu	0.000378

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
PAK2	-17637	-6091
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

FBXL7 down-regulates AURKA during mitotic entry and in early mitosis

FBXL7 down-regulates AURKA during mitotic entry and in early mitosis

metric	value
setSize	53
pMANOVA	3.31e-08
p.adjustMANOVA	5.17e-07
s.dist	0.506
s.bl	0.412
s.gu	0.295
p.bl	2.15e-07
p.gu	0.000207

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842
SKP1	245	2633

Click HERE to show all gene set members

All member genes

	bl	gu
AURKA	-88	-639
CUL1	-10922	-3518
FBXL18	-10641	-2830
FBXL7	-10309	-14162
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RBX1	-3011	5968
RPS27A	2633	5083
SKP1	245	2633
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Condensation of Prometaphase Chromosomes

Condensation of Prometaphase Chromosomes

metric	value
setSize	11
pMANOVA	0.0198
p.adjustMANOVA	0.0703
s.dist	0.506
s.bl	0.142
s.gu	0.485
p.bl	0.415
p.gu	0.00533

Top 20 genes

Gene	bl	gu
SMC2	63	5783

Click HERE to show all gene set members

All member genes

	bl	gu
CCNB1	-15483	5329
CCNB2	-18433	3729
CDK1	-1204	1566
CSNK2A1	-5463	1253
CSNK2A2	-9549	-1047
CSNK2B	-3053	-4459
NCAPD2	-5182	-2935
NCAPG	-5877	5515
NCAPH	-5610	-2551
SMC2	63	5783
SMC4	-5949	3384

---

---

APC/C:Cdc20 mediated degradation of Securin

APC/C:Cdc20 mediated degradation of Securin

metric	value
setSize	66
pMANOVA	7.78e-10
p.adjustMANOVA	1.85e-08
s.dist	0.503
s.bl	0.381
s.gu	0.329
p.bl	8.61e-08
p.gu	3.79e-06

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
ANAPC10	1568	7316
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
ANAPC1	-214	5021
ANAPC10	1568	7316
ANAPC11	-853	1262
ANAPC15	-3568	-5708
ANAPC16	-3038	5076
ANAPC2	-6999	3577
ANAPC4	-12035	-5819
ANAPC5	-13436	3996
ANAPC7	-14	2634
CDC16	-5235	-1817
CDC20	-4067	100
CDC23	1982	-12630
CDC26	-4616	5368
CDC27	-17169	-12590
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
PTTG1	-2416	717
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
UBE2C	-148	-1659
UBE2D1	-11102	2093
UBE2E1	-12259	826
UBE2S	-11896	5126

---

---

Mitochondrial iron-sulfur cluster biogenesis

Mitochondrial iron-sulfur cluster biogenesis

metric	value
setSize	12
pMANOVA	0.0209
p.adjustMANOVA	0.0739
s.dist	0.503
s.bl	0.281
s.gu	0.417
p.bl	0.0919
p.gu	0.0124

Top 20 genes

Gene	bl	gu
ISCU	1883	7056
HSCB	1181	5397

Click HERE to show all gene set members

All member genes

	bl	gu
FDX1	-9798	1832
FDXR	-1318	587
FXN	-11416	-5075
GLRX5	-135	2738
HSCB	1181	5397
ISCA1	-9350	-1871
ISCA2	1068	-13696
ISCU	1883	7056
LYRM4	-13231	-5673
NFS1	-9701	2853
SLC25A28	-1784	6079
SLC25A37	-8597	6182

---

---

Mitophagy

Mitophagy

metric	value
setSize	27
pMANOVA	0.000168
p.adjustMANOVA	0.00128
s.dist	0.5
s.bl	0.256
s.gu	0.429
p.bl	0.0212
p.gu	0.000114

Top 20 genes

Gene	bl	gu
UBB	3278	4141
RPS27A	2633	5083
TOMM6	2444	721

Click HERE to show all gene set members

All member genes

	bl	gu
ATG12	-7618	-6545
ATG5	-10356	2224
CSNK2A1	-5463	1253
CSNK2A2	-9549	-1047
CSNK2B	-3053	-4459
MAP1LC3A	-16409	2604
MAP1LC3B	-6322	4627
MFN1	-938	4389
MFN2	-8895	2711
MTERF3	418	-4922
PARK2	-5767	-8511
PGAM5	-6348	3837
PINK1	-578	4062
RPS27A	2633	5083
SQSTM1	-4938	-851
SRC	-10340	-1794
TOMM20	-6383	-2940
TOMM22	-3837	-1943
TOMM40	-5635	7261
TOMM5	-12296	-2157
TOMM6	2444	721
TOMM7	-4647	4769
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
ULK1	-6159	589
VDAC1	-17004	1350

---

---

Aspirin ADME

Aspirin ADME

metric	value
setSize	44
pMANOVA	7.56e-07
p.adjustMANOVA	8.53e-06
s.dist	0.498
s.bl	-0.255
s.gu	-0.428
p.bl	0.00344
p.gu	8.73e-07

Top 20 genes

Gene	bl	gu
UGT2B11	-21337	-17278
UGT2B4	-21311	-16951
ACSM2A	-20361	-16931
GLYATL3	-20243	-16326
UGT2B7	-19466	-16802
CYP2D6	-19988	-16358
UGT2B10	-21288	-15316
ALB	-20900	-15234
UGT2B28	-21526	-14687
CYP2C19	-19552	-16117
BCHE	-19886	-15627
CYP2C8	-20447	-12768
UGT2A2	-18383	-12817
UGT2A1	-20687	-11233
UGT2A3	-20744	-9744
UGT1A1	-11541	-16565
GLYATL2	-17487	-9653
UGT1A8	-12587	-13229
SLC22A7	-9693	-15565
UGT1A7	-11787	-12600

Click HERE to show all gene set members

All member genes

	bl	gu
ABCC2	-8826	-9881
ABCC3	-5425	-9679
ACSM2A	-20361	-16931
ACSM2B	3514	2656
ACSM4	720	-5188
ACSM5	3774	-16228
ALB	-20900	-15234
BCHE	-19886	-15627
BSG	-6243	-10202
CES1	-711	-94
CES2	1469	-2861
CYP2C19	-19552	-16117
CYP2C8	-20447	-12768
CYP2C9	1974	-2058
CYP2D6	-19988	-16358
CYP2E1	-18631	-3171
CYP3A4	-15821	-8770
GLYAT	-9060	-13895
GLYATL1	-1686	-15826
GLYATL2	-17487	-9653
GLYATL3	-20243	-16326
SLC16A1	-8056	6007
SLC22A7	-9693	-15565
SLCO2B1	596	-3822
UGT1A1	-11541	-16565
UGT1A3	-9171	-12535
UGT1A4	-8869	-10588
UGT1A5	-9602	-11810
UGT1A6	-9529	-13378
UGT1A7	-11787	-12600
UGT1A8	-12587	-13229
UGT1A9	-10674	-13288
UGT2A1	-20687	-11233
UGT2A2	-18383	-12817
UGT2A3	-20744	-9744
UGT2B10	-21288	-15316
UGT2B11	-21337	-17278
UGT2B15	-13049	-10893
UGT2B17	-20950	1510
UGT2B28	-21526	-14687
UGT2B4	-21311	-16951
UGT2B7	-19466	-16802
UGT3A1	-1170	-4112
UGT3A2	-12605	5872

---

---

Response of EIF2AK4 (GCN2) to amino acid deficiency

Response of EIF2AK4 (GCN2) to amino acid deficiency

metric	value
setSize	95
pMANOVA	6.8e-14
p.adjustMANOVA	3.76e-12
s.dist	0.498
s.bl	0.427
s.gu	0.256
p.bl	5.9e-13
p.gu	1.62e-05

Top 20 genes

Gene	bl	gu
EIF2S2	3185	7441
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
ATF4	679	5685
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
ASNS	-1523.0	-8674.0
ATF2	749.0	-815.0
ATF3	-3893.0	-4204.0
ATF4	679.0	5685.0
CEBPB	-7941.0	6378.0
CEBPG	-16760.0	639.0
DDIT3	2210.0	-10839.0
EIF2AK4	-18322.0	-7163.0
EIF2S1	-5280.0	-4814.0
EIF2S2	3185.0	7441.0
FAU	339.0	-8142.0
GCN1	-16505.0	-3688.0
IMPACT	-16476.0	-10581.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
TRIB3	-7142.0	5293.0
UBA52	-1582.0	2411.0

---

---

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC)

metric	value
setSize	89
pMANOVA	5.01e-13
p.adjustMANOVA	2.09e-11
s.dist	0.497
s.bl	0.427
s.gu	0.254
p.bl	3.05e-12
p.gu	3.51e-05

Top 20 genes

Gene	bl	gu
RPL35	2168	7809
RPL35A	3383	4815
RPL34	3183	4879
RPS27A	2633	5083
RPL41	2936	3725
RPS19	2541	4237
RPS27	1289	6541
RPL7	1457	5763
RPL23	1855	4346
RPS16	1209	4604
RPL28	2510	1892
RPS17	1222	3419
RPSA	559	7037
RPL27A	930	2052
RPS18	709	1936
RPS23	983	1243
RPL18	293	40

Click HERE to show all gene set members

All member genes

	bl	gu
EIF4G1	-4091.0	-1993.0
ETF1	-3072.0	-10743.0
FAU	339.0	-8142.0
GSPT1	-8626.0	1941.0
NCBP1	-11452.0	-1118.0
NCBP2	-12763.0	-1208.0
PABPC1	-15538.0	-7224.0
RPL10A	-2144.0	5287.0
RPL10L	-18378.0	4231.0
RPL11	-8721.0	-2458.0
RPL12	-421.0	1662.0
RPL13	-280.0	-4022.0
RPL13A	-4574.5	-7793.5
RPL14	1943.0	-5790.0
RPL15	77.0	-187.0
RPL17	-4268.0	-14466.0
RPL18	293.0	40.0
RPL18A	-559.0	-12160.0
RPL19	-9095.0	-3132.0
RPL21	-6004.0	2122.0
RPL22	-3790.0	-11781.0
RPL22L1	-12462.0	-13526.0
RPL23	1855.0	4346.0
RPL23A	-998.0	1814.0
RPL24	-3971.0	5895.0
RPL26	-2641.0	4899.0
RPL26L1	-6478.0	-3312.0
RPL27	-330.0	-9130.0
RPL27A	930.0	2052.0
RPL28	2510.0	1892.0
RPL29	-2423.0	-8184.0
RPL3	-3206.0	5585.0
RPL30	9.0	-4032.0
RPL31	-9354.0	2635.0
RPL32	2647.0	-6251.0
RPL34	3183.0	4879.0
RPL35	2168.0	7809.0
RPL35A	3383.0	4815.0
RPL36	-1907.0	7118.0
RPL36AL	-4561.0	1249.0
RPL37	-3913.0	-9634.0
RPL37A	-2984.0	5752.0
RPL38	-14119.0	4190.0
RPL39L	1290.0	-4045.0
RPL3L	-9104.0	-16679.0
RPL4	2609.0	-3763.0
RPL41	2936.0	3725.0
RPL5	-4937.0	-6727.0
RPL6	-16335.0	2149.0
RPL7	1457.0	5763.0
RPL7A	-753.0	-3583.0
RPL8	-617.0	-1876.0
RPL9	-3269.0	3686.0
RPLP0	550.0	-4334.0
RPLP1	-12497.0	-6793.0
RPLP2	1382.0	-8896.0
RPS10	-4517.0	2368.0
RPS11	2207.0	-13804.0
RPS12	3518.0	-1497.0
RPS13	-3760.0	-14339.0
RPS14	-8453.0	7156.0
RPS15	-5601.0	3218.0
RPS15A	-3699.0	4700.0
RPS16	1209.0	4604.0
RPS17	1222.0	3419.0
RPS18	709.0	1936.0
RPS19	2541.0	4237.0
RPS2	-830.0	-12504.0
RPS20	-1591.0	-5511.0
RPS21	908.0	-5285.0
RPS23	983.0	1243.0
RPS24	-5861.0	5913.0
RPS25	-3493.0	-1399.0
RPS26	-7211.0	6898.0
RPS27	1289.0	6541.0
RPS27A	2633.0	5083.0
RPS27L	859.0	-7524.0
RPS28	-13883.0	-2888.0
RPS29	1292.0	-12538.0
RPS3	-747.0	1694.0
RPS3A	-699.0	-804.0
RPS5	-9203.0	-15424.0
RPS6	-9677.0	325.0
RPS7	-4265.0	-4644.0
RPS8	-2232.0	5018.0
RPS9	-7704.0	-9762.0
RPSA	559.0	7037.0
UBA52	-1582.0	2411.0
UPF1	-11718.0	1763.0

---

---

Digestion

Digestion

metric	value
setSize	18
pMANOVA	0.00342
p.adjustMANOVA	0.0176
s.dist	0.497
s.bl	-0.273
s.gu	-0.415
p.bl	0.0453
p.gu	0.00228

Top 20 genes

Gene	bl	gu
LIPF	-20262	-17214
PNLIPRP3	-20689	-16570
PNLIP	-20281	-13530
AMY2A	-16371	-15095
CHIA	-20583	-11981
ALPI	-14618	-15947
CEL	-15999	-13747
AMY2B	-19612	-10144
LCT	-9863	-9414
GUCA2B	-6553	-13387
CLPS	-7290	-9627
PNLIPRP1	-4238	-13317
PNLIPRP2	-10499	-4654
MGAM	-12568	-3309
TREH	-2796	-14407
GUCY2C	-2313	-8964

Click HERE to show all gene set members

All member genes

	bl	gu
ALPI	-14618	-15947
AMY2A	-16371	-15095
AMY2B	-19612	-10144
CEL	-15999	-13747
CHIA	-20583	-11981
CHIT1	-2167	5673
CLPS	-7290	-9627
GUCA2A	-13132	2823
GUCA2B	-6553	-13387
GUCY2C	-2313	-8964
LCT	-9863	-9414
LIPF	-20262	-17214
MGAM	-12568	-3309
PNLIP	-20281	-13530
PNLIPRP1	-4238	-13317
PNLIPRP2	-10499	-4654
PNLIPRP3	-20689	-16570
TREH	-2796	-14407

---

---

CASP8 activity is inhibited

CASP8 activity is inhibited

metric	value
setSize	11
pMANOVA	0.0259
p.adjustMANOVA	0.0873
s.dist	0.496
s.bl	0.461
s.gu	0.184
p.bl	0.0081
p.gu	0.291

Top 20 genes

Gene	bl	gu
CASP8	2222	5385

Click HERE to show all gene set members

All member genes

	bl	gu
CASP8	2222	5385
CFLAR	-129	-1701
FADD	-6056	1668
FAS	-385	5000
FASLG	3492	-17314
RIPK1	-12287	-6219
TNFRSF10A	-7625	-11302
TNFRSF10B	-557	7040
TNFSF10	-1643	-16223
TRADD	-4346	1334
TRAF2	-3336	5275

---

---

Dimerization of procaspase-8

Dimerization of procaspase-8

metric	value
setSize	11
pMANOVA	0.0259
p.adjustMANOVA	0.0873
s.dist	0.496
s.bl	0.461
s.gu	0.184
p.bl	0.0081
p.gu	0.291

Top 20 genes

Gene	bl	gu
CASP8	2222	5385

Click HERE to show all gene set members

All member genes

	bl	gu
CASP8	2222	5385
CFLAR	-129	-1701
FADD	-6056	1668
FAS	-385	5000
FASLG	3492	-17314
RIPK1	-12287	-6219
TNFRSF10A	-7625	-11302
TNFRSF10B	-557	7040
TNFSF10	-1643	-16223
TRADD	-4346	1334
TRAF2	-3336	5275

---

---

Regulation by c-FLIP

Regulation by c-FLIP

metric	value
setSize	11
pMANOVA	0.0259
p.adjustMANOVA	0.0873
s.dist	0.496
s.bl	0.461
s.gu	0.184
p.bl	0.0081
p.gu	0.291

Top 20 genes

Gene	bl	gu
CASP8	2222	5385

Click HERE to show all gene set members

All member genes

	bl	gu
CASP8	2222	5385
CFLAR	-129	-1701
FADD	-6056	1668
FAS	-385	5000
FASLG	3492	-17314
RIPK1	-12287	-6219
TNFRSF10A	-7625	-11302
TNFRSF10B	-557	7040
TNFSF10	-1643	-16223
TRADD	-4346	1334
TRAF2	-3336	5275

---

---

Vif-mediated degradation of APOBEC3G

Vif-mediated degradation of APOBEC3G

metric	value
setSize	50
pMANOVA	1.72e-07
p.adjustMANOVA	2.14e-06
s.dist	0.495
s.bl	0.404
s.gu	0.286
p.bl	7.52e-07
p.gu	0.00046

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
APOBEC3G	-15296	-17185
CUL5	-10822	-3464
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
RBX1	-3011	5968
RPS27A	2633	5083
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1

APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1

metric	value
setSize	72
pMANOVA	2.43e-10
p.adjustMANOVA	7.02e-09
s.dist	0.495
s.bl	0.368
s.gu	0.331
p.bl	6.42e-08
p.gu	1.16e-06

Top 20 genes

Gene	bl	gu
PSMC2	2516	6995
PSMA5	2533	6234
UBB	3278	4141
RPS27A	2633	5083
ANAPC10	1568	7316
PSMD7	1895	4703
PSMD3	966	5596
PSME1	492	7331
PSMA3	835	3842

Click HERE to show all gene set members

All member genes

	bl	gu
ANAPC1	-214	5021
ANAPC10	1568	7316
ANAPC11	-853	1262
ANAPC15	-3568	-5708
ANAPC16	-3038	5076
ANAPC2	-6999	3577
ANAPC4	-12035	-5819
ANAPC5	-13436	3996
ANAPC7	-14	2634
AURKA	-88	-639
AURKB	-2451	-5471
CDC16	-5235	-1817
CDC20	-4067	100
CDC23	1982	-12630
CDC26	-4616	5368
CDC27	-17169	-12590
FZR1	-15242	5573
PLK1	-3953	681
PSMA1	-5876	3462
PSMA2	1248	-11310
PSMA3	835	3842
PSMA4	-277	3194
PSMA5	2533	6234
PSMA6	-1416	5811
PSMA7	-2787	6338
PSMA8	-4183	-4629
PSMB1	240	-2634
PSMB10	-7218	3436
PSMB11	802	-15989
PSMB2	-2726	1785
PSMB3	-1103	-5374
PSMB4	-7988	-12102
PSMB5	-3757	-2106
PSMB6	-5082	-8902
PSMB7	-4730	6188
PSMB8	-826	-4144
PSMB9	586	-6287
PSMC1	166	-8003
PSMC2	2516	6995
PSMC3	-2335	-5531
PSMC4	2790	-933
PSMC5	-7018	-1882
PSMC6	-9714	5528
PSMD1	-18772	-9583
PSMD11	-1036	2222
PSMD12	2017	-8571
PSMD13	-4023	4757
PSMD14	-18653	-2522
PSMD2	-4043	-965
PSMD3	966	5596
PSMD4	-2101	-612
PSMD5	-253	-577
PSMD6	-16102	-9371
PSMD7	1895	4703
PSMD8	-13096	1578
PSMD9	-3309	-320
PSME1	492	7331
PSME2	-7	1209
PSME3	1918	-1755
PSME4	-13353	-9824
PSMF1	-7580	-2334
PTTG1	-2416	717
RB1	-11703	-2971
RPS27A	2633	5083
SKP2	-1221	1281
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764
UBE2C	-148	-1659
UBE2D1	-11102	2093
UBE2E1	-12259	826
UBE2S	-11896	5126

---

---

RIPK1-mediated regulated necrosis

RIPK1-mediated regulated necrosis

metric	value
setSize	27
pMANOVA	0.00026
p.adjustMANOVA	0.00189
s.dist	0.494
s.bl	0.348
s.gu	0.35
p.bl	0.00173
p.gu	0.00162

Top 20 genes

Gene	bl	gu
UBB	3278	4141
RPS27A	2633	5083
CASP8	2222	5385

Click HERE to show all gene set members

All member genes

	bl	gu
BIRC2	-2998	-235
BIRC3	-2648	3567
CASP8	2222	5385
CDC37	-328	885
CFLAR	-129	-1701
FADD	-6056	1668
FAS	-385	5000
FASLG	3492	-17314
FLOT1	-8417	2094
FLOT2	-10026	3345
HSP90AA1	-4051	1448
MLKL	-464	1384
PDCD6IP	-14253	-529
PELI1	-9084	-6593
RIPK1	-12287	-6219
RIPK3	-7719	6119
RPS27A	2633	5083
SDCBP	-9081	2782
STUB1	-18005	-9270
TNFRSF10A	-7625	-11302
TNFRSF10B	-557	7040
TNFSF10	-1643	-16223
TRADD	-4346	1334
TRAF2	-3336	5275
UBA52	-1582	2411
UBB	3278	4141
UBC	-1010	1764

---

---

Here is the session info with all the versions of packages used.

sessionInfo()

## R version 4.3.1 (2023-06-16)
## Platform: x86_64-pc-linux-gnu (64-bit)
## Running under: Ubuntu 22.04.3 LTS
## 
## Matrix products: default
## BLAS:   /usr/lib/x86_64-linux-gnu/openblas-pthread/libblas.so.3 
## LAPACK: /usr/lib/x86_64-linux-gnu/openblas-pthread/libopenblasp-r0.3.20.so;  LAPACK version 3.10.0
## 
## locale:
##  [1] LC_CTYPE=en_US.UTF-8       LC_NUMERIC=C              
##  [3] LC_TIME=en_US.UTF-8        LC_COLLATE=en_US.UTF-8    
##  [5] LC_MONETARY=en_US.UTF-8    LC_MESSAGES=en_US.UTF-8   
##  [7] LC_PAPER=en_US.UTF-8       LC_NAME=C                 
##  [9] LC_ADDRESS=C               LC_TELEPHONE=C            
## [11] LC_MEASUREMENT=en_US.UTF-8 LC_IDENTIFICATION=C       
## 
## time zone: Etc/UTC
## tzcode source: system (glibc)
## 
## attached base packages:
## [1] stats4    parallel  stats     graphics  grDevices utils     datasets 
## [8] methods   base     
## 
## other attached packages:
##  [1] pkgload_1.3.2.1                                    
##  [2] GGally_2.1.2                                       
##  [3] ggplot2_3.4.4                                      
##  [4] reshape2_1.4.4                                     
##  [5] beeswarm_0.4.0                                     
##  [6] gplots_3.1.3                                       
##  [7] gtools_3.9.4                                       
##  [8] tibble_3.2.1                                       
##  [9] dplyr_1.1.3                                        
## [10] echarts4r_0.4.5                                    
## [11] eulerr_7.0.0                                       
## [12] kableExtra_1.3.4                                   
## [13] data.table_1.14.8                                  
## [14] IlluminaHumanMethylationEPICanno.ilm10b4.hg19_0.6.0
## [15] minfi_1.46.0                                       
## [16] bumphunter_1.42.0                                  
## [17] locfit_1.5-9.8                                     
## [18] iterators_1.0.14                                   
## [19] foreach_1.5.2                                      
## [20] Biostrings_2.68.1                                  
## [21] XVector_0.40.0                                     
## [22] SummarizedExperiment_1.30.2                        
## [23] Biobase_2.60.0                                     
## [24] MatrixGenerics_1.12.3                              
## [25] matrixStats_1.1.0                                  
## [26] GenomicRanges_1.52.1                               
## [27] GenomeInfoDb_1.36.4                                
## [28] IRanges_2.34.1                                     
## [29] S4Vectors_0.38.2                                   
## [30] BiocGenerics_0.46.0                                
## [31] mitch_1.12.0                                       
## [32] limma_3.56.2                                       
## 
## loaded via a namespace (and not attached):
##   [1] splines_4.3.1             later_1.3.1              
##   [3] BiocIO_1.10.0             bitops_1.0-7             
##   [5] filelock_1.0.2            preprocessCore_1.61.0    
##   [7] XML_3.99-0.15             lifecycle_1.0.3          
##   [9] lattice_0.21-8            MASS_7.3-60              
##  [11] base64_2.0.1              scrime_1.3.5             
##  [13] magrittr_2.0.3            sass_0.4.7               
##  [15] rmarkdown_2.24            jquerylib_0.1.4          
##  [17] yaml_2.3.7                httpuv_1.6.11            
##  [19] doRNG_1.8.6               askpass_1.2.0            
##  [21] DBI_1.1.3                 RColorBrewer_1.1-3       
##  [23] abind_1.4-5               zlibbioc_1.46.0          
##  [25] rvest_1.0.3               quadprog_1.5-8           
##  [27] purrr_1.0.2               RCurl_1.98-1.13          
##  [29] rappdirs_0.3.3            GenomeInfoDbData_1.2.10  
##  [31] genefilter_1.82.1         annotate_1.78.0          
##  [33] svglite_2.1.2             DelayedMatrixStats_1.22.6
##  [35] codetools_0.2-19          DelayedArray_0.26.7      
##  [37] xml2_1.3.5                tidyselect_1.2.0         
##  [39] farver_2.1.1              beanplot_1.3.1           
##  [41] BiocFileCache_2.11.1      illuminaio_0.42.0        
##  [43] webshot_0.5.5             GenomicAlignments_1.36.0 
##  [45] jsonlite_1.8.7            multtest_2.56.0          
##  [47] ellipsis_0.3.2            survival_3.5-7           
##  [49] systemfonts_1.0.4         tools_4.3.1              
##  [51] progress_1.2.2            Rcpp_1.0.11              
##  [53] glue_1.6.2                gridExtra_2.3            
##  [55] xfun_0.40                 HDF5Array_1.28.1         
##  [57] withr_2.5.0               fastmap_1.1.1            
##  [59] rhdf5filters_1.12.1       fansi_1.0.4              
##  [61] openssl_2.1.0             caTools_1.18.2           
##  [63] digest_0.6.33             R6_2.5.1                 
##  [65] mime_0.12                 colorspace_2.1-0         
##  [67] biomaRt_2.56.1            RSQLite_2.3.3            
##  [69] tidyr_1.3.0               utf8_1.2.3               
##  [71] generics_0.1.3            rtracklayer_1.60.1       
##  [73] prettyunits_1.1.1         httr_1.4.7               
##  [75] htmlwidgets_1.6.2         S4Arrays_1.0.6           
##  [77] pkgconfig_2.0.3           gtable_0.3.4             
##  [79] blob_1.2.4                siggenes_1.74.0          
##  [81] htmltools_0.5.6           scales_1.2.1             
##  [83] png_0.1-8                 knitr_1.43               
##  [85] rstudioapi_0.15.0         tzdb_0.4.0               
##  [87] rjson_0.2.21              nlme_3.1-163             
##  [89] curl_5.0.2                cachem_1.0.8             
##  [91] rhdf5_2.44.0              stringr_1.5.0            
##  [93] KernSmooth_2.23-22        AnnotationDbi_1.62.2     
##  [95] restfulr_0.0.15           GEOquery_2.68.0          
##  [97] pillar_1.9.0              grid_4.3.1               
##  [99] reshape_0.8.9             vctrs_0.6.3              
## [101] promises_1.2.1            dbplyr_2.4.0             
## [103] xtable_1.8-4              evaluate_0.21            
## [105] readr_2.1.4               GenomicFeatures_1.52.2   
## [107] cli_3.6.1                 compiler_4.3.1           
## [109] Rsamtools_2.16.0          rlang_1.1.1              
## [111] crayon_1.5.2              rngtools_1.5.2           
## [113] labeling_0.4.3            nor1mix_1.3-0            
## [115] mclust_6.0.0              plyr_1.8.9               
## [117] stringi_1.7.12            viridisLite_0.4.2        
## [119] BiocParallel_1.34.2       munsell_0.5.0            
## [121] Matrix_1.6-1              hms_1.1.3                
## [123] sparseMatrixStats_1.12.2  bit64_4.0.5              
## [125] Rhdf5lib_1.22.1           KEGGREST_1.40.1          
## [127] shiny_1.7.5               highr_0.10               
## [129] memoise_2.0.1             bslib_0.5.1              
## [131] bit_4.0.5

END of report